|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/29 ¤W¤È 03:19:23²Ä 2120 ½g¦^À³
|
¬Q¤Ñ¼ÒÀÀªº±¡§Î¬OA¡BB¯Zªº¦Ñ®v¤@¼Ë¦n¡A¨C¦^©M¾Ç¥Í³Q·íªº¤ñ¨Ò¬O8%¡C¤µ¤Ñ¦b¥[¤W¨âºØ±¡§Î¡A²Ä¤@ºØ¬OB¯Z¦Ñ®v¤ñ¸û·|±Ð¡AÅý¾Ç¥Í³Q·íªº¤ñ¨Ò¤U°¨ì5%¡A²Ä¤GºØ¬OB¯Zªº¦Ñ®v±Ð±o¤ñ¸û®t¡AÅý³Q·íªº¾Ç¥Í¤ñ¨Ò¤W¤É¨ì11%¡C¥t¥~¤]¥[¤W¨C¦^¦Xªº·ÀI¤ñ¡C ¥ý§â¨â¯Z¦Ñ®v¤@¼Ë¦n¡A¤£¼vÅT¾Ç¥Í¦¨ÁZªº¼Æ¾Ú¦A¶K¤@¦¸¡A¤è«K¤ñ¸û ¦^¦X/¤H¼Æ__A¯Z¶}©l__B¯Z¶}©l__A¯Z³Q·í__B¯Z³Q·í__A¯Z³Ñ¤U__B¯Z³Ñ¤U__AÂàB 0__________________________________________________500________0 1____________450_______50_____36 (8%)_____4 (8%)_____414_______46_______50 2____________373_______87_____30 (8%)_____7 (8%)_____343_______80_______41 3____________309______114_____25 (8%)_____9 (8%)_____284______105_______34 4____________256______133_____20 (8%)____11 (8%)_____236______122_______28 5____________212______146_____17 (8%)____12 (8%)_____195______134_______24 6____________176______154_____14 (8%)____12 (8%)_____162______142_______20 7____________162______142_____13 (8%)____11 (8%)_____149______131________0 8____________149______131_____12 (8%)____10 (8%)_____137______121________0 9____________137______121_____11 (8%)____10 (8%)_____126______111________0 10___________126______111_____10 (8%)_____9 (8%)_____116______102________0 ¦]¬°¾ãÓ¹Lµ{Á`¦@¦³197ӾǥͱqA¯ZÂà¨ìB¯Z¥h¡A©Ò¥H·í®É¶¡=0®É¡AB¯Z²ÕÃnÀI¤H¼Æ=197¡AA¯Z²ÕÃnÀI¤H¼Æ=303¡Cpºâ¥XªºKM¦±½u¬°¡G _______________________________A¯Z²Õ______________________________B¯Z²Õ ¦^¦X_____ÃnÀI¤H¼Æ__·í±¼¤H¼Æ___KM curve______ÃnÀI¤H¼Æ___·í±¼¤H¼Æ___KM curve___·ÀI¤ñ¨Ò 0______________________________100%_______________________________100% 1__________303________36________88%___________197_________4________98%________17% 2__________267________30________78%___________193_________7________94%________27% 3__________237________25________70%___________186_________9________89%________37% 4__________212________20________63%___________177_________11_______83%________46% 5__________192________17________57%___________166_________12_______77%________53% 6__________175________14________52%___________154_________12_______71%________60% 7__________161________13________48%___________142_________11_______66%________65% 8__________148________12________44%___________131_________10_______61%________70% 9__________136________11________40%___________121_________10_______56%________73% 10_________125________10________37%___________111__________9_______51%________78% ·ÀI¤ñ¨Ò¨Ã¤£¬O©T©wªº¡AÀHµÛ®É¶¡·|¦³©ÒÅܤơC ·íB¯Z¦Ñ®v¤ñ¸û·|±Ð®É ¦^¦X/¤H¼Æ__A¯Z¶}©l__B¯Z¶}©l__A¯Z³Q·í__B¯Z³Q·í__A¯Z³Ñ¤U__B¯Z³Ñ¤U__AÂàB 0__________________________________________________500________0 1____________450_______50______36 (8%)____3 (5%)_____414_______47_______50 2____________373_______88______30 (8%)____4 (5%)_____343_______84_______41 3____________309______118______25 (8%)____6 (5%)_____284______112_______34 4____________256______140______20 (8%)____7 (5%)_____236______133_______28 5____________212______157______17 (8%)____8 (5%)_____195______149_______24 6____________176______169______14 (8%)____8 (5%)_____162______161_______20 7____________162______161______13 (8%)____8 (5%)_____149______153________0 8____________149______153______12 (8%)____8 (5%)_____137______145________0 9____________137______145______11 (8%)____7 (5%)_____126______138________0 10___________126______138______10 (8%)____7 (5%)_____116______131________0 ¦]¬°¾ãÓ¹Lµ{Á`¦@¦³197ӾǥͱqA¯ZÂà¨ìB¯Z¥h¡A©Ò¥H·í®É¶¡=0®É¡AB¯Z²ÕÃnÀI¤H¼Æ=197¡AA¯Z²ÕÃnÀI¤H¼Æ=303¡Cpºâ¥XªºKM¦±½u¬°¡G _______________________________A¯Z²Õ______________________________B¯Z²Õ ¦^¦X_____ÃnÀI¤H¼Æ__·í±¼¤H¼Æ___KM curve______ÃnÀI¤H¼Æ___·í±¼¤H¼Æ___KM curve___·ÀI¤ñ¨Ò 0______________________________100%_______________________________100% 1__________303________36________88%___________197_________3________98%________17% 2__________267________30________78%___________193_________4________96%________18% 3__________237________25________70%___________186_________6________93%________23% 4__________212________20________63%___________177_________7________89%________30% 5_ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/28 ¤U¤È 10:02:41²Ä 2119 ½g¦^À³
|
Pie¤j §Ú¬O»{¬°822°ª§C§ÜÅé¨â²ÕªºHR ¹ê»Ú¤W¤£¬OÀHµÛ®É¶¡¶b¦Ó©T©wªº ³oÓ³¡¤À ¥i¥H¦^¥h§äCliff¤jªºPO¤å ¦³´£¨ì¹L ¦AªÌ °ª§ÜÅé²Õ HR»P§C§ÜÅé²ÕªºHR ·íµM¦b©µ¿ð¤ÏÀ³¿ú³£¬O¤@¼Ë ¥i¬O¤§«áÀ³¸Ó¤£¤@¼Ë Á`¤§ §ÚÓ¤H»{¬° ´N822²Îp¤W ©|¨S¦³ÃÒ¾ÚÅã¥Ü¤½¥q½Ðªº¥Íª«²Îp±M®a¦³°¾»~ |
|
|
·|û¡G¼ï¤¤Áú10141277 µoªí®É¶¡:2016/6/28 ¤U¤È 06:20:29²Ä 2118 ½g¦^À³
|
Pie¤j ±z¬O»¡¡G¦Ñ®v±Ð¦b¦h¡]º¡9°w¡^¦ý²¦³ºA,B¨â¯Z¡A¾Ç¥Í¥»¨ªº¾Ç²ß©Î²z¸Ñ¯à¤O¦³®t¡]¯f¥v¡A¨Å骬ªp¡^¡A©Ò¥H¤~¦³¤£©T©w¤§¥i¯à¡C ¤£ª¾¤p§Ìªº²z¸Ñ¬O§_¦³»~¡C¡]>_<¡^................ |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/28 ¤U¤È 05:56:12²Ä 2117 ½g¦^À³
|
¯E§J¤j ¦b§Úªº¨Ò¤l¤¤¡A¬°¤F¤è«K»¡©ú¡A»P¥YÅã®ÄªG¡A°µ¤F«Ü¦h²¤Æªº³]©w¡A¨Ò¦pA¡BB¯Z¨C¦^¦X³£¦³5%³Q·í¡C ½Ð°Ý§A«üªº¤£©T©w¡A¬O«üA¯Z©MB¯Z³Q·íªº¤ñ¨ÒÀ³¸Ó¤£¤@¼Ë¡AÁÙ¬O¨C¦^¦X³Q·íªº¤ñ¨ÒÀ³¸Ó¤£¤@¼Ë¡AÁÙ¬O¨âªÌ³£À³¸Ó¤£¤@¼Ë©O¡H §Ú¥i¥H®Ú¾Ú§Aªº·N¨£¡AÀÀ©w±¡¹Ò¡A±À¾É¥X·sªº¼Æ¾Ú¡A¬Û«H·|±o¨ìÃþ¦üªºµ²ªG¡C ¦b§Úªº¨Ò¤l¤¤¡A¨è·NÅýA¡BB¯Z³Q·íªº¤ñ¨Ò¤@¼Ë¡A¬O·Qn¥YÅã¥X¡i²Îpµ²ªG¡j©M¡i¯u¹ê¡j¤§¶¡ªº¸¨®t¡C¦b³oӳ̲³æªº¨Ò¤l¤¤¡A³Ì®e©ö¬Ý¥X²Îpµ²ªG¤£¯à¤Ï¬M¾Ç¥Í¯u¹êªºµ{«×¡CY¶i¤@¨B¦Ò¼{½ÆÂø¤@ÂIªº±¡§Î¡AB¯Zªº¦Ñ®v¥i¯à±Ð±o¤ñA¯Zªº¦Ñ®v¦n¡A¾Ç¥Í¾Ç²ßªº¤ñ¸û¦n¡A¾Ç¥Í¨ìB¯Z¤§«á³Q·íªº¤ñ¨Ò±q5%¤U°¨ì2%¡C¤ÏÀ³¦bKM¦±½u¤W¡AA¡BB¨â¯ZKM¦±½uªº®t²§¡A©M²³æªº¨Ò¤l¬Û¤ñ¡A·|©Ô±o§ó¶}¡C¤Ï¤§¡AB¯Zªº¦Ñ®v¥i¯à±Ð±o¤ñA¯Zªº¦Ñ®v®t¡A¾Ç¥Í³£Å¥¤£À´¡A¾Ç¥Í¨ìB¯Z¤§«á³Q·íªº¤ñ¨Ò±q5%¤W¤É¨ì10%¡C¤ÏÀ³¦bKM¦±½u¤W¡AA¡BB¨â¯ZKM¦±½uªº®t²§¡A©M²³æªº¨Ò¤l¬Û¤ñ¡A·|³Q©Ôªñ¡C¦Ñ®vªº±Ð¾Ç¹ïA¡BB¨â¯Z¾Ç¥Íªº®t²§¡A©M¤À²Õ³y¦¨ªº¼vÅT¥[°_¨Ó¡A´N·|¬O³Ì«á¬Ý¨ìªºKM¦±½u¡C¤À²Õ¥»¨¹ïKM¦±½u³y¦¨ªº¼vÅT´N¤w¸g«Ü¤j¤F¡A·|¨Ï±o¦Ñ®v±Ð¾Çªº¼vÅT¬Û¹ï¤£©úÅã¡A¤£®e©öµû¦ô¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/28 ¤U¤È 05:22:34²Ä 2116 ½g¦^À³
|
Pie¤j ¨â¯Z³Q·í¤ñ¨Ò¬O©T©wªº Áö»¡²Å¦Xcox model HR©T©wªº°²³] ¦ý¬O¹ê»Ú¤W822¤G´Á¬ã¨s´N¤£¬O©T©wªº |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/28 ¤U¤È 03:57:10²Ä 2115 ½g¦^À³
|
§g¤j ·Ó²z»¡¤½¥q¦³«Ü¦hªº±M®a¡A¹ï³o¼Ëªº²Îp°ÝÃDÀ³¸Ó¯à¥[¥HÁקK¡C ©Ò¥H§ÚÁÙ·Q¦hťť¤£¦Pªº·N¨£¡A¬Ý¬Ý¬O¤£¬O¦Û¤vªº·Qªk¦³°ÝÃD¡C ¯E§J¤j ½Ð°Ý¡i°²³]±ø¥ó ¨â¯Z³Q·í©T©w¤ñ¨Ò¡j¬O¤°»ò·N«ä¡H ¹x¥Û¤j Ãö©ó¡i°ª§ÜÅé¤ÏÀ³»P§C§ÜÅé¤ÏÀ³¤]¬O«ùÄò©Êªº¡A¤£·|³o¶g¬O°ª¤ÏÀ³¤U¶gÅܦ¨§C¤ÏÀ³¡A¤Ï¤§¥çµM¡j¡A§Ú»{¬°¦³¤@¥b¬O¹ïªº¡C ªº½T¤£·|¦³²£¥Í°ª§ÜÅ骺¤H¡A¦AÅܦ^§C§ÜÅé²Õ³oºØ±¡§Î¡C¦ý¬O§C§ÜÅéÅܦ¨°ª§ÜÅé¬O¦¨¥ßªº¡C ±qASCO§ë¼v¤ù¥iª¾¹D¡A²£¥Í°ª§ÜÅé¬O»Ýn®É¶¡ªº¡A¦³¨Ç¤H»Ýn¨â¶g¡A¦³¨Ç¤H»Ýn¥|¶g¡A¦³¨Ç¤H»Ýn¤K¶g¡A¦³¨Ç¤Hn§ó¤[¡C ©Ò¦³°ª§ÜÅé²Õªº¤H¡A³£¬O³°³°ÄòÄò±q§C§ÜÅéÂà´«¦¨°ª§ÜÅ骺¡C ¦pªG¦b¹êÅç³Ì«áª½±µ²Îp°ª§ÜÅé²Õ¤H¼Æ¡A´N¬Ý¤£¨ì³oÓ¹Lµ{¡C ©Ò¥H¦b§Úªº¨Ò¤l¤¤¡A¤]¥u¦³A¯ZÂà¨ìB¯Zªº¡A¨S¦³Ë¹L¨Óªº¡C ¦Ó¥B¬O³°³°ÄòÄòªºÂà¡A´N¹³¨CÓ¤H²£¥Í§ÜÅé»Ýn¤£¦Pªº®É¶¡¤@¼Ë¡C ¦pªG³Ì«áª½±µ²ÎpÂà´«¨ìB¯ZªºÁ`¤H¼Æ¡A¤]¬Ý¤£¨ì¤¤¶¡ªº¹Lµ{¡C Y¬O¥Î³Ì«á¥[Á`ªºÁ`¤H¼Æ¨Ó°µ²Îp¡A´N·|¬Ý¨ìA¡BB¨â¯Z®t¶Z«Ü¤jªºµ²ªG¡C |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/28 ¤U¤È 02:32:01²Ä 2114 ½g¦^À³
|
822 IgG¬O§_ªø®Ä ¹ï¬ì¾Ç«n ¹ï¥«³õ¤£«n µu®Ä §óÀWÁcÄ~Äò¥´ ¤½¥q½æªº¦h ªø®Ä¸û¤£ÀWÁcÄ~Äò¥´ ¤½¥q½æªº¤Ö -------->´N¤HÅé§K¬Ì¾÷¨î¨Ó»¡ ¸g¹L822¨ë¿E«á ·íÅ餺GLOBE HªºÀù²ÓM®ø¥¢«á IgGªº¤U° ¬O¥i¥H²z¸Ñªº ¡]¦]¬°Å餺·|½Õ¸`IgGªº»s³y¡^ ¦ý ¦b822¨ë¿E¦P®É ¤]·|²£¥Í¼È®É¤£·|¤ÀªcIgGªº°O¾ÐB²ÓM ³o´N¬O§êºtªø´Á§K¬Ì¤Oºû«ùªº¨¤¦â ¥unGLOBE HªºÀù²ÓM §Üì ¦A¦¸¥X²{ °O¾ÐB CELL·|¤£¬q¼W¥Í¤Î¤À¤Æ ¦¹®É IgG´N¤S·|³Q¤Àªc ³o±¡§Î´N¹³¬OB¨x¬Ì] ¹L¤F¤@©w¦~«á nÀˬdÅ餺¬O§_ÁÙ¦³§ÜÅé ¦³¤@¬£»{¬°n¸É¥´ ¦Ó¦³¤@¬£»{¬°¤£¥Î ¦]¬°¥unB¨x§Üì ¥X²{ Å餺´N·|¤Àªc§ÜÅé¤@¼Ë... |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/28 ¤U¤È 01:18:01²Ä 2113 ½g¦^À³
|
¯E§J¤j: ÁÂÁ±zªº¤À¨É. §O¥¢¸¨, ¦³±z¤Î«¤j¤j¦b, ¥Ã»·³£·|¦³¤¬¬Û¯¡Är¡@¥O¤H¯dÅʪº®ð®§. ¦]¬°°é¦í¤j®aªº¬O¹ï¯E¹©ªº¤ä«ù, ¹ï§K¬ÌÀøªkªº´Á³\, ¹ï¥xÆWªºÃö·R. ¤j®a¥[ªo, ¤¬¬Û«jÀy. ´N¹³±i¸³»¡ªº, ¤Ñ¤W±¼¤U¨Óµ¹§Ú̪ºÂ§ª«, Åý§Ṳ́@°_¸òµÛ¯E¹©¾Ç²ß, ¤@°_©¹«e¨«. ·P®¦¦U¦ì¤j¤jªu¸ô¬Û¦ñ. ©êºp¦]¬°n¦^ÂЯE§J¤j, ©Ò¥H©ñ¦b¦¹ª©¤F. ½Ð¨£½Ì |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/28 ¤U¤È 12:29:26²Ä 2112 ½g¦^À³
|
¹x¥Û¤jªº¤À¨É ¯u¬Oºë´ï 822 IgG¬O§_ªø®Ä ¹ï¬ì¾Ç«n ¹ï¥«³õ¤£«n µu®Ä §óÀWÁcÄ~Äò¥´ ¤½¥q½æªº¦h ªø®Ä¸û¤£ÀWÁcÄ~Äò¥´ ¤½¥q½æªº¤Ö 888 ¤H·½³æ§Ü ¶}µo§óºC§óÃø ¤p§Ì»{¬° ³Ì¤j«GÂI¬O833/834 106 Q1·Ç³ÆIND ¹w¦ô¾AÀ³¯gÀ³¸Ó·|¸ò¤§«e822/821 ©Î833/821ªº¤£¦P ·m¶}¤£¦P¥«¦û |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/28 ¤W¤È 10:46:34²Ä 2111 ½g¦^À³
|
¥ýÁÂÁ¯E¤ÍÌ´£¨Ñªº¿ýµÄÒ¡C¤p§Ì±N¿ýµ¤ÏÂÐÅ¥¤F´X¦¸¡A¤@¨Ç·Qªk¤À¨É¡C±µ¦b¥xÁÞ¤j¡B¯E§J¤j¡B²³¤j¤jµo¤å¤§«á¡A¤]ºâª¯§ÀÄò¶I§a¡C ¤½¥q¹ï¡y822¬O§_¹ï§C§K¬Ì¤ÏÀ³ªÌ¦³®`¡z³oÓ°ÝÃDªºµªÂФ@ª½¸ò¯E¤Í̪º´Á«Ý (»P»{ª¾) ¦³¬Û·í¸¨®t¡C¥H¤p§ÌªºÅÞ¿è¨Ó¸ÑÄÀ 6/5 °OªÌ·|²Ä 16/17 ¨â¶ªº®t¶Z¡A³Ì²³æªºµ²½×´N¬O¡y¹ï¥D°Ê§K¬ÌÀøªk¦Ó¨¥¡APFS¨Ã¤£¬OOS¦X²zªº´À¥N«ü¼Ð (surrogate endpoint) ¡C¯E¹©ªºÃÄ®ÄÀ³¸Ón¬ÝOS¦Ó¤£¬OPFS¡CÁöµM§C¤ÏÀ³ªÌªºPFS¤ñ¹ï·Ó²Õ®t¡A¦ý¬OOS»P¹ï·Ó²ÕµL²Îp®t²§¡Aªí¥Ü§C¤ÏÀ³±Ú¸s¨Ã¥¼¦]¬I¥´822¦Ó¨ü®`¡z¡C¦ý¬O¤½¥q¤è±¹ï¦¹«o¤@ª½¤£ÃP¤f¡A¤p§Ì»{¬°¡A¬O¦]¬°¦pªG©ñ±óPFS¥u¬ÝOS¡A¨º822¤T´ÁÁ{§É´Nn°µ«Ü¤[¡A©Ò¥H¤½¥qÁÙ¬O§Æ±æ¯à°÷§ä¨ì§ó¦nªºPD§PŪ¤è¦¡¡AÅý¯àPFS¦¨¬°OSªº¦X²z´À¥N«ü¼Ð¡A¥H¥[³t«á±©Ò¦³Á{§É¸ÕÅ窺±À¶i¡C¬Ý°_¨Ó¤½¥q¹ï¦¹¤w¸g¦³¸¡®×¡A¤p§Ì¿ï¾Ü¬Û«H¡C ¹ï©ó³oÓijÃD¡A pie ¤j±Nì¦]Âk©S©ó¯f¤Hªº¤À²Õ¤è¦¡³oÓÅÞ¿è¡A¤p§Ì¤]Ãø¥H»{¦P¡A¦]¬°¦P¤@Ӿǥͦb¨C¦¸¦Ò¸Õªº¦¨ÁZ¤À¥¬¤W¨ä¹ê¨Ã¤£¬OÀH¾÷ªº¡A¦n¾Ç¥ÍÁöµM¤£¬O¨C¦¸³£³Ì°ª¤À¡A¦ý¬O¬Û¹ï°ª¤Àªº¾÷²v«ùÄò°¾°ª¡A³o¸ò822¹êÅç²Õªº¯f¤H¤@¼Ë¡A°ª§ÜÅé¤ÏÀ³»P§C§ÜÅé¤ÏÀ³¤]¬O«ùÄò©Êªº¡A¤£·|³o¶g¬O°ª¤ÏÀ³¤U¶gÅܦ¨§C¤ÏÀ³¡A¤Ï¤§¥çµM¡C ¦³Ãö822©Ò¿EµoGH-IgGªºªø®Ä©Ê°ÝÃD¡A¤½¥qªºµªÂЫܼҽk¡C¦pªGIgGªºhalf-life¬O¤T©P¥ª¥k¡A¨º¸g¹L¤TÓ¤ë«á³Ñ¾lªºIgG´N¬O 1/16¡A¤»Ó¤ë¤§«á´N·|°¨ì 1/256¡A¤w¸g§C©ó baseline¡C¦ý¬O±q¥´²Ä¤E°w¨ì²Ä24Ó¤ëÆ[¹î´Áµ²§ô¡A¤¤¶¡¸g¹L¤Q¤Ó¤ë¡A¦Ón¦bÆ[¹îµ²§ô®ÉÁÙ¯à¦b¯f¤H¦å²G¤¤§ä¨ì¬Û·íªºGH-IgG¡A¨ºÅãµM¥²¶·¦b²Ä¤E°w¤§«á¯f¤H¨¤WÁÙn«ùÄò²£¥Í·sªºIgG¡C³o¨s³º¬O¥¿±`ªº§K¬Ì¤ÏÀ³ÁÙ¬O¯E¹©¦³¤°»ò¿Wªù¯µ¤è¡A¤½¥q¤£Ä@³zÅS¡A¥u»¡³o¬O°Ó·~¾÷±K¡C¦P¼Ëªº¡A¤p§Ì¿ï¾Ü¬Û«H¡C ¦³Ãö¤E°w¤§«án¤£n¨C¹j´XÓ¤ë¦A¥´¤@°wboosterªº°ÝÃD¡A¬Ý¨Ó¤½¥qªºµªÂЬO¥¿±ªº¡C¦Ü©ón¹j´XӤ르¤@°w¡A¤½¥q»¡¤F¡A¬ÝÁ{§É¼Æ¦r»¡¸Ü¡C©Î³\¤T´ÁÁ{§É¹êÅç©Ò¦³¯f¤Hªº«e¤E°w¬O¬Û¦Pªº®É¶¡ªí¡A¦ý¬O¤E°w¤§«á´N¦A¤À¦¨¤G¨ì¤T²Õ¡A¥]¬A¥´©Î¤£¥´booster¡B´XӤ르¤@¦¸µ¥µ¥¡A¦A¬Ý²Îp®t²§ªºÅãµÛ©Ê¡A¨M©w³Ì²×¥Ó½ÐÃÄÃҥΪºÀøµ{¡C¦h¥´°w·|´£°ªÀøµ{ªº¦¨¥»»P©w»ù¡A¥²¶·¦³¬ÛÀ³ªº§ïµ½®ÄªG¨Ó¤ä«ù¡C 833¬O§Æ±æÂÇ¥ÑDT¤Þµo§ó°ª¼Æ¶qªºGH-IgG¡C³o¦b°Êª«¸ÕÅç¤w¦³¼Æ¾ÚÃÒ©ú¡A´N¬Ý¤HÅé¸ÕÅç¼Æ¾Ú¬O§_¦³¬Û¦PÀu¶Õ¡C·íµM¡A¦w¥þ©ÊÁÙ¬O¤@ÓªùÂe¡A¼Æ¾Ú»¡¸Ü¡C 888ªºµªÂг̥X¤H·Nªí¡C¤H¤H³£¯à°µ888¡A¦ý¬O²Ä¤@n¬Ý½Ö°µ±o§Ö¡A²Ä¤Gn¬Ý½Ö°µ±o³Ì±µªñ¤H·½§ÜÅé¡C²¦³ºGH»â°ì¬O¯E¹©ªº¥D³õ¡A¨ä¥L¤Hn°l»°©Î¬O¶W¶V¦³¨ä§xÃø¡A³o¤]¬O¬°¦ó¯E¹©¥[ºò±À¶i888¡An½T«O¾ÔªG¡C»PÁÞ°ò¤§ª§¡A±i¸³»¡±o«Ü¤j®ð¡A³o¬O¹ê¤Oªº°ÝÃD¡C§¡¬Û¤Æ¬O¤@Ó§Þ³N¡A¦Ó888¬O¤@Ó²£«~¡A¯à¤W¥«ªº¬O²£«~¡A¤£¬O§Þ³N¡C888¤H·½¤Æ¤§«á¯à¦³¤@©wÀø®Ä´N¯à®³ÃÄÃÒ¤W¥«¡A¯à°µ¨ì¤H·½§ÜÅé´N§ó»â¥ý¡A¯à§¡¬Û¤Æ³Ì¦n¡C©Ò¥H§¡¬Û¤Æ§Þ³N¬O good-to-have¡A¤£¬Omust-have¡C¦pªGÁÞ°ò¤ñ¯E¹©§ó§Ö°µ¥X¤H·½¤Æ888¡A¥[¤W§¡¬Û¤Æ§Þ³N¡AÁÙn¦³¯à¤O°õ¦æ¼Ú¬üÁ{§É¸ÕÅç¡A¨º»ò¥¦¸ò¯E¹©´N·|¦¨¬°ª½±µÄvª§ªÌ¡A¯E¹©¥u¯à·Q¿ìªk¸ò¤¤¬ã°|¨ú±o±ÂÅv¦Û¤v¬ãµo¡C¦ýYÁÞ°ò¤£¥´ºâ°µ©Î¬O°µ¤£¥X888¡A¨º»ò¦ó¤£§â§¡¬Û¤Æ§Þ³N±ÂÅvµ¹¯E¹©¡A¹ïÂù¤è³£¦³§Q¡H°Ó³õ¤WªººA¶Õ¡A¦P·~Á`¬O¥ýÄvª§¡AµM«á¬Ý¬Û¹ï¥«³õ¦a¦ì»PÀu¦H¶Õ¤¬¸ÉÃö«Y¡A¦A¨M©w¬O§_¦X§@¡B¦p¦ó¤À§Q¡A¤£·|¦³¤H¤£¥´´N©ñ±óªº¡C½Í¦X¨Ö¤]¬O¤@¼Ë¡AÁ`n¸û¶q¹L¦Ù¦×¤§«á¦A»¡¡A§_«h´Nºâ»¡¤è¦³·NÄ@¡A»ù®æn¦p¦óq¡H©Ò¥H¡A©È¼ö¤£n¶i¼p©Ð¡A¯E¹©¸òÁÞ°ò¤@©w¬O¥ýÄvª§¡A¦X§@»P§_´N¦A»¡¤F¡C ¯E¹©¤U¤@¨BªºÃöÁä¤u§@¬O§ä¦X§@¹Ù¦ñ¡A¬¡°Êªº¥D¶b·|²¾©¹®ü¥~¡C¯E¹©¤]¯uªº¶}©l¨«¦V¼Ú¬üªº¸ê¥»¥«³õ¡B±µÄ²¯u¥~¸ê (·s¥[©Y»P»´äÁöµM¦³¯u¥~¸ê¡A¦ý¤p§ÌÃhºÃ¥L̤£À´¥Í§Þ·~) ¡C¬ü°êªº¥Í§Þ§ë¸ê¤H¸ò¥xÆW¤£¬O¦b¤@Ó¤ô·Ç¤W¡A³\¦h¤H®Ú¥»¦Û¤v´N¸gÀç¹L¥Í§Þ¤½¥q¡B¸òFDA¥´¹L¥æ¹D¡A¥L̰ݪº°ÝÃDªÖ©w¤ñ¯E¤Í̧ó¦y¾U¡A¦ý¤]§óÃѳf¡Cµ¥¥¦Ì¤@Ó¤@Ó¸õ¤W²î¡A¥[»ù¶R¶À¤û²¼¡A¨º´²¤á©Î¹ê¤á (¥]¬A°²¥~¸ê) ¥i´NnÅý¦ì¤F¡C¦pªG¯uªº¦³¤j§ë¸ê¤H¦³¿³½ì¡Aı±o¥«³õ¤W¦¬³f¤£¦Eºâ¡A¤½¥q¤]¥i¥H¿ìADR¡A¤£¨£±o¥u©wµo¦æµ¹µ¦²¤¦X¹Ù¤H»P¼Ú¬ü¹Î¶¤¡C¥xÆWªºªk¤H§ë¸ê¤H³W¼Ò¤Ó¤p¡A¹ï¥Í§Þ»â°ì¤S¨S¦³¸gÅç¡A¥u¦³¯u¥~¸ê¤~¯àÅý¯E¹©ªº»ùȯB²{¡C¨ä¹ê´N³s¹q¤lªÑ¤]¬O¤@¼Ë¡AþÓ¦n¤½¥q¤£¬O¥u³Ñ¥~¸ê¸ò¤jªÑªF¡A´²¤á¹ê¤á³q³q³Q±½¥ú¡H¦U¦ì¨ì®É¬O·Q·íÁÈ¿ú¤U²îªº¶À¤û¡AÁÙ¬O°í«ù§¤¦b²î¤W¾C¹C¥|®ü¡A³£¬OÓ¤Hªº¿ï¾Ü¡C¤p§Ì»{¬°³oӮɶ¡¤@¦~¥ª¥k´N¨ì¤F¡A¤£¥²µ¥¤W¤T¤¦~®³¨ìÃÄÃÒ¤~·|¬Ý¨ì¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/28 ¤W¤È 07:16:43²Ä 2110 ½g¦^À³
|
¶Â³Ç§J¤j §Ú¤ñ¸û¤£¬Ý¦n½×¾Â¥i¥H«ì´_©õ¤é´º¶H pie¤j ±z¥ÎAB¨â¯Zªº²ÎpÁ|¨Ò¨Ó»¡©ú°ª§C§ÜÅé²Õ¦³²Îp»~®t ¨Ã¤£¾A¦X °²³]±ø¥ó ¨â¯Z³Q·í©T©w¤ñ¨Ò ´N¦³¤j°ÝÃD |
|
|
·|û¡G§g10000178 µoªí®É¶¡:2016/6/28 ¤W¤È 06:00:18²Ä 2109 ½g¦^À³
|
pie¤j¨¯W¤F¡A©Ò¥H§C§ÜÅé²ÕªºPFSªí²{¨ä¹ê©M¹ï·Ó²ÕÀ³¸Ó¬O®t¤£¦h¡A ¦ý¥Î¿ù¤H¼Æ¥¢¤§²@Âç®t¤§¤d¨½¡A¯uªºn¤½¥q¤p¤ß¡A«Øij±z¥i¥Hª½±µ±H ¨ì¤½¥qªºµ¡¤f¡A·|¦³¤H¦^À³¡A¤p§Ì¤§«e¤]¦³±H¹L¤@¦¸¡A¥i¦b¤½¥qºô¯¸ ¤W§ä¨ì¤U±ªº³sµ¸¤è¦¡¡C www.obipharma.com/index.aspx?lang=chi&fn=index#CONTACT ©Î info@obipharma.com |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/28 ¤W¤È 02:46:16²Ä 2108 ½g¦^À³
|
¤µ¤ÑªºªÑªF·|¨S¾÷·|°Ñ¥[¡AÁÂÁ¤j®aÀ°¦£¤À¨É¡A¤]µ¹¤½¥q¨I꺪í²{©ç©ç¤â¡C ³Ìªñ·Q¨ì¤@Ó¨Ò¤l¡AÅý¼Æ¦r¨Ó»¡¸Ü¡A¥i¥H¤ñ¸û¦³·P»¡©ú¤§«e´£¹Lªº¤À²Õ³y¦¨ªº²Îp»~®t¡C °²³]¤@©Ò¾Ç®Õ¸Ì¦³A¡BB¨â¯Z¡AA¯Z¤@¶}©l¦³¾Ç¥Í500¤H, B¯Z¤@¶}©l¦³¾Ç¥Í0¤H¡C¨CӾǥͳ£n³q¹L10¦^¦Xªº¦Ò¸Õ¡A¥§¡¨C¦^¦X·|·í±¼8%ªº¾Ç¥Í¡C²Ä1¦^¦X¨ì²Ä6¦^¦Xµ²§ô«á¡AA¯ZÁٳѤUªº¦P¾Ç·|¤À°t10%ªº¤H¼Æ¨ìB¯Z¥h¡C¾ãÓ¦Ò¸Õªº¹Lµ{¤j·§·|¬O³oӼˤl¡G ¦^¦X/¤H¼Æ___A¯Z¶}©l___B¯Z¶}©l___A¯Z³Q·í___B¯Z³Q·í___A¯Z³Ñ¤U___B¯Z³Ñ¤U____AÂàB 0__________________________________________________500________0 1____________450_______50_______36________4________414_______46_______50 2____________373_______87_______30________7________343_______80_______41 3____________309______114_______25________9________284______105_______34 4____________256______133_______20_______11________236______122_______28 5____________212______146_______17_______12________195______134_______24 6____________176______154_______14_______12________162______142_______20 7____________162______142_______13_______11________149______131________0 8____________149______131_______12_______10________137______121________0 9____________137______121_______11_______10________126______111________0 10___________126______111_______10________9________116______102________0 °²³]¾Ç¥ÍÂà¯Z¡Aµ{«×¤£ÅÜ¡A¨C¦^¦X¤@¼Ë¦³5%³Q·í±¼ªº¾÷²v¡C¦pªG§â´¿¸gÂà¨ìB¯Z¥hªº¾Ç¥Í¤À¦¨¤@²Õ¡A§â¤@ª½¯d¦bA¯Zªº¾Ç¥Í¤À¦¨¥t¤@²Õ¡A°µÓ¦s¬¡¤ÀªRªº²Îp¡Apºâ¨â²Õ¤§¶¡³Q·í±¼¾÷²vªº®t²§¡A²z½×¤W¾Ç¥Íªºµ{«×¬O¤@¼Ëªº¡A²Îp¥X¨Ó¨â²Õªºµ²ªGÀ³¸Ó¬O®t¤£¦h¡C¦]¬°¾ãÓ¹Lµ{Á`¦@¦³197ӾǥͱqA¯ZÂà¨ìB¯Z¥h¡A©Ò¥H·í®É¶¡=0®É¡AB¯Z²ÕÃnÀI¤H¼Æ=197¡AA¯Z²ÕÃnÀI¤H¼Æ=303¡Cpºâ¥XªºKM¦±½u¬°¡G _______________________________A¯Z²Õ______________________________B¯Z²Õ ¦^¦X_____ÃnÀI¤H¼Æ__·í±¼¤H¼Æ___KM curve______ÃnÀI¤H¼Æ___·í±¼¤H¼Æ___KM curve 0______________________________100%_______________________________100% 1__________303________36________88%___________197_________4________98% 2__________267________30________78%___________193_________7________94% 3__________237________25________70%___________186_________9________89% 4__________212________20________63%___________177_________11_______83% 5__________192________17________57%___________166_________12_______77% 6__________175________14________52%___________154_________12_______71% 7__________161________13________48%___________142_________11_______66% 8__________148________12________44%___________131_________10_______61% 9__________136________11________40%___________121_________10_______56% 10_________125________10________37%___________111__________9_______51% ¥HKM¦±½u¨Ó¬Ý¡A«Ü©úÅ㪺B¯Zªºªí²{¤ñA¯Z¦n«Ü¦h¡C¦pªG¥hºâPÈ¡AÀ³¸Ó·|»·¤p©ó0.05¡A¨âªÌ¶¡¹F¨ì²Îp¤WªºÅãµÛ®t²§¡C³oÓµ²ªG¬O¤£¬O©M§Ú̪ºª½Ä±¬Û¥Ù¬Þ©O¡H¬°¤°»ò©ú©ú¬O¦P¼Ëµ{«×ªº¾Ç¥Í¡A¥u¬O¤ÀÓ²Õ¡A¨S°µ¨ä¥L¨Æ¡A¦b²Îp¤W´N·|¦³ÅãµÛªº®t²§©O¡H³o´N¬O§Ú·Qªí¹Fªº¤À²Õ³y¦¨ªº²Îp°¾®t¡C ²Îp¤èªk»¡Â²³æÂI´N¬O¤@°ï¥[´î¼°£¡A§â¤@²Õ¼Æ¦r¸ê®Æ¥á¶i¥h¡A¦ÛµM·|±o¨ì¥t¤@²Õ²Îpµ²ªGªº¼Æ¦r¡C¤£½×¸ê®Æ¬O«ç»ò²£¥Íªº¡A³£¥i¥H®³¥h°µ²Îp¹Bºâ¡C¦ý¬OY¤£·íªº¨Ï¥Î¡A¥i¯à·|¨Ï±o²Îpµ²ªGªº¼Æ¦r¡A¥¢¥h¥¦À³¦³ªº·N¸q¡C¦b¤W±ªº¨Ò¤l¤¤¡AA¯Z²Õ©MB¯Z²Õªº¸ê®Æ¡A´N¤£¾A¦X¥ÎKM¦±½u©MPȨÓpºâ¨ä¾Ç¥Íµ{«×ªº®t²§¡C ¤W±ªº¨Ò¤l´N¬O¦b¤ñ³ë³o¦¸ªºÁ{§É¹êÅç¡CA¯Z²Õ¤ñ³ëªº¬O§C§ÜÅé²Õ¡AB¯Z²Õ¤ñ³ëªº¬O°ª§ÜÅé²Õ¡C¨C¤@©P¨â²Õ³£·|¦³¤@©w¤ñ¨Òªº¤HPD¡C¦]¬°§K¬Ì©µ¿ð¤ÏÀ³¡A³Ìªì¥þ³¡ªº¤H³£¬O§C§ÜÅé²Õ¡AºCºCªº¦³¨Ç§C§ÜÅé²Õªº¤H²£¥Í¥X§ÜÅé´N·|Âà¨ì°ª§ÜÅé²Õ¡C³Ì«á§Ú̦A¥Î¡i´¿¸g²£¥Í°ª§ÜÅé¡j¨Ó¤À²Õ¡A¥h°µKM¦±½u©MPȪºpºâ¡A´N·|²£¥Í¤Wzªº²Îp°¾®t¡C¦Ó¦b³oÓ©úÅ㪺²Îp°¾®t¤§¤U¡A§ÚÌ«ÜÃø¦A¥hµû¦ô°ª§ÜÅé²Õ¤¤822¹ïPFSªº°^Äm¡C ¦AÁ|¤@Ó¨Ò¤l¡A¦b¤@Ó©M³o¦¸Á{§É¹êÅç±ø¥ó¬Û¦üªº¨ÅÀù¥½´ÁÁ{§É¹êÅ礤¡A¹êÅç²Õ¥´ªºÃľ¯¬°¡iB¨x¬Ì]¡j¥[cyclophosphamide¡A¹ï·Ó²Õ¥´ªº¬Ocyclophosphamide¡C¤j®aÀ³¸Ó³£¦P·NB¨x¬Ì]©M¨ÅÀùªºªvÀø¬O¨S¦³¬ÛÃö©Êªº¡A©Ò¥H³Ì«á¹êÅç²Õ©M¹ï·Ó²ÕªºPFS KM¦±½uÀ³¸Ó¬Oºòºò¶K¦b¤@°_¡A¨S¦³²Îp¤WªºÅãµÛ®t²§¡C´N¦³ÂI¹³³o¦¸Á{§É¹êÅ窺µ²ªG¡C±µµÛ¡A§Ú̥Ρi´¿¸g²£¥Í°w¹ïB¨x§Ü쪺IgG titer >= 1:160¡j¬°±ø¥ó¨Ó¤À²Õ¡A¤À¦¨°ª§ÜÅé²Õ©M§C§ÜÅé²Õ¡ApºâKM¦±½u¥H¤ÎPÈ¡C´N¦p¦P¤W±Á|ªº¨Ò¤l¡A³o®ÉÔ°ª§ÜÅé²Õ©M§C§ÜÅ骺ªºKM¦±½u´N·|¤À±o«Ü¶}¡A¹F¨ì²Îp¤WªºÅãµÛ®t²§¡C°ª§ÜÅé²Õ©M¹ï·Ó²Õ¤ñ¸û¡A¤]¥i¥H¹F¨ì²Îp¤WªºÅãµÛ®t²§¡C±µµÛ§Ú̦ü¥G¥i¥H |
|
|
·|û¡G¶Â³Ç§J10142064 µoªí®É¶¡:2016/6/28 ¤W¤È 12:07:32²Ä 2107 ½g¦^À³
|
¯E§J¤j ¦w¦n ¤p§Ìı±o¤@©w·|¦³ªº !! ¥un¦³§A̳o¨Ç°ísªº¤¸¦Ñ«e½ú¦b , ¬Û«H¤õºØ¤£·|º¶ªº ~~ ¥u¬O¦³¤HÁÙ¦b¥ð¾i¥Í®§ , ¦³¤HÁÙ¦bÅCÃܤ£«e .. µ¥¤ßÅ]°¥ñ«á §Æ±æ¤§¥ú¤@©w·|¦A«×°Á{ªº ~~ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/27 ¤U¤È 11:05:49²Ä 2106 ½g¦^À³
|
¢ß¢ß¤j¡@¤p§Ì·PÁ±z¥N¬°´£°Ý ¸ò±z¤À¨É¤µ¤Ñ¾ã²z¤ß±o¡@¨Ñ°Ñ drive.google.com/file/d/0B6poLqRh-kUHdTc0Q1EtUXpNVms/view?usp=sharing §Æ±æ³o½×¾ÂÁÙ¦³¥H«e¤¬¬Û¯¡Är¡@¥O¤H¯dÅʪº®ð®§ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/27 ¤U¤È 11:02:48²Ä 2105 ½g¦^À³
|
QQ¤j¡A ÁÂÁ±z¡I ¤p§Ì¤ß¤¤¤w¸g¦³Ó©³¤F ¦³¨S¦³¦^µª¨ì§Úªº°ÝÃD ¨S¦³¼vÅT ·PÁ¡I |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/27 ¤U¤È 07:30:10²Ä 2104 ½g¦^À³
|
¦U¦ì¤j¤j¡A ¤p§Ìªñ¤é©Ò´£ªº°ÝÃD¡A¤µ¤é´X¥G³£±o¨ì¤½¥qµªÂÐ (ÁöµM¥¼¥²µª±o«Ü²M·¡)¡CµL½×¬Oþ¦ì¤j¤j¥N¬°´£°Ý¡A¤p§Ì«ôÁ¦U¦ì¯E¤Íªº¬Û§U¬Û®¼¤§±¡¡I |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/27 ¤U¤È 02:56:05²Ä 2103 ½g¦^À³
|
¤p©_¤j, ¦Ñ´¤j, ¯E§J¤j: ±z̪º´£°Ý§Ú³£¦b·|«e¦¬°Ý¨÷³æ®É´£¥X, ¥i±¤¤µ¤Ñ¤½¥q¹ï©Ò¦³¦³Ãö¼Æ¦rªº°ÝÃD ´X¥G¥þ¨S¦³¦^µª. ¦³»¡±N¨Ó·|¦b¤£¦PªºÂåÀø·|ij¶°´Á¥Z¤W»¡¥X, ·|¦b¾A·í®É¾÷±N¼Æ¦r»¡²M·¡. ½T»{¦³NEDªº¤H, ¦ý¤H¼Æ¤£³zÅS. NEDªº¤H¤¤¦³¤T³±©Êªº±wªÌ. ¯u©êºp, ¨S¯àÀ°¤W¦£. |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/27 ¤U¤È 12:49:43²Ä 2102 ½g¦^À³
|
tw.stock.yahoo.com/news_content/url/d/a/20160627/ÓªÑ-¯E¹©-4174-»PÁÞ°ò¦X¨Ö-¸³¨Æªø±i©À·Oªí¥Ü-041329674.html ªGµM¬O³o¼Ë ¯u¦³·N«ä |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/6/27 ¤W¤È 12:16:16²Ä 2101 ½g¦^À³
|
NED ªº¤H¼Æ¬O¤µ¤éªº«ÂI |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/26 ¤U¤È 10:12:09²Ä 2100 ½g¦^À³
|
§Æ±æ©ú¤Ñ¯à¥hªÑªF·|ªºªO¤Í¯à°Ý¤@¨Ç±M§Qªº¨Æ±¡ |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/26 ¤U¤È 09:53:18²Ä 2099 ½g¦^À³
|
¥Ó¤j»¡ªº¦n §Úı±o¤w¸g¦³¤Ó¦h«½ÆªºªF¦è¤F ©Ò¥H....¹ï¥xÆW¨Ó»¡ ¤£¦n ¹³¥x¿n¹q¸òÁp¹q ¹³¤U±»¡ªºglycan array ÁÞ°ò¤£¤]¦³¶Ü? |
|
|
·|û¡Gming10140949 µoªí®É¶¡:2016/6/26 ¤U¤È 09:40:26²Ä 2098 ½g¦^À³
|
Ó¤H¤§«e¤]°lÂܹL¤¤¤Ñ¸ò¦X¤@,¦ý°l¤F¤@¬q®É¶¡«á, ı±o¤¨¸ò¸ô·|¨«¨ì¤À¹D¤£¬O¨Sì¦], ¤@Ó¯uªº¦b§@¨Æ,¤@Ó¯uªº¯B¸Ø, ¬Ý¤§«e·s»D´N¯à²¤ª¾¤@¤G, ©Ò¥H§â¸ôªºªÑ²¼¥þ¥X¤F |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/6/26 ¤U¤È 09:22:50²Ä 2097 ½g¦^À³
|
ÁÂÁÂ¥Ó¤jªºz»¡¡A«Ü¦³·N«ä¡AÄv¦XÃö«Y¼vÅT¥¼¨Óµo®i¡AȱoÃöª`¡C ÁÞ°ò¥ÍÂå¡A¤µ¦~¤¤ë§C½Õ´«¸³¨Æªø¡A¸ô¤U¥x¡A¥H²ÓM¥Íª«¾Ç±Mªøªº®È¬ü±M®a³¯¨}³Õ±µ¥ô¸³¨Æªø¡C¦³¤@»¡¬O¸ô¥D°Ê§ä³¯¨ÓÀ°¦£¡C¦ý³¯¦ü¥G¬O¤½¦Ð¥ý¥Í¥H¤Î±i©À·O¥S§ÌªºÂÂÃѦѦP¨Æ¡CÁÞ°ò»P¯E¹©¡A¸ô»P¤¨¡A¨}©ÊÄvª§©Î´c°«¡H¥H¤½¦Ð©M¤¤¬ã°|ªº¥ß³õ¡A·Q¹³À³¸Ó¯à«P¶iÂù¤è¦X§@¡C¡H¡H |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/26 ¤U¤È 08:26:56²Ä 2096 ½g¦^À³
|
¼íx©M¤¤x¶°¹Î¦b¥Í§Þ§G§½¦b³o´X¦~¤w¤À¹D´Åß¡A¼íx©M¥Ãx¶°¹Î¥ç¬O¡C ¼íx¤H°¨ºM¥X¤¤x¤l¤½¥q¬ux¡A¦Ó¤¤x¤l¤½¥q¥X²M¯E¹©¡A¥Ãx¤]¥X²M¯E¹©¡A¼íx¤]°h¥X¥Ãxª÷±±¡C Æpx¥Í§Þ±±ªÑº¥º¥¬°¸ô©Ò´x±±¡A¼íx¤]¥¢¥h¹ïÁÞ°ò´x±±ªº¯à¤O¡A¦]¦¹¤¨¤S¥t°_¥Í§Þ±±ªÑ¤½¥q¡C ¤T¤À¤Ñ¤U¦ü¥G¤w¦¨©w§½¡C ¹x¥Û¤j»¡ªº¨S¿ù¡A¯E¹©©MÁÞ°ò³o¨â®a¤½¥q¶¡·íµM¬OÄvª§Ãö«Y¡C¤£ª¾¦U¦ìÁÙ°O±o³o«h·s»D¶Ü¡H ¸ô»¡¡A¤§«e¤w¸g¼á²M¦Û¤v¤Î®aÄݱq¥¼ª½±µ©Î¶¡±µ«ù¦³¯E¹©ªÑ²¼¡A¨Ã¥Bªí¥Ü¤£·|¥h¤¶¤J¤@®aÁ{§É¥¢±Ñªº¤½¥q news.ltn.com.tw/news/business/paper/993612 ª`·N¥ÎÃã¤@®aÁ{§É¥¢±Ñªº¤½¥q¡A¸ô¤w¸g¤Uµ²½×¡C ¸Ü»¡ªº¦hÅS°©¡A¥u®t¨S¦³¦RX¤ô¤F¡I ¤T¤À¤Ñ¤U¬O¦p¦¹ªº®ù·Æ¤À©ú¡A¥xÆW¥Í§Þ·~n¾ã¦X¬O¤£¥i¯àªº¨Æ¤F¡A ±N¨Ó¥u¦³¬Ý½Öªº®±ÀY¤j¤F¡I½Ö¦Y½Ö¡H½Ö¥ý¼µ¤£¤U¥h¡H |
|
|
·|û¡G¤p·s10141589 µoªí®É¶¡:2016/6/26 ¤U¤È 08:04:26²Ä 2095 ½g¦^À³
|
ÁÙ¦³¥Ø«e¦×¬r±ìµß©MÁÞ´¹¤ùªº¶i«×,©ú¤ÑªÑªF·|ªº¥i¥H°Ý¤½¥q¬Ý¬Ý |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2016/6/26 ¤U¤È 07:57:47²Ä 2094 ½g¦^À³
|
¤j¤j¡AªÑªF·|n´£°Ý¡A¤×¨ä¸òÁ{§É¦³Ãöªº¼Æ¾Ú¡A·|«e¼Æ¤Ñ´£¥X¡A¾¨¥i¯àµ¹¤½¥q¦³¹w¥ý·Ç³Æ®É¶¡¡A³o¼Ë¤½¥q¦^µª¸û¯à§¹¾ã¨Ç¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2016/6/26 ¤U¤È 07:31:45²Ä 2093 ½g¦^À³
|
¦U¦ì¤j¤j ¤p§ÌµLªk°Ñ¥[ªÑªF·|¡A¥i§_¥N¤p§Ì´£°Ý¡H 1.¥¼PD¤H¼Æ¬ù78¤H¡]¦Ü104.10.PD¬ù233+DROP OUT37¡AÀ³¥]§t¹êÅç²Õ¤Î¹ï·Ó²Õ¡^¡C©Ò¿×¡Ö160°ª§Ü±Ú¸s¬O³o78¤H¸Ì¦û´X¤H¡H³o78¤H¸Ì±¬O¦h¤Ö¤H¦³¸g¶Pº¸»XÀøªk¡H 2.©Ò¿×¡u¦³§ÜÅé´N¦³Àø®Ä¡v¤§»¡ªk¡A¹ï©ó°ª§Ü²Õ122¤H¤¤²zÀ³¨ãÀø®Ä¡A¸ÕÅç³£ÁÙ¤£¨ì5¦~«ç·|µo¥Í21¤H¦º¤`¡H ¥H¤W¨â°ÝÃD¥i¯à¦³³\¦h¯E¤Í»P¤p§Ì¤@¼Ë§x´b |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/26 ¤U¤È 04:59:28²Ä 2092 ½g¦^À³
|
³on¥ý¬Ý¤¤¬ã°|ªº±M§Q±ÂÅv¬O±MÄÝÁÙ¬O«D±MÄÝ¡B¯E¹©¦³µL¨ú±o±ÂÅv¡A¥H¤ÎÁÞ°òªº¬ÛÃö±M§Q¬O°ò¦ÁÙ¬O©µ¦ù±M§Q¡C °Ó³õ¤W¨â®a¤½¥q¶¡·íµM¬OÄvª§Ãö«Y¡A¤Z¨Æn·Ó³W¯x¨Ó¡C¼í®õ¦bÁÞ°ò¥u¦³¤@®u¸³¨Æ¡AÁÞ°ò¨ä¥LªºªÑªF»P¸³¨Æ¤£·|¤¹³\¯E¹©«I¥Ç¥¦ªº±M§Q¡C¯E¹©¯à¹ï¥~ÁnºÙn¨Ï¥Î³oÓ§¡¬Û¤Æ§Þ³N¡A·íµM¤£·|¦³±M§Q«IÅvªº°ÝÃD¡C©ú¤ÑªÑªF·|°Ý²M·¡´N¦n¡A¤£¥²²{¦b²q´ú¡C |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/26 ¤W¤È 11:41:26²Ä 2091 ½g¦^À³
|
·íµM§Æ±æ¬O©¼¦¹¦X§@Åo ¤£§Æ±æ¬Ý¨ì±N¨Ó¨â¶¡¤½¥q¥Î±M§Q¤¬¥´ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/26 ¤W¤È 11:20:32²Ä 2090 ½g¦^À³
|
1Faith ¤j¶K¤å²Ä¤GÂI´£¨ì¯E¹©¤w©w¥X¾A¦Xµo®iªº§ÜÅéµ²ºc¡A¨Ã¤w´£¥X±M§Q¥Ó½Ð¡C 2¦A¾\Ū¤¤¬ã°|2016¦~3¤ë8¤é°ò¦]Å餤¤ß¦³§¡¬Û¤Æ§ÜÅ骺¸ê°T(Æ[©À)¡A´£¨ìµ²ºc¡A¯E¹©¤w©w¥X¾A¦Xµo®iªº§ÜÅéµ²ºc»P§¡¬Û¤Æ¥²µM¦³Ãö¡A§Öªº¸Ü¦~©³©Î©ú¤Ñ²Ä¤@©u¦³¾÷·|¶i¤JÁ{§É¶¥¬q¡C 3´N³æ§Ü¦Ó¨¥¯E¹©»PÁÞ°ò¬OÄvª§Ãö«Y¡A§¡¬Û¤Æ¤£¬O¥u¦³ÁÞ°ò¤~¯à¬ãµo¡A¥t¥~ÁÞ¤À¤lÀù¯g·sÃįE¹©¬O»â¥ý¥þ²y¡AÁÞ°ò«ÜÃø±æ¨ä¶µI¡C |
|
|
·|û¡G¤p²ø10140417 µoªí®É¶¡:2016/6/26 ¤W¤È 10:57:18²Ä 2089 ½g¦^À³
|
¼í®õ¶°¹Î¤]¦³Âà§ë¸êÁÞ°ò¡A¦b¤jªÑªF¥X±¤U¡A¤]³\¤£¬O°ÝÃD»¡¡I |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/26 ¤W¤È 10:20:54²Ä 2088 ½g¦^À³
|
§ÜÅéÁÞ¤À¤l§¡¬Û¤Æ¤£¬OÁÞ°òªº±M§Q¶Ü |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/26 ¤W¤È 10:17:06²Ä 2087 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j ¦p¦¹¹ªÀy¦U¦ì¯E¤Í |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/26 ¤W¤È 08:15:38²Ä 2086 ½g¦^À³
|
D¥þ²yÃÄ«~¥«³õ¶W¹L¤@¥ü¬ü¤¸¡AÀù¯g¬ãµoÃĪ«60%ÄÝ©ó³æ§ÜÃĪ«¡A³æ§ÜÃĪ«¬OÄÝ©ó¤j¤À¤lªº³J¥Õ½èÃÄ¡A«~½è¯Â«×¤£©ö´x±±¡A§¡¬Û¤Æ¥Øªº¦b¨Ï§ÜÅ鬡©Ê¹F¨ì³Ì¨Î¤Æ¡A2014¦~¤Q¤jºZ¾PÃĦ³6Áû¬OÄÝ©ó³æ§ÜÃĪ«¡A2016¦~¦]¦³C¨xÃĪ«²§x¬ð°_¡A§_«h¤Q¤jÃĪ«¤]±N³Q³æ§ÜÃĪ«©Ò¥]¿ì¡C ¯E¹©¿W¦Û¬ãµoªºOBI888¦b©µÅó¿à³Õµ¥Àu¨q¤H¤~¥[¤J¬ãµo«á¥¼¨ÓªºÄvª§¤O´£¤É¤£¤Ö¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/26 ¤W¤È 07:39:43²Ä 2085 ½g¦^À³
|
Faith ¤j ÁÂÁ§Aªá®É¶¡¾ã²z¥X888«n¸ê°T!ÆgÆgÆg!!! 1¯E¹©ªºÁÞ¤À¤l·sÃĬO¤HÃþ¾ú¥v¤W²Ä¤@¦¸«¤jªºµo²{¡Aµo²{Àù²ÓM¤WªºGlobo-H¨t¦CÁÞ¥i¥H·í¼Ð¹v¡A¤£¶Ë¤Î¥¿±`²ÓM¡A³o¬O¤@Áû¶}³Ð·s§½ªºÃĪ«¡A¤]¬O¤@Áûº¡¨¬¥¼³Qº¡¨¬ÂåÀø»Ý¨Dªº±Ï©RÃĪ« 2¥xÆW¤T´ÁÁ{§É¼Æ¾Ú¥[³t¤F¯E¹©¹ïOBI888ªº¬ãµo»P±j¤j¥ø¹Ï¤ß¡A²z¥Ñ¦p¤U A ¾÷¨î»P¼Ð¹v¬Û¦P¡A¯à²£¥Í¨¬°÷§ÜÅé´N·|¦³Àø®Ä¡A888ÄÝ©ó³æ§ÜÃĪ«¡A¤@©w·|«Ü§Ö²£¥Í§ÜÅé B ³æ§Ü§¡¬Û¤Æ«á¨Ï±oÃĮĴ£¤É¡A°Æ§@¥Î°§C C ³æ§ÜÃĪ«¥Ø«e¤´µM¬OÀù¯gÃĪ«ªº¤j©v¡A¨Ï¥Î½d³ò«Ü¼s¡A¯S§O¬O¥«³õ«Ü¤jªº¦ÛÅé§K¬Ì¯e¯f |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/24 ¤W¤È 08:06:56²Ä 2084 ½g¦^À³
|
ªm¤j¡A ±zª½±µ»¡n¤p§Ì¥h¦~³ø¸Ì§ä¸ê®Æ´N¦n¤F¡A¤£´±³Ò±zªá²´¤O¥´¦r¡C¤p§Ì¸o¹L¡I Cliff¤j¡A ¦hÁ±zªº»¡©ú¡C³o¬O®Ú¥»°ÝÃD¡C¿ïÄâ±a³J¥Õ¡A¤£¥u¬Ýupside¡A¤]¦Ò¼{downside¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2016/6/24 ¤W¤È 07:26:04²Ä 2083 ½g¦^À³
|
¹x¥Û¤j 888¥Ø«e¶i«×¨Ñ°Ñ~¶¼Æ¬°104¦~¦~³ø¤W¤èPDFÀɶ¼Æ 1. p5~³Ì¥O¤H´Á«Ýªº¬O¡A±qOBI-822 Á{§É¸ÕÅç©ÒÀò±oªº·§©À©ÊÅçÃÒ±oª¾¯f¤HÁÞ§ÜÅ骺²£¥Í©M§Ü¸~½F¤ÏÀ³¦³«D±`±jªº¥¿ÃöÁp©Ê¡A¦]¦¹¥xÆW¯E¹©±N¥þ¤Oµo®i³æ®è§ÜÅéOBI-888¡A´£¨Ñ³Q°Ê§K¬ÌÀøªk¡A³yºÖµLªk¹ïÁÞ¬Ì]²£¥Í§ÜÅé¤ÏÀ³ªº¯f±w¡C 2. p73~OBI-888 Globo H ³Q°Ê¦¡Àù¯g§K¬ÌÀøªk¡G³æ®è§ÜÅé¥Ø«e¤´¬°Àù¯gªvÀø³Ì¦h¨Ï¥Îªº¼Ð¹v¼Ð¹v§K¬ÌÀøªk¡AOBI-888 ¬O°w¹ïGlobo H ¬°¼Ðªº³] pªº³Q°Ê¦¡§K¬ÌÀøªk³æ®è§ÜÅé¡C¥xÆW¯E¹©¤w©w¥X¾A¦Xµo®iªºÃĪ«ªº §ÜÅéµ²ºc§Ç¦C¡A¨Ã¤w´£¥X±M§Q¥Ó½Ð¡CºI¦Ü105 ¦~4 ¤ë©³¡A¤w§¹¦¨µU¤l ªº³æ¤@¾¯¶q¬r©Ê¸ÕÅç¡A¨Ã¥¼µo²{¥ô¦óÁ{§É¯gª¬¡F¨Ã¤w¿ï¥X°ª²£¶qªº §ÜÅé²ÓM®è¡A¥¿¦b¶i¦æ¶q²£¤¤¡C¥¼¨Ó·|¶i¦æµU¤l»P¤j¹«ªº«½Æ¾¯¶q¬r©Ê¸ÕÅç¡A¶i¤@¨Bµû¦ô 2.p89~OBI-888 ªº¦w¥þ©Ê¡CºI¦Ü105 ¦~3 ¤ë©³¡A¤w¿ï¥X°ª²£¶qªº§ÜÅé²ÓM®è¡A¨Ã¶i¦æ¶q²£¡A¶i«×²Å¦Xpµe®Éµ{¡F¨Ã¤]¤w¸g°w¹ï°ê¤º¥~¦X®æ¼t°Ó¶i ¦æ¦¨«~ÃÄ¥R¶ñ¤u¼tµû¦ô¡C 3.p89~¥t¥~¥»¤½¥q¥ç¦³OBI-888 ¬ãµo¤¤ ³Q°Ê¦¡³æ®è§ÜÅé§K¬ÌÀøªk¡A³£¬O°w¹ïGlobo ¨t¦CÁÞ¦bÀù¤Æ²ÓM¤Wªº ¯S®í©Ê¡C¥Ø«e³Ì·sªº¬ã¨s«ü¥X¡A°ª¹F14 ºØ¥H¤WªºÀù²ÓMªí±¤Wªí ²{Globo ¨t¦CÁÞ¡A¦]¦¹¦¹ÃþÀøªk¹ïÀù²ÓM¨ã¦³°ª±M¤@©Ê¡BªvÀø¦w¥þ ©ÊªºÀu¶Õ¡A¥H¤ÎÃe¤jÀ³¥Î½d³òªº¼ç¤O¡C¯E¹©pµe¤¤ªº²£«~¡A±N¶}µo Globo ¨t¦C²£«~¦Ü¨ÅÀù¡B¤j¸zÀù¡B¯ØŦÀù¡BªÍÀù¡BGÀùµ¥ÃøªvÀù¯g ¤¤¡A´Á´£¨ÑÀù¯g¯f¤H¸û²{¦æÃĪ«§ó¦w¥þ¦³®Äªº¿ï¾Ü¡C 4. p126~Àù¯gÁÞÃþ³æ®è§ÜÅé(OBI-888) OBI-888 ¬O¥»¤½¥q¥þ·s¶}µoªº²£«~pµe¡A¤]¬O°w¹ïGlobo ¨t¦CÁÞ¬°§Üì¡A ©Òµo®iªº³Q°Ê§K¬ÌÀøªk·sÃÄ¡F¥¼¨Ó±µ¨ü¥D°Ê§K¬ÌÀøªk®ÄªG¤£¦nªº¯f±w¡A¥i ¦A¬I¤©³æ®è§ÜÅéOBI-888¡A¥H¸É¥D°Ê§K¬ÌÀøªk¤§¤£¨¬¡A¹F¨ì¥þ¤è¦ì§ÜÀù¥Ø ªº¡F¥Ø«e OBI-888 ¤w¶i¤JÁ{§É«e¸ÕÅ綥¬q¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/24 ¤W¤È 01:09:04²Ä 2082 ½g¦^À³
|
¹x¥Û¤j¡A¡u±Ä¥Î DT ¨ú¥N KLH °µ³sµ²³J¥Õ¡A¥Ø¼Ð¨s³º¬O©µªø§K¬Ì´Á¶¡¡AÁÙ¬O´£°ª§K¬Ì¤ÏÀ³¤ñ²v¡H¡v³oÓ°ÝÃDªº½T»Ýn¥Ñ¤½¥q¨Ó¦^µª¡C ¤£¹L¡AÓ¤Hı±oÁÙ¦³¥H¤U¦Ò¶qªº¦]¯À¡G ºK¿ý¡u2015/9/28 ¤U¤È09:18:04 ²Ä 423 ½g¦^À³¡F¥»ª©page 9¡v °Ñ¦Ò¤åÄm¡G¡uA fully synthetic self-adjuvanting globo H-Based vaccine elicited strong T cell-mediated antitumor immunity¡v 2015/09/25¡]pubs.rsc.org/en/content/articlepdf/2015/sc/c5sc01402f ¡^¡v ¡u822ªº¯ÊÂI¡G¡]¤w¿Ä¦X¥»¤å¤º®e¤ÎÓ¤H·N¨£¡^ 1. °Êª«¹êÅ礤©Ò²£¥ÍªºIgM»·¦h©óIgG¡A¦Ó¥B²£¥ÍªºÂøÂø§ÜÅé¦h¡]²£¥Í¸û¦h¤£¬O°w¹ïGHªº§ÜÅé¡A¥]¬A§ÜKLH§ÜÅéµ¥¡^¡F¤HÅ骺³¡¤À¸Ô²Óªºnµ¥¸Ñª¼«á¤ÀªR¡C 2.¡]²¤¡^ 3. GH»PKLH±µ¦X«×¤£¬O«Üéw¡C¡]³o¥i¯à¬OIriswu¤j©Ò»¡ªºÅܲ§©Êªº°ÝÃD¡^¡A¦b³o¤@½g¤å³¹¤¤´£¨ìªº¬O¡udifficult quality control¡v¡B¡udifficulties in control of conjugate quality¡v¡CKLH¤À¤l¶q¤j¡A±i¸³»¡¹L¨C¤@ÓKLH¥i¥H±µ¤W1500±øGH¡A§Ú²q·Q¡A¥i¯à¾ÉP¦³¨ÇKLH¤W±µ¦X¤F1500±øGH¡A¦³¨ÇKLH¤W±µ¦X¤F´X¦Ê±øGH¦Ó¤w¡A³o¥i¬O·|¼vÅT822ÃĮġA¦b«áÄòªºCMC¤è±¦p¦óµo®iȱoÃöª`¡]¥Ó½ÐÃÄÃÒ®Én³q¹LÃĪ«³sÄò¤T§å¦¸½T®Ä¼f®Ö¡^¡C ¸É¥R¤Wzªº²Ä¤@ÂI¡A¤å¤¤Á|¥X¶q¤Æ¼Æ¦r·í°Ñ¦Ò¡G 822¥i»¤µo²£¥Í§ÜGH§ÜÅé¿@«×23177³æ¦ì¡A§ÜKLH§ÜÅé293919³æ¦ì¡]12.7¿¤§¦h¡^¡]«È¤ñ¥D±j¡^¡F GH-MPLA¥i»¤µo²£¥Í§ÜGH§ÜÅé¿@«×63038³æ¦ì¡A§ÜMPLA§ÜÅé59666³æ¦ì¡]¥D«È¥¼©ö¦ì¡^¡C §Ú·Q³o¥i¯à¬O833»P°|ªøª©ªº²Õ¦X¤£¦A¦Ò¼{¥HKLH¬°Äâ±a³J¥Õªºì¦]¤§¤@§a¡H¡v ºK¿ý¡u2015/10/27 ¤U¤È 12:10:14²Ä 473 ½g¦^À³ ¥»ª©page 9¡v 2011¦~¤@¥÷°|ªø¼gªº¡uToward Automated Oligosaccharides synthesis¡vªº¤åÄm¤¤¡]onlinelibrary.wiley.com/doi/10.1002/anie.201100125/full ¡^¡A¡u7.3.1.1. Globo H¡v¸`¤´´£¨ì¡G ¡uAlthough there are several successful examples, some limitations of semisynthetic conjugate vaccines remain. First,the carbohydrate density achieved on protein glycoconjugates is highly variable. Thus,the resulting batch to batch variations may influence the clinical evaluation and vaccine efficacy. Moreover, the production of irrelevant antibodies against the carrier protein or linker may lead to carrier-induced epitopic suppression.¡v¡C §Úªº¸ÑŪ¡G ¡u¦ý³o¨Ç¹ï§ÜÄâ±a³J¥Õªº§ÜÅé¦b¦X¦¨ªºÁÞ§Üì²Õ¦X¤¤¡A¤´·|³y¦¨ÁÞ§Üì»PÄâ±a³J¥Õ¤§¶¡ªº¥iÁäµ²§Üì¹ï¦ì¼Æ¥Ø¡]epitope¡^°§C¡]µù¡^¡Aªø»·¤§p´N¬O´«±¼KLH¡A©Ò¥H¥i¯à°ò©ó³o¼Ëªº¦Ò¶q¡A¦b833´N§ï¥ÎDT-CRM197¬°Äâ±a³J¥Õ¡C¡v µù¡G¡uCarrier-induced epitopic suppression, a major issue for future synthetic vaccines.¡v¡]www.ncbi.nlm.nih.gov/pubmed/2411793 ¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/24 ¤W¤È 12:07:49²Ä 2081 ½g¦^À³
|
IgM§ÜÅéºû«ù®É¶¡¬O4-6¶g IgG§ÜÅéºû«ù®É¶¡¬O3-6Ó¤ë ¥xÆW¯E¹©¬ãµo¹Î¶¤¬O¯«¤H¹Î¶¤¡A¨ì©³¥Î¦óºØ¤èªk»P§Þ³N½Âà¹L¥hªº»{ª¾¡AÅܦ¨¥H¦~¬°³æ¦ìpºâ¡A¨ì©³¬O¦h¤Ö¦~?¤E°w«á¤£¦A¥´¥i¼µ¦h¤[? ¤E°w«á¦A¨C¹jX¤ë¸É¥´¤@°w¯à§_¼WªøÁ`¦s¬¡´Á? ¦pªG¥i¥HÀ³Ä~Äò¸É¥´¥H©µªø¯f±w¥Í©R¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/23 ¤U¤È 11:54:40²Ä 2080 ½g¦^À³
|
²³¤j¡A ¨Ì·Ó¤U±³o¤@½g¤¶²Ð¡AIgGªº¥b°I´Á¥u¦³¤£¨ì¤@Ó¤ë¡C en.wikipedia.org/wiki/Immunoglobulin_G ©Ò¥H¤p§Ì¦³¦p¤U°ÝÃD¡CY¯E¤Į́S¦³©ú½Tµª®×¡A·Q½Ðþ¦ì¤è«K¦bªÑªF·|®É¦V¤½¥q½T»{¡A¤Uz´yz¬O§_¥¿½T¡G 1. 822¬O±Ð¨|§K¬Ì¨t²Î¡A¨Ï±o§K¬Ì¨t²Î¦bµo²{GHÁÞ§Üì®É²£¥ÍIgG²y³J¥Õ¡C§K¬Ì¨t²Îªº°O¾Ð¤O¥i¥Hªø¹F¼Æ¦~¡A¦]¦¹ÁöµMIgGªº¥b°I´Á¤£¨ì¤@Ó¤ë¡A¦ý¬O¦]¬°«ùÄò¦³·sªºIgG¦b¸É¥R¡A©Ò¥H¥i¥H«ùÄò§í¨îÀù²ÓM®i¡C³o¬O¥D°Ê§K¬ÌªºÀu¶Õ¡C ³Q°Ê§K¬Ì©Òª`¤Jªº§ÜÅé(µL½×¬O³æ®è§ÜÅéÁÙ¬O§K¬Ì²y³J¥Õ)ªº¿@«×¥²¶·§ó°ª¡A¤~¯à§JªA¥b°I´Áªº°ÝÃD¡A¦³¥i¯à¾ÉP§ó°ªªº°Æ§@¥Î¡C 2. ¤S¡A888¬O³æ®è§ÜÅé¶Ü¡H¦³¨S¦³pµe¦ó®É¶i¤JÁ{§É¡H 3. 833ªº¥Dn¥Øªº¬O©µªø§K¬Ì®É¶¡¡AÁÙ¬O´£°ª§K¬Ì¤ÏÀ³ªº¤ñ¨Ò¡AÁÙ¬O§ó§Ö³t¿Eµo§K¬Ì¤ÏÀ³¡H ¦hÁ¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/23 ¤U¤È 11:44:37²Ä 2079 ½g¦^À³
|
±qK-M¦s¬¡¦±½u¹w¦ôIgG/IgM§ÜÅé¤ÏÀ³²Ö¿n¾÷²v(§ë¼v¤ù15:¯S©w®É¶¡ÂIIgG/IgM§ÜÅé®Ä»ù >=1:160)µo²{§ÜÅéºû«ù®É¶¡¬O¥H¦~¬°³æ¦ìpºâ¡Aºû«ù¤@¦~¬O¥H¦~¬°³æ¦ìpºâ¡A¨â¦~¤]¬O¥H¦~¬°³æ¦ìpºâ¡A¤T¦~¤]¬O¥H¦~¬°³æ¦ìpºâ¡A²³¤j¤j¤@©w«Ü·Qª¾¹D¨ì©³³o¨âºØ§ÜÅé¡A¯S§O¬OIgG§ÜÅé¨ì©³¥i¥H¼µ¦h¤[«á¶}©l¤U°? ¯E¹©¬ãµo¹Î¶¤¬O¥Î¤°»ò¤èªk°µ¥X¨Óªº?ªÑªF¤j·|´N·|¦³µª®× |
|
|
·|û¡G¶À§õ10141253 µoªí®É¶¡:2016/6/23 ¤U¤È 04:33:32²Ä 2078 ½g¦^À³
|
°O±o3¤ëªº»¡©ú·|¦³»¡¨ì§ÜÅ骺¦³®Ä´Á¶¡¬O¥H¦~pªº |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/23 ¤U¤È 03:47:48²Ä 2077 ½g¦^À³
|
©Ó¤Ñ¤j¡A ±Ä¥Î DT ¨ú¥N KLH °µ³sµ²³J¥Õ¡A¥Ø¼Ð¨s³º¬O©µªø§K¬Ì´Á¶¡¡AÁÙ¬O´£°ª§K¬Ì¤ÏÀ³¤ñ²v¡H©Î³\ªÑªF·|®É¥i¥H°Ý¤@¤U¤½¥q¡C |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/6/23 ¤U¤È 03:02:57²Ä 2076 ½g¦^À³
|
·N«ä´N¬O»¡¡A²{¦bªº822´N¬O¤@±ø¤û¥i¥Hé¦n´X¦¸¥ÖÅo! |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/23 ¤U¤È 02:07:39²Ä 2075 ½g¦^À³
|
´N¬O³o¼Ë©Ò¥H¤~n833 822¬O¥ýproof of concept |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/23 ¤U¤È 01:58:39²Ä 2074 ½g¦^À³
|
¯E¹©¬ãµo¹Î¶¤¬Û·í§V¤O¤]Àò±oÀu²§ªº¦¨ªG¨ÓÄAÂЪѪF¥H©¹ªº»{ª¾¡A»¡¤£©w¯E¹©¬ãµoªº¤U¤@¥NÀù¯g¬Ì]©Ò²£¥ÍªºIgG§ÜÅé«ùÄò®É¶¡¬O¥H¤T¦Ü¤¦~¬°³æ¦ì¨Ópºâªº¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/23 ¤U¤È 01:42:44²Ä 2073 ½g¦^À³
|
¥H¤W¨â¤jÃöÁä°ÝÃD¦pªG¦b27¤éªÑªF¤j·|Àò±o¥¿±¦^µª¡A³o³õÁɧ½´N¤w¸gµ²§ô¤F¡A´NÅé²G§K¬Ì©Ò²£¥ÍªºIgM,IgG³o¨âºØ§ÜÅé¦Ó¨¥¡A³o¦¸Á{§É¸ÕÅ窺µ²ªGÄAÂФF¥H©¹ªº¨â¤j»{ª¾: 1 OBI822¥HIgM§ÜÅ鬰¥D¡AIgG§ÜÅé¸û¤Ö 2 IgG§ÜÅé«ùÄò®É¶¡3-6Ó¤ë«K·|¶}©l¤U° |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/23 ¤U¤È 01:24:25²Ä 2072 ½g¦^À³
|
¦Ñ´¤j¦«¯E¤Í°Ýªº°ÝÃDÀò±o¥¿±¦^µª §Ú³Ì·Qnª¾¹Dªº°ÝÃD: IgG§ÜÅé«ùÄò®É¶¡¬O¥H>=¦~¨Ópºâ ³o³õOBI822ªºÁɧ½´N¤w¸gµ²§ô¡A¦h¤è³Ó¥X ©¹«áªº±ÂÅv,ÃÄÃÒ,¥þ²y¤T´Á³£·|¦³«Ü¦nªºµ²ªG |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/20 ¤U¤È 10:14:21²Ä 2071 ½g¦^À³
|
ÁÂÁ¦Ѵ¤jªºÀ°¦£ ÁÂÁ©ӤѤjªº¤À¨É POLIO ¤p¨à³Â·ô¯g ¤SŪ¨ì°ê¤¤Åª¹Lªº¨F»«/¨F§J¬Ì] ¥¿½T³sµ²¬°www.who.int/vaccine_safety/initiative/tools/polio_vaccine_rates_information_sheet.pdf Vaccine-associated paralytic polio (VAPP) ³oÓ¦³½ì¤F |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/20 ¤U¤È 08:44:44²Ä 2070 ½g¦^À³
|
www.google.com.tw/url?sa=t&source=web&rct=j&url=www.who.int/vaccine_safety/initiative/tools/polio_vaccine_rates_information_sheet.pdf&ved=0ahUKEwiv7dvl0LbNAhXDNpQKHXEgBAIQFggZMAA&usg=AFQjCNG-GmfIDnlJntcIMfw-SuaK6ERY1w&sig2=QFv6J5J8SFYeXjSmeU5xCg |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/20 ¤U¤È 12:36:57²Ä 2069 ½g¦^À³
|
¥xÁÞ¤j,¤Ó¹L¤F,¦Ñ´ÁÙ¦³¦Ûª¾¤§©ú,¦A»¡°µªÑªF³Ì¦n,¥i¥H°á¤H¤£·|³Q¤H°á^^ ¯E¤j,¬¡©Ê´î¬r®è,·íµM¦b°ö¾iªº®ÉÔ¦³¥i¯à´_¬¡,§Þ³N°ÝÃD,Y¬O¤w¸g¶q²£¥Î¦bÁ{§Éªº... ¨S«ç»òÅ¥»¡... ¦Ñ´¬d¬Ý¬Ý¦³µLÃþ¦üªºcase reports |
|
|
·|û¡Ge36510142697 µoªí®É¶¡:2016/6/19 ¤W¤È 10:00:45²Ä 2068 ½g¦^À³
|
³o«h³ø¾É´£¨Ñµ¹¦U¦ì¤j¤j°Ñ¦Ò¡C ¡m·¶Ç´C¡nºë·ÇÀ»±þÀù²ÓM¡B©ñ¹L°·±d²ÓM ¬ü°ê¬ì¾Ç®a¬ãµo¡u¤ÆÀø¸¼u¡v www.storm.mg/article/131489 |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/19 ¤W¤È 12:36:18²Ä 2067 ½g¦^À³
|
·PÁÂQQ¤j´£¨Ñªº·s»D ¤p§Ì¬Ý§¹ªº·Qªk¬O¡G 1.PD-1 ¸ò 822¨ä¹ê¦bªÍÀù³o¶ô¬O¦³¬Û»²¬Û¦¨ªº®ÄªG¡A°²³]822 ¥i¥H¿ëÃÑ¥XªÍÀù²ÓM¤WªºGLOBE H¡A¦ý¦]¬°ªÍÀù²ÓMªí±¤WªºPD-1¡A·|Åý822©Ò²£¥Íªº§ÜÅéµLªk¤ÞµoT CELL¹ïªÍÀùªº§ðÀ»¡C¬Û¦Pªº¡A§Y¨ÏPD-1 inhibiter¥i¥Hµo¥Í®ÄªG¡A¦ý§K¬Ì¨t²ÎµLªk²£¥Í GLOBE H§ÜÅé¡AÀù²ÓM¤]¬O¦s¬¡¤U¨Ó¡C 2.PD-1¬O³J¥Õ½è¡A³J¥Õ½èªº¦X¦¨¦b¥Í¤Æ¾Ç¬É¨Ó»¡¡A¬O¬Û¹ï¦X¦¨ÁÞ¤À¤l¨Ó»¡¬O²³æªº¨Æ¡A¥B¼t°Ó¤Jªù¬Û·í®e©ö¡A©Ò¥H¤å³¹¤¤¦³´£¨ìPD-1 inhibiter me toÁͶաA¥i¬Ý¥X³o¶ôªº°Ó¾÷¤w¸g¬O¬õ®ü¤F¡A¦Ó822¦³¯Î°|ªø¦bÁÞ¦X¦¨¬Éªº±M§Q°ªÀð¡A¨ä¥L¼t°Ó´Nºâª¾¹DGLOBE Hµ²ºc¡A¥H¥Ø«eÁÞ»â°ìªºªº¶iµ{¡A´N¬O¯E¹©´N¦n¹³¬OTSMC¦b°µ7©`¦Ì»sµ{¤F¡A¨ä¥L¼t°ÓÁÙ¦b·L¦Ìªº¶¥¬q±Ã¤ã¡C 3.822¥un²Ä¤T´Á¹êÅç³]pªº¦n¡A¤]¥i¥H¹³Keytruda²Ä¤T´Áµ²ªG«ÜÅãµÛ¡A¥i¥H´£«eµ²§ô¹êÅç¡A¥[³t¤W¥«´Áµ{¡C ¤p§Ì·N¨£ ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~ ·q½Ð«ü¥¿ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/18 ¤U¤È 11:21:27²Ä 2066 ½g¦^À³
|
KeytrudaªÍÀù¤T´Á临§É´£«e终¤î¡A³¡¤À¯f¤H¦³±æ摆脱¤Æ疗§é¿i news.bioon.com/article/6684359.html ³o½gÆZȱo°Ñ¦Ò. ¤j¤jÌ©Î¥i±q¤¤ºÝ¸Ô¥X822ªºÀu¶Õ¤Î»ùÈ. |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/18 ¤U¤È 07:07:36²Ä 2065 ½g¦^À³
|
©Ó¤Ñ¤j ÁÂÁ±zªº¤À¨É ¤p§Ì¦³¬d¨ì³oÓ¾ú¥v¬G¨Æ |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/18 ¤U¤È 05:23:10²Ä 2064 ½g¦^À³
|
¥H«e¤fªA¤p¨à³Â·ô¬Ì] ¬¡¬r¦³¬r©Ê ©Ò¥H§ä¤@ºØ´î¬r®è ¦ý¦b°ö¾iªº®ÉÔ ¤SÅܦ^¥¿±`®è ©Ò¥H.... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/18 ¤U¤È 05:10:07²Ä 2063 ½g¦^À³
|
¦Ñ´¤j ¤µ¦~¥xÆW¯E¹©¥Í§Þ¥Ñ©ó¬ãµo¶µ¥ØnÂX¥R¡A±N¤jÁ|¼x¤~¡A¤H¼Æ¬ùÂX¥R¤@¿¡A¦Ñ´¤j¦bÁ{§ÉÂå¾Ç¤è±²z½×¹ê°È¨ã³Æ¡A¤p¤ß¤µ¦~¯E¹©«õ¨¤! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/18 ¤U¤È 04:34:44²Ä 2062 ½g¦^À³
|
¦Ñ´¤j¤ÀªRªº«Ü´Î! ¨¥Â²·N¸ð¡A¤Á¤¤°ÝÃD®Ö¤ß¡A¦Ñ´¤j¤£¦ý¥i¥H·í±Ð±Â¡A§ó¯à·í¸³¨Æªø¡A «Øij¥xÆW¯E¹©¥Í§Þ¤½¥qÀ³¸u½Ð¦Ñ´¤j¬°°ª¯ÅÅU°Ý¡C(¤p¤ß°h¥ð«á³Q¯E¹©«õ¨¤) |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/18 ¤U¤È 04:12:03²Ä 2061 ½g¦^À³
|
·PÁ¦Ѵ¤jªº»¡©ú°Õ ¤p§Ì»{¦P ¥ý¦A¦¸ÀËÅç°ª§C¤ÏÀ³¨â²Õ»P¹ï·Ó²Õ¦b°ò·Ç½u¤Wªº®t²§ ¦A¨Ó¤ñ¸ûÀø®Ä ·|§ó¦n ©Î³\¤½¥q¤w¸g°µ¤F ¥u¬OPPT½g´T¤£°÷©ñ ¦A½Ð±Ð±z ¹L¥hÂå¾Ç¥v¤W ¬O§_¦³¥´¬Y¯e¯f¤§¬Ì]¡A«o³y¦¨¸Ó¯e¯f´_µoªºª¬ªp? ¥i§_µ¹¤@¨Ç°Ñ¦Ò®×¨Ò ÁÂÁ |
|
|
·|û¡G¤pcc10140141 µoªí®É¶¡:2016/6/18 ¤W¤È 11:56:46²Ä 2060 ½g¦^À³
|
¤p©_¤jªº¤ÀªR»¡©ú¯u¬O¤ÓÆg¤F~¯u¬O¨¯W±z¤F.. |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/18 ¤W¤È 11:41:23²Ä 2059 ½g¦^À³
|
½²±Ð±ÂªGµM¤£¦P¤ZÂQ,Ãø©Ç¥i¥H°µ¸³¨Æªø! ±Ð±Â³q±`¬O§â²³æªº¨Æ±¡Á¿ªº«Ü½ÆÂø,¸³¨Æªø¤~¥i¥H§â½ÆÂøªº¨Æ±¡Á¿ªº«Ü²³æ! ¯u¬O©_©Ç,causal effect & association,¨âÓ´X¥G¨CÓ§«ô³£nÁ¿¤@¦¸ªºµü·J, ¦Ñ´«ç»ò´N¬OÁ¿¤£¥X¨Ó©O?«¢«¢........¤Ó¦³½ì¤F! ¤p©_¤j,±z¤Ó¬Ýªº°_¦Ñ´¤F,immuneªºbiomarker°ÝÃDÁÙ±o¦b¤W¯Z¤é§äÓinfection or AIRªº°Ý°Ý¬Ý,¬Û«HÀ³ ¸Ó¤]°Ý¤£¥X¤°»òµ²½×! ¥H¤U¬O¦Ñ´ªº·Qªk: 1. ÁÙ¦³¤°»ò¬O¤ñ±i¸³»¡ªº§óª½±µªº?¥´¥|°w,IgG,ÁÙ¦³¤°»òimmuneªºbiomarker¤ñIgG§ó¦³·N¸q? 2. ºJ¶}¤°»òimmuneªºbiomarker¤£¬Ý,¨â²Õ¥un¦¬®×¦b¬Û±µªñªº°_¶]ÂI´N¥i¥H¤F,¦p¦ó±µªñ©O? Age,ECOG¦A¥[¤@ÓCBC/DC(³£³Qchemotherapy¶Ê´Ý¹LªºCBC/DCµ´¹ï¦³°Ñ¦Òªº»ùÈ),³o¤T¶µ¨â²Õ³£¨S¦³ÅãµÛ ªº®t²§´NOK¤F!----Åé¯àª¬ºA®t¤£¦h,´N¥i¥H¥Nªí§K¬Ì¤O®t¤£¦h¶Ü?----¦Ñ´»{¬°¥Ø«e¥i¥H! °ÝÃD¦^¨ì¦Ñ´ªº¦Ñ°ÝÃD,¦ó¥²µ¥¤T´Á,¤½¥q¥un§âresponder²Õªºage, ECOG, hormone therapy©M¹ï·Ó²Õ¦A ¶]¤@¦¸p-11ªºªí,´N¥i¥HÃÒ©ú¤@¤Á¤F!post-hoc¤S«ç»ò¼Ë?¨â²Õ¥un±ø¥ó¬Û·í,´N¨S¦³selection bias! ·íªì³o¨Ç¯f¤H¤@©w¨C¤@¦¸¦^¶E³£¦³©â¦å,³Ì°ò¥»ªºCBC/DC¤@©w¨C¤@¦¸³£¦³,§â²Ä¤@¦¸ªºCBC/DC³£¤ÀªR¤@¦¸, ¨â²ÕÁÙ¬O±ø¥ó¬Û·í,¨º¤£´N§ó¥i¥HÃÒ©ú¤@¤Á¶Ü?Y¬O¨â²Õ±ø¥ó¤£¬Û·í,¦ý¬O¬Oresponder²Õ¤ñ¸û®t¤£¬O§ó¦n ¶Ü?(·íµM³o¼Ëªº±¡ªp¬O¤£¤j¥i¯àªº) post hoc¨Ã¤£¬O»¡°¨«á¬¶°Õ!post hoc°ò¥»¤W¥u¬O´Á¤¤¤ÀªR®É,®³¨Óºâsample sizeªºpower°÷¤£°÷,n¤£n ¦A¦h¼x¥l¯f¤H¥[¤J¦Ó¤w! a priori¤]¬On¥ý¦³5~10Ó¯f¤Hªºpilot study©Î¬O°Ñ¦Ò²Ä¤@´Á©Î¬O§O¤Hªºstudyªºmean and SD,¦A¥Ñ Cohen¡¦s Dµ¥¤½¦¡ºâ¥Xeffect size¤§«á,¦Aºâ¥Xn¦h¤Öcase, power¤~°÷!---¤]¤£¬O©Ò¿×ªº¥ý¨£¤§©ú! ³o¨Ç¤½¥q¤£¬O¦´Nºâ¹L¤F¶Ü?power 90%? ü~ÁÙ½Ðcliff¤j,«Ó¥v¤j,¤p©_¤j,¥xÁÞ¤j,¯E§J¤j¤Î¦U¦ì¤jÀ°¦£¼íÄÀ¼íÄÀ... ¤£ª¾¹D¦³¨S¦³¶VÁ¿¶V½ÆÂø?½Ðì½Ìì½Ì,¦Ñ´´N¤£¬O°µ¸³¨Æªøªº®Æ§r!~~ |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/6/18 ¤W¤È 09:48:48²Ä 2058 ½g¦^À³
|
½Ñ¦ì°ª¤H¤j¤j¡A¤p§Ì¦³ÓºÃ°Ý½Ð±Ð±zÌ¡C ®û¼í¡A©µ¿ð¡A¬õ¸~¡A¤½¥qÃÒ¹ê¡AÂå®v¯f¤H¬Òª¾¡C¤T´Á LR §PŪªº¤ßÃÒ¨Mµ¦¥²µM»P¤G´Á¦³®t¡C¥[¤W¥´4°w¿z¿ï¡C ¦b³o¨Ç±¡ªp¤U¡A¤T´ÁÁÙ¬OÂùª¼¸ÕÅç¶Ü¡H¨º麽©ú¥Õ¡A¿z¿ï¡A¦p¦ó¡§ª¼¸Õ¡¨¡H¥i¯à¬Oopen label¶Ü¡H |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/18 ¤W¤È 09:12:32²Ä 2057 ½g¦^À³
|
¤p©_¤jªº³o½g¤å³¹¡A¬Û«HÀ´ªº¤H¥i¿E¥X¨Çªá¤õ¡A¤£²M·¡ªº¤H¤]¥iɦ¹¾÷·|¤@¿s¸Ñª¼°ó¶ø¡C ·PÁ±z¡I |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/17 ¤U¤È 10:20:07²Ä 2056 ½g¦^À³
|
ÁÂÁ¤p©_¤jªººë±m¦n¤å ¯E§J¤j ¦pªG¤T´Á¯à°÷¥ý¡¦¡¦¨Æ«e¥B¦³®Ä¡¦¡¦ªº¿z¿ï°ª§C¨â²Õ, ¨º»ò§Ú¹w´ú ¦bPFSªº³¡¤À, °ª§ÜÅé²ÕKM¦±½u·|¤ñ¤G´Á®t, §C§ÜÅé²ÕKM¦±½u·|¤ñ¤G´Á¦n ¦bOSªº³¡¤À, ¤T´Á©M¤G´ÁÀ³¸Ó³£®t¤£¦h ¦p¦ó¨Æ«e¥B¦³®Äªº¿z¿ïªº½T¬OÓ°ÝÃD |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/17 ¤U¤È 09:51:34²Ä 2055 ½g¦^À³
|
Pie¤j Y²Ä¤T´Á¯à°÷¥ý¡¦¡¦¨Æ«e¥B¦³®Ä¡¦¡¦ªº¿z¿ï°ª§C¨â²Õ ¨º»ò¤T´Áªºµ²ªG¤@©w¤ñ¤G´Á§ó¦n °ÝÃD¬O¦p¦ó ¨Æ«e¥B¦³®Äªº¿z¿ï? ³oÓ»Ýn¤½¥q¦n¦n·Q·Q |
|
|
·|û¡G¸¯T10140363 µoªí®É¶¡:2016/6/17 ¤U¤È 08:26:44²Ä 2054 ½g¦^À³
|
·q¥õªº¤p©_¤j Æg¡I±z»¡ªº«D±`¦n¡I¨¯W¤F¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/17 ¤U¤È 07:40:31²Ä 2053 ½g¦^À³
|
¥H¤U¬O¤p§ÌÃö©ó½²±Ð±Â¼gªº¡u¯ª¥À©w«ß¡vªº·Qªk¡C Cliff¤j¤À¨Éªº³o¤@½g½²¸³ªº¬ì¬ã¡u¯ª¥À©w«ß¡v¡A§â¥«³õ«H»P¤£«Hªº¤Hªº·Qªk´yø±o²OºvºÉP¡A¼g±o«Ü´Î(¥Î¦r«Üºë·Ç¡A¤ñ¤§«e´£¥X½èºÃªº¤H°ª©ú¦h¤F)¡I§â«HªÌ»P¤£«HªÌªº·Qªk°µ¤F§óª½±µªº©w¸q¡A¥ý«e¦³©Ò¿×ªº¬D¡u«e¬q¯Z¡v¨Ó¤ñ¹ï·Ó²Õ©ÎªÌ¬D¡uª¬ªp¦n¡vªº¤H¨Ó¤ñ¹ï·Ó²Õªº»¡ªk¡A¦ý¨â²Õ¨S¦³¦b¥µ¥ªº°ò¦¤W°µ¤ñ¸û¡A¦]¦¹¯ª¥À¬Ý¤£À´¡A¤]¤Þ¨Ó¤F³\¦hªºª§Ä³¡C³o¼Ëªºª§Ä³¡A½²¸³¤µ¤Ñ¥Î¤F¨âÓµü¨Ó©w¸q¡A¡u¦]ªG¡v»P¡u¬ÛÃö¡v¡A³o¨âÓµü¡u¦]ªG¡v»P¡u¬ÛÃö¡v¥Î±o¯u¦n¡A«Hªº¤H»¡¬O¦]ªG(822³y¦¨Àø®Äªº®t²§)¡A¤£«Hªº¤H»¡¬O¬ÛÃö(¬Dª¬ªp¦nªº¤H¨Ó¤ñ¡Aª¬ªp¦nªº¤H²z©Ò·íµMÀø®Ä¤ñ¸û¦n¡Aª¬ªp¦n»P§e²{¸û¦nªºÀø®Ä¨ã¦³¬ÛÃö©Ê)¡A¨ì©³¬O¦]ªGÁÙ¬O¬ÛÃö¡HÁÙ¬O¤j³¡¤Àªº¦]ªG¤Î¤@ÂIÂIªº¬ÛÃö¡H«ç»òÃÒ©ú¬O¦]ªGÁÙ¬O¬ÛÃö¡H¡C ¥ý¬ÝPFS¡A224¤H»P124¤H¡AM PFS¤]¨S¹L¡APȤ]¨S¹L¡A¯E¹©´N¬D¤F°ª§K¬Ì¤ÏÀ³²Õ¡A¤À§O»P¹ï·Ó²Õ»P§C§K¬Ì¤ÏÀ³²Õ°µ¤ñ¸û¡A³£¦³ÅãµÛ®t²§¡A¦ý224¤H³Q¬D¨«¤F§K¬Ì¤O¦nªº(½²¸³¥Îªºµü¡A§K¬Ì¤O¦nªº»PPFSÀø®Ä¦n§e°ª«×¡u¬ÛÃö¡v)¡A¯d¤U§K¬Ì¤O®tªº(»PPFSÀø®Ä®t°ª«×¡u¬ÛÃö¡v)¡A¦]¦¹´N¥X²{¤FP16ªºPFSªºKM curve¡A¦pªG³o¬O¦]¬°§K¬Ì¤O»PÀø®Ä¡u¬ÛÃö¡v³y¦¨ªºKM curveªº®t²§¡A¨ºp16¤£¹L¬O¦bª±²Îp¦Ó¤w¡C ÁÙ¦n¡AÁÙ¦³p13»Pp17ªºOS¤ÀªR¡A¦ÓOS¤~¬O±wªÌªº³Ì²×Àø®Ä«ü¼Ð¡A¦bPFS¤W·íµM¥i¥H«ùÄò¥h¬ã¨s¡B°Q½×¡B¤ÀªR¥¦I«á§Î¦¨ªº¬ì¾Çì¦]¡A¦ý¦pªGÁÙn¥ÎP12©MP16ªºPFS¹Ï¡A½èºÃ¯E¹©¦bª±²Îp¡A³o¼Ëªº¤H¤ñ¯ª¥ÀÁÙÃø·¾³q¡A´N¤£n¦A®ö¶O®B¦Þ°Q½×»y¥L°Q½×°Q¤F¡A³£»¡¤£¤ñPFS¤F¡AÁÙ¤@ª½®³PFSªºKM curve¨Ó½èºÃ¡A¦A¥X²{³o¼Ë½èºÃªº¤H¡A´Nºâ¬OÑ¡¯ª¶ý¤]¤£n²z¥L¡C OS´Á¤¤¤ÀªRKM curve¥Ø«e¬Ý°_¨Ó¦³®t²§¡A¥B®t²§¦ü¥G¤j¨ìȱoÄ~Äò¬ã¨s°Q½×¡A¨ì©³³o®t²§¬O¡u¦]ªG¡vÁÙ¬O¡u¬ÛÃö¡v¡HÁÙ¬O¦³³¡¤Àªº¡u¦]ªG¡v»P³¡¤Àªº¡u¬ÛÃö¡v¡H±q½²¸³ªºÆ[ÂI¡A¨â²Õ¨S¦³¦b¥µ¥ªº°ò¦¤W¤ñ¸û¡H´N¤@©w·|³Q¤H½èºÃ¡AP13ªºOS¹Ï¬O¥þ³¡224¤H»P124¤H°µ¤ñ¸û¡Aì¥Äì¨ý¡A¦ý¥i±¤¬O´Á¤¤¤ÀªR¡A¤@¤j°ï³]¸ê®Æ¡APÈÁÙ¦b0.289¡A½²¸³¥i¯à¦]¬°OS´Á¤¤¤ÀªRªº¼Æ¾Ú¥¼¦¨¼ô¦Ó¼È¤£°Q½×¡A¯ª¥À»¡¡A¨â²ÕÁö¦b¥µ¥ªº°ò¦¤W¤ñ¸û¡A¦ýPȨS¦³¤p©ó0.05¡A¤£¯à»¡ªA¦o¡A¦A»¡§a¡I¦ýPȪººâªk¬O¥X²{¤@Өƥóµo¥Í¡A´N¥i¦b¥d¤èȤW²Ö¿n¤@¨Ç¼ÆÈ¡A¥Ø«eOS¨Æ¥ó¥u¦³85¤H¡A¦©°£¤w½T©wªºdrop out¥Ã»·ªº³]¸ê®Æ¡AÁÙ¦³200¦hÓÀHµÛ®É¶¡±Nº¥º¥¥Ñ³]¸ê®ÆÂনOS¸ê®Æ¡A¥unP13¨â²Õªºªº®t²§ªºÁͶիùÄòµÛ¡AÀHµÛ®É¶¡¦¨¼ô¡APȲױN¤p©ó0.05¡A³o¬O¤@Ó¥i¹w´úªº¥²µM©Ê¡A·íPȤp©ó0.05¡A¯ª¥À´N¬ÝÀ´¤F¡A¶â¡A²Å¦X¨â²Õ¦b¥µ¥ªº°ò¦¤W¤ñ¸ûªºì«h¡A²Îp»PÁ{§É¤]³£¦³®t²§¡A224¤H¬Û¸û©ó124¤H³o¨â²Õ¡A¡A¨S¿ù¡A822»PÀø®Ä¦³¡u¦]ªG¡vªºÃö«Y¡C µù¡G¥d¤èȤ]´N¬OPȪºpºâ¤½¦¡¡GX^2 = (O1 ¡V E1)^2/ E1 + (O2 ¡V E2)^2/ E2 ¦pªG¯E¹©¤£¤À²Õ©O¡H¥H¥þÅé224¤H¹êÅç²Õ¥h¥Ó½ÐÃÄÃÒ¡A©MYervoy¡BOpdivo¡BKeytrudaµ¥§K¬ÌÀøªkÃĪ«¤@¼Ë¡A¥Ø«e©|µLºë·Çªº¤èªk§ä¥Xªø§Àªº³Ì¾A¥Î±Ú¸s¡A³\¦h§K¬ÌÀøªkªºÃĤj³£¦b«á¥b¬q(¤j¬ù50%¥ÎÃĪÌ)¤~¯à©úÅã®i²{¥XOSªºÀø®Ä(°Ñ¦Òwww.nejm.org/doi/full/10.1056/NEJMoa1003466#t=articleªºFIGURE 1)¡A¥B³Ì²×¯àÀò±oOSªøªø§ÀÀø®Äªº±wªÌ¡A¾÷²v¤£¹L´N20%~30%¡A¬JµMµLªk¦b¥ÎÃÄ«e§ä¥X³Ì¾A¦X¥ÎÃĪº¨º20%~30%¾A¥Î±Ú¸s¡A¨CÓ¥ÎÃĪºÀù¥½±wªÌ³£§Æ±æ¦Û¤v¦¨¬°¨º©¯¹Bªº20%~30%±Ú¸s¡A¦ý¨Æ¹ê¬O¡A±wªÌ³q±`nµ¥¨ì¦Û¤vÃxÁ{¦º¤`¤F¡A¤~ª¾¹Dì¨Ó¦Û¤v¤£¬O¨º20%~30%ªº©¯¹B¨à¡C ¨º¯E¹©¦pªG¤£¤À²Õ©O¡H°²³]P13¥Ø«e32Ӥ몺¦s¬¡¾÷²vÈ=69.3%¡A¨ì5¦~OS°lÁa´Áº¡¡A¦]¬°224¤H¥]¬A¤F¦³¤ÏÀ³»PµL¤ÏÀ³¡A¦]¦¹5¦~ªº¦s¬¡¾÷²v°¨ì40%¡A¦Ó¹ï·Ó²Õªº5¦~¦s¬¡²v°¨ì30%¡A¾ãÅé¹êÅç²Õ±N¹ï·Ó²Õªº5¦~¦s¬¡²v±q30%±À¤É¨ì¤F40%¡APȤ]°¨ì0.05¥H¤U¡A¥B§C°Æ§@¥Î¡A³o¼Ë¤l®³ÃÄÃÒÀ³¸Ó¨S°ÝÃD§a¡I¦ý»¡¹ê¸Ü¡A¾ãÅé¹êÅç²ÕùزV¤F¤@¨Ç§¹¥þ¨S¦³GH§ÜÅé¤ÏÀ³ªº¥H¤Î§C§ÜÅé¤ÏÀ³ªº¡A¦pªG¬ì¾Ç¤W´N¥i¥H±À´ú¥L̬O¨S¦³Àø®Äªº©ÎÀø®Ä´¶´¶ªº¡A¥i¥H¸ûºë·Çªº§ä¥X¦³·¥¨ÎÀø®Äªº±Ú¸s¡A¬°¦ó¤£¦bÁ{§É¹êÅç´N§â¤£¾A¥Îªº±Ú¸s±Æ°£±¼¡H¥Î¤FÃÄÁÙ¨S®Ä¡AÁÈ¥L̪º¿ú°µ¤°¡H©Ò¥H¯E¹©²{¦b¦b°µªº°ò¥»¤W¤w¸g¦b§ä´M§K¬ÌÀøªkªººë·ÇªvÀø¤F¡C ¨º¤À²Õ©O¡H½Í¤@¤U¤À²Õ¬O§_¦³ª±²Îpªº¶ûºÃ¡H³o¬O¥Ø«e³Q½èºÃ³Ì¦hªº°ÝÃD¡C ¥Î¤@Ó²³æªº¤ñ³ë¡A°²³]¦³¤@ÓÁ{§É¹êÅç¡A¹êÅç²Õ¬Û¸û¹ï·Ó²ÕªºKM curve´X¥GÂH¦b¤@°_¡APÈ»·¤j©ó0.05¡A³q±`³o¼ËªºÁ{§É¹êÅç´N·|³Q§ô¤§°ª»Õ¡A¤£·|Ä~Äòª±¤U¥h¡A·íµM¤]·|°µ¨Æ«á¤ÀªR¡A¬Ý¬Ý¦³¨S¦³¤°»ò¬ì¾Çªºµo²{¡C¥unªÖªá®É¶¡°µ¨Æ«á¤ÀªRªº¤À²Õ¡A´N¦³¾÷·|§ä¥X¤@²Õ¦¸±Ú¸s»P¹ï·Ó²Õ¦b²Îp¤W¦³ÅãµÛªº®t²§(P¤p©ó0.05)¡A¦ýn¬ÝÃļt´±¤£´±¦A¯{¤j¿ú¤U¥h°µ¶i¤@¨BªºÁ{§É¨ÓÅçÃÒ¡C¥ÎÓ²³æªº¼Æ¾Ç¨Ó¬Ý¦³¨S¦³ª±²Îpªº¥i¯à¡A¥ý¥H¹ï·Ó²ÕªºÀø®Ä=0·í°µ°ò¦¡A¥¼¤À²Õ«e¥þ³¡ªº¹êÅç²Õ»P¹ï·Ó²Õ¨S¦³ÅãµÛ¡A©Ò¥H¥þ³¡ªº¹êÅç²ÕÀø®Ä¤]¬O=0¡A°²³]¤À¤F¤@Ó²Õ¥X¨Ó¡A¥Î¥ô¦ó¤èªk¤À¤@Ó»P¹ï·Ó²Õ¬Û¤ñÀø®Ä=+3ªº¦¸±Ú¸s¥X¨Ó¡A¦]¬°¾ãÅé¹êÅç²ÕªºÀø®Ä=0¡A¦ýµw³Q¤À¥X¤@²Õ(¥ý°²³]³Q¤À¥X¥hªº»P¯d¤U¨Óªº¡A¤H¼Æ¤ñ=1¡G1)Àø®Ä=+3ªº¦¸±Ú¸s¡A¨º¯d¤U¨Óªº¨º¤@Ó¦¸±Ú¸sªºÀø®Ä´N |
|
|
·|û¡Gwalker10141977 µoªí®É¶¡:2016/6/17 ¤U¤È 07:23:03²Ä 2052 ½g¦^À³
|
¯ª¥À©w«ß: ¤j¦h¼ÆÀù¯gªºµo¥Í¬O¦]¬°¡u¹B®ð¤£¦n¡v www.bbc.com/zhongwen/trad/science/2015/01/150102_cancer_bad_luck (¦p: ¤HÅ骺®ø¤Æ¨t²Î¤ñ¤j¸£±µÄ²ªº¬r¯Àn¦h±o¦h¡A¦ý¬O¸£Àù«o¤ñ¤p¸zÀùªºµo¯f¾÷²v°ª¥X¤T¿) OBI822 ´N¬O¦b»ë¤l¸Ì¥[¹]¶ô... |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/6/17 ¤U¤È 05:40:22²Ä 2051 ½g¦^À³
|
±i¸³´¿»¡ÁÙ¦³«Ü¦hPÈ¡AÃø¹D³£Show Hand¤F¡H |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/6/17 ¤U¤È 04:55:40²Ä 2050 ½g¦^À³
|
¤j¦hªº¼Æ¾Ú¤w¸g¤½¥¬¤F¡A§Ú·Q¥H½²ªG¯þ±Ð±Âªº¾Ç¸g¾ú¡AÀ³¸Ó¦³¸ê®æ·íFDAªº¼f¬dû¡A§Úı±o½²±Ð±Â³oºØ¦³¤ô·Çªº½èºÃ¶V¦h¶V¦n¡A<¦]¬°FDA¤]¥i¯à·|¦³¬Û¦PªººÃ°Ý>¡A<§Æ±æ¯E¹©¤½¥q¯à±N³o¨Ç°ÝÃD¾ã²z¤§«á>¡A¨Æ¥ý·Ç³Æ¦n¸Ñµª¡A<¤~¯à¬°FDAÄÀºÃ>¡A¦Ó¤£¬OFDA¥s§A°µ¤p¤T´Á¡A§A´N¨Ä¨Äªº°µ¤p¤T´Á¡A¤@¥÷¼Æ¾Ú¥i¥H±q«Ü¦h¨¤«×³£¥i¥H¬Ý±o¨ìÀø®Ä¡A¦pªG¬Ý¨ìÀø®Äªº¨¤«×¤£°÷¦h¡A¤@©wn¦h¥h½Ð±Ð´XÓ°ª¤H¡A±qþ¨Ç¨¤«×¤Á¶i¥h¥i¬Ý¨ìÀø®Ä¡A±qþ¨Ç¨¤«×¤Á¶i¥h¥i¶¶§Q»¡ªAFDA¡C §Ú·Q½²±Ð±Â¬O·Q±qFDA¼f¬dû¥i¯àªº¨¤«×¥Î»Ä·È·Èªº¨¥½×¡A¦n·N´£¿ô¯E¹©°µ¦n·Ç³Æ¤u§@¡C¬Û±æ»P¯E¹©¤½¥q¦³Ápôªº¤j¤j¡A¯à´°«P´£¿ô¡C |
|
|
·|û¡GLIN10137582 µoªí®É¶¡:2016/6/17 ¤U¤È 03:24:44²Ä 2049 ½g¦^À³
|
½Ð°Ýª©¤W¦U¦ì¤j¤j ³Ì«á¹êÅç²Õ¥¼PD¦³´X¤H?¹ï·Ó¦³´X¤H? ÁÂÁÂ!! |
|
|
·|û¡GLIN10137582 µoªí®É¶¡:2016/6/17 ¤U¤È 03:09:56²Ä 2048 ½g¦^À³
|
½Ð°Ýª©¤W¦U¤j¤j ³Ì«á¹êÅç²Õ¥¼PD¦³´X¤H? |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/17 ¤U¤È 12:23:54²Ä 2047 ½g¦^À³
|
Globo H series ´N¹³¬O®a±Ú¦¡¶BÄF¶°¹Î SSEA3 ¬O¶ý¶ý¡A¶ý¶ý¨ì³B¥Í¶BÄF¨â¥S§Ì SSEA4 ¬Oôô¡A¤ñ¸û¤p§À Globo H ¬O§Ì§Ì¡A§Ì§Ì¤ñ¸û¨g¦k¡A¥Ç¦æ¦h(¦b¦UÀù¯gªí²{²v°ª) ¤µ¤Ñ822¬O°ê¥~¶Â¤âÄÒKLHÁp¦X§Ì§Ì¡A¸ó°ê¶BÄF¡A±q°ê¥~¶i¨ì¥xÆW(¨ÅÀù¨ü¸ÕªÌÅ餺)¶BÄF¡Aµ²ªG¤Þ°_§ÚÌÀ˽ըt²Î(¥D°Ê§K¬Ì¨t²Î)ª`·N¡A¦ý¬OÀ˽ըt²Î³£¬O«ÜºC°Ê§@(©µ¿ð¤ÏÀ³)¡A¥²¶·µ¥«Ý¦³¤@¨Ç¤H³QÄF¿ú¡A¤Þ°_¤j®aª`·N¡AÀ˽դ~·QnÂX¤j°»¿ì¡A©Ò¥H¤~¤Þ°_CDCÀ˹î¸p¸òADCC½Õ¬d§½ªº°l®·¡A¨ä¤¤IgM´N¬Oĵ¹î¡AIgG´N¬O¾Ë§L¡Aĵ¹î¥ý¥X°Ê¡A¦ý¬O¶Ô°È¤ñ¸û¦h¤ñ¸û²Ö¡A°l®·¤£«ù¤[¡AIgG´N¤ñ¸û«ù¤[¡A¥B±Mºë§ìÃa¤H¡A¦]¬°¦³°O¾Ð®ÄÀ³¡C ¦p¤µ§Ì§ÌGlobo H¦h¤Ö¤H¡A«¤£«n?¥i¯à«n¡A¦]¬°¨ÅÀùªí²{²v²[»\60-80%¡A¦ý¬O¬Û¸û¥þ®a±ÚGlobo H series ´N¤£«n¡A¦]¬°¥þ®a²[»\98%¡C¦]¬°822n§ì¡A§Ú̧Ʊæ³Ì¦n§ì¥þ®a¡C IgMĵ¹î»PIgG¾Ë§L¼Æ¶q«¤£«n? ·íµM¬O³Ì«n¡A¤£µM822À˽ըt²În¥Î¤°»ò§ì¶BÄF¶°¹Î? ¥H¤W´N¬O§ÚªüÀ¨ªº±`ÃÑ |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/17 ¤W¤È 10:56:16²Ä 2046 ½g¦^À³
|
¤p©_¤j, ¯E§J¤j °²³]±N¨Ó¤½¥q§ä¨ì¤F¤@Ó¤èªk, ¥i¥H·Ç½T¦a¦b¨Æ«eÀË´ú¥X¨º¨Ç±wªÌ¥i¥H²£¥ÍIgG titer >= 1:160 ¨Ã¥B¥Î³oÓ¤èªk, ¦b¤T´Á¹êÅç«e´N±N¹êÅç²Õ©Ò¦³¤H¤À¦¨°ª§ÜÅé²Õ©M§C§ÜÅé²Õ¨â²Õ, ¨Ó¶i¦æ¹êÅç ½Ð°Ý§AÌı±o, ³o¼Ë¤T´Á§@¥X¨Óªº°ª§ÜÅé²Õ©M§C§ÜÅé²ÕKM¦±½u, ·|©M¥Ø«e¤G´Á©Ò°µ¥X¨ÓªºKM¦±½u¤@P¶Ü? ¤]´N¬O»¡, ¥i¥H¥Î¤G´Á¨Ó¤jP¹w´ú¤T´Á¹êÅ窺Àø®Ä¶Ü? ÁÙ¬O»¡, ³oÓ°ÝÃD¨Ã¤£«n©O? §Ú·Q¬Ýªk¬O, ¦pªG¥i¥H¨Æ«e¤À¦n²Õ, ¨º°µ¥X¨ÓªºKM¦±½u·|©M²{¦b¤G´Á¬Ý¨ìªº¤£¤@¼Ë, ¤×¨ä¦bPFSªº³¡¤À·|®t«Ü¤j. ¦pªG¥i¥H¨Æ«e¤À¦n²Õ, Æ[¹î¨ìªºÀø®Ä¤~¬O¦U²Õ¯u¥¿ªºÀø®Ä. ²{¦b¥Î¨Æ«á¤À²Õªº¤è¦¡Æ[¹î¨ìªºÀø®Ä, ¨ä·N¸q¦³«Ý°Óºe. |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/17 ¤W¤È 10:43:54²Ä 2045 ½g¦^À³
|
ÁÂÁÂCliff¤j©M¤p©_¤jªº¶}¾É¡A ¤p§Ì¤@¤é¤£¬Ý±z̪º¤å³¹¡A¤º¤ß«K¦³¨ÇªÅµê¡C ·PÁ±z̬°¯E¤Íªº¥I¥X¡AÁÂÁ¡I ¤p§Ì¨cÄ̪º¸Ü´N²¾¨ì²á¤Ñ«Ç¦n¤F¡AÙT¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/17 ¤W¤È 10:04:09²Ä 2044 ½g¦^À³
|
Pie¤j¡A §Ú¤F¸Ñ±zªº·N«ä¤F ¯E§J¤j¤]´£¨ì¤F ¼Æ¾Ú«ç»ò¨Óªº¬O¤@¦^¨Æ¡A¶]²Îp¤S¬O¥t¤@¦^¨Æ ©Ò¥H¦pªG¦³¥ô¦ó¨â²Õ¤ñ¸ûªº¼Æ¾Ú ´Nºâ¬O¤p§ÌÀH«K½s¨â²Õ¼Æ¾Ú ¨â²Õ¼Æ¾Úªº¤H¼Æ¦U¬ON1¡BN2 ¨º»ò¶]²Îp®É¡A¨â²Õªºnumber at risk¦U¬ON1¡BN2 µM«á´N¨Ì·ÓKM curveªº³B²zì«h number at riskÀHµÛ³]¸ê®Æ»P¨Æ¥óªºµo¥Í¡A³vº¥´î¤Ö ±z´£¨ìªº¤À²Õì«hªº°ÝÃD¡A ¤p§Ì±ß¤@ÂI¤@°_¸ÑÄÀ ¥|®ü¤j¡A ¤p§Ìª¾¹D±zªº·N«ä ±q¤£¦Pªº¨¤«×¬Ý½²¸³ªº¤å³¹¡A·|¦³¤£¤@¼Ëªº·Qªk»P·N¨£¶]¥X¨Ó ºJ¶}±z»¡ªº½²¸³¬O§_¦³¡u©¶¥~¤§µ¡v ½²¸³¬O¯uªº¸òFDA¥´¹L¥æ¹D ¥Lªº¬Ýªk»PÆ[ÂI¯uªºÈ±o§Ú̲`«ä»P°Q½× ¯E¹©¥H«án¦¨¬°±z¤ß¥Ø¤¤ªº¤½¥q ¯E¹©¥H«án¦¨¬°¯¸¤W°ê»Ú»R¥xªºÀùÃÄ»â¾É¼t°Ó¨Î´f³\³\¦h¦hªºÀù¥½±wªÌ ¤@©wn§â©Ò¦³ªººÃ¼{³£µ¹Âç²M ¤~¯àÅýÀù¯g±wªÌ¯uªº¨ü¨ì822¡B833ªº¦n³B ¦p¦¹¡A¯E¹©ªºªÑ»ù±N¤£·|¬O¤@³õµê¤Ûªº¬üÄRªº»~·| Åý¬Ý±oÀ´¼Æ¾Úªº¡B¥Î¥\ªº¡B¹ï¤½¥q¦³«H¤ßªº§ë¸ê¤H³£¦]¬°¥¼¨Ó·sÃĤW¥««áªº°ªEPS¦Ó¦³§ë¸ê¤WªºÀò§Q ªp¥B½²¸³´£¥Xªº¨âÓµü¡u¦]ªG¡v»P¡u¬ÛÃö¡v¥Î±o¯u¦n ¦Ó¥B´£¥X¤F¨âӸѰ£µ~¹Òªº§@ªk¤]ȱo§ÚÌ«ä¦Ò ¤p§Ì¬Q±ß¤w¦³·Qªk¥B¥´¤F¦r ¦ýÁÙn®É¶¡°µÂI¾ã²z ±ß¤@ÂI¶K¤W¹ï½²¸³ªº¤å³¹ªº·Qªk »P±z¤Î²³¤j¤À¨É |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/17 ¤W¤È 08:18:19²Ä 2043 ½g¦^À³
|
¹x¥Û¤j ÁÂÁ±zªº»¡©ú ¤p§Ì¨ü¯q¨}¦h cliff¤j ¥HIgM¨Ó¹w§@¤À²Õ ¤]¬O¥i¯à ¦ý¬O¦Ò¶q¬ã¨s³]p¤§¤è«K²¼ä ¥HIgG¬°©y pie¤j ±zªº«ä¦Ò¦³°ÝÃD ±N¹êÅç¹Lµ{²£¥Í¼Æ¾Ú¹Lµ{»P²Îp¤ÀªR¼Æ¾Ú¹Lµ{ ·d¶Ã¤F ²Îp¤ÀªR¼Æ¾Ú¬O³Ì«á¼Æ¾Ú³£¦¬¶°¨ì¤F¤~¤ÀªR ¤ñ¸û1:160°ª§C¨â²Õ ´N¬O¼Æ¾Ú¦¬¶°¦n ¤~¨Æ«á¤ÀªRªº |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/17 ¤W¤È 12:52:52²Ä 2042 ½g¦^À³
|
¶Â½ü§B: «D±`ÁÂÁ±z¦b¦Ê¦£¤¤¦^ÂÐ. ¸g¥Ñ±zªº¸Ñ»¡¤Î©Ò´£¨Ñªº¸ê°T, §Ú¤ñ¸û¯à²z¸Ñ±z¤§«e©Ò»¡ªº : ·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/15 ¤W¤È 09:36:01²Ä 2027 ½g¦^À³ ¡K¡K¡K ³o¦¸822ªº¹êÅç ¯uªºn¥hÂç²M ¨º¨Ç¨S§K¬Ì¤ÏÀ³ªº¤H ¨ì©³¬O¦³¦h¤Ö¤H¬O¤Þµo§ÜÅé¯à¤O¯Ê¥F ¦³¦h¤Ö¬O§K¬Ì줣¨¬©Î¤ÏÀ³®É¶¡¤£°÷ ³o¹ï888ªº¥¼¨Ó¬O¦³«Ü«nªº«ü¤Þ ¡K¡K¡K ¬Ý¶}ªÑªF·|®É, ¤½¥q·|¤£·|¦³¶i¤@¨Bªº¸ê°T´¦¾å, ¤£¹L¥H±i¸³´¿»¡¹Lªº, 888·|¥[§Ö¶i¦æ, À³¸Ó¬O¤w¦³¤@©wµ{«×ªº§â´¤¤F¡K.. Cliff ¤j: ¦pªG¯uªº§ä¨ì°ª«×¬ÛÃöªºÃÒ¾Ú, ¨º¯u¤S¬O¬ü¬O¤@¼Î. ©Î³\¦bªÑªF·|®É¥i¦V¤½¥q¨DÃÒ? ÁÂÁ±z¶Kªº½²±Ð±Â¤å, µo¤H²`¬Ù, ¨ü¯q¨}¦h. ¹x¥Û¤j: ±z¤§«en¥hªÑªF·|®É´£ªº°ÝÃD¬O§_¯E§J¤jªº¦^ÂФw¨Ï±z±o¨ì¸Ñµª? ¦pªG©|¥¼, ½Ð±z¤è«K®É¦A±N°ÝÃD¾ã²z¤@¤U¶K¤W, §Ú¦A¤@¨Ö¥N¬°´£°Ý. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/16 ¤U¤È 11:45:17²Ä 2041 ½g¦^À³
|
¹x¥Û¤j©Ò¨¥¬Æ¬O¡C¦b¦¹¶È°µ¤@ÂI¤p¤p¸É¥R¡G 1.¡u¡K¡KIgM¤W¤Éªº³t«×¤ñ¸û§Ö¡A¦ý¬O¯f¤HªºIgM»PIgGªº§K¬Ì¤ÏÀ³¬O§_°ª«×¥¿¬ÛÃö¡A§Ṳ́£±o¦Óª¾¡C¦pªG°ª«×¬ÛÃö¡A´N¯à¥HIgM¨Ó±À´úIgGªº§K¬Ì¤ÏÀ³±j«×¡A¨º·¥¦n¡K¡K¡v¡C¾Ú±x¥Ø«eªº½T¦³¦¹¦Ò¶q¡A©Ò¥HÓ¤H±À´ú¡A¡u¥i¯à¡v¤w¸g§ä¨ì¡u°ª«×¬ÛÃö¡vªºÃÒ¾Ú¡C 2.·íªì°lÂÜIgG/IgMªº®Éµ{¬O²Ä3¶g¡B²Ä5¶g¡B²Ä9¶g¡B²Ä13¶g¡B²Ä17¶g¡B²Ä25¶g¡K¡]¥i¥H¬Ý¨ì¦b³o¨Ç¶g¼Æ®É¡A¦bY¶b¤Wªº¨è«×·|©¹¤W©úÅã©Ô¤É¡^¡A©Ò¥H®M¥Î¦bNo.15ªº¹Ï¨Ó¬Ý¡AIgM¦b²Ä9¶g¹F¨ìY¶b50%¦ì¸m¡F¦b²Ä17¶g°lÂܮɹF¨ìY¶bªñ60%ªº¦ì¸m¡C³o¤ñ°_IgGn¨ì²Ä25¶g¤~¹F¨ìY¶b50%¦ì¸mn´£¦³\¦h¡C |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/16 ¤U¤È 11:44:14²Ä 2040 ½g¦^À³
|
¤p©_¤j §Úèè·NÃѨì, ¤U¤Èªº¯d¨¥, ¹ï©ónumber of riskªº©w¸q»P§Aªº¨ä¹ê¤£¤@¼Ë ¤W¤@½g¯d¨¥, ¬O¥H§A©Ò©w¸qªºnumber of risk, ¨ÓÄÄz§Ú·Qªí¹Fªº¨Æ±¡ ¯Âºé¼á²M¤@¤U |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/16 ¤U¤È 11:05:43²Ä 2039 ½g¦^À³
|
¯E§J¤j¡A §ë¼v¤ù²Ä15¶¡AIgG titer >= 1:160 ªº¯f¨Ò¼Æ¬O³vº¥»¼¼Wªº ( >= 1:160 at any time during the trial )¡A©Ò¥H¦³¨Ç¯f¤H¶V¹LªùÂeªº®É¶¡¦¡A¦³¨Ç¯f¤H¶V¹LªùÂeªº®É¶¡±ß¡C¦pªG¬O¥H50%¯f¤H¨ì¹F³oÓªùÂe¡A©Ò»Ýnªº®É¶¡¬O24¶g¡A¤»Ó¤ë¡C¦pªG¬O²Ä8¶g¡A¶V¹LªùÂeªº¯f¤HÁÙ¤£¨ì20%¡C¨ì12Ó¤ë®É¡A²Öp¹L 1:160 ªùÂeªº´N¦³60%¯f¤H¤F¡C IgM¤W¤Éªº³t«×¤ñ¸û§Ö¡A¦ý¬O¯f¤HªºIgM»PIgGªº§K¬Ì¤ÏÀ³¬O§_°ª«×¥¿¬ÛÃö¡A§Ṳ́£±o¦Óª¾¡C¦pªG°ª«×¬ÛÃö¡A´N¯à¥HIgM¨Ó±À´úIgGªº§K¬Ì¤ÏÀ³±j«×¡A¨º·¥¦n¡A¦]¬°IgM¨ì²Ä8¶g´N¦³40~50%¨ü´ú¯f¤H¶V¹LªùÂe¡C (¨£BH567¤jªº¦^¤å) ÂåÃIJ¦³º¬O¬Û·í¨Ì¿à¸gÅç»P²Îp¬ÛÃö©Êªº¤@ªù¬ì¾Ç¡A¤£§¹¥þ¬O¾a¸ÌßA´N¯à·d©w¡C©Ò¥H¤T´ÁÁ{§É®É¡A«ç¼Ëªº¿z¿ï¾÷¨î¥i¥H³Qµø¬°a priori¡A«ç¼Ë·|³Qµø¬°post-hoc¡A³o¬On¸òFDA¥h°Q½×ªº¡C§ÚÌ»¡¯}¤F¼L¤]¨S¥Î¡C¤£¹L¡A³o¦¸Á{§Éµ²ªG¤ÀªR©Ò¨Ï¥ÎªºIgG titer >= 1:160 subgroup¡AªÖ©w¬Opost-hoc¡C³o¤£¬O°ÝÃD¡A¦]¬°±qpost-hoc¤ÀªR¤¤§ä¨ì¿z¿ï¾÷¨î¡A¦A¥Ñ¤T´ÁÁ{§É¥hÅçÃÒ³oÓ¿z¿ï¾÷¨î©Ò§ä¥Xªºsubgroup¥i¥H³Q822¦³®ÄªvÀø¡A´N¤£¬O¥ý®g½b¦Aµe¹v¤F¡C Theratopeªºpost-hoc¤ÀªR©Ò§ä¨ìªºÀø®Ä¬ÛÃö©Ê¡A¨Ã¤£¯àÅý¥L®³ÃÄÃÒ¡C¦]¬°±q¤@°ïÀH¾÷¼Æ¾Ú·í¤¤¡A¥Î¦UºØ¤£¦Pªº¼Ò«¬¥hfit¡A¤@©w·|¤S¦³¤@¨Ç¼Ò«¬·|Åã¥Ü¥X¬ÛÃö©Ê¡C©Ò¥H¨Æ«áµo²{ªº¬ÛÃö©Ê¬O¨S¦³»¡ªA¤OªºÃÒ¾Ú¡C¦pªG¦A¶]¤@§åÀH¾÷¼Æ¾Ú¡A¥Î³oÓ¼Ò«¬¥hfit´N¬Ý¤£¨ì¬ÛÃö©Ê¤F¡A¦]¬°¥À¼Æ¬OÀH¾÷ªº¡CTheratope©Òµo²{ªº¤@Ó¯S©w¦³®Ä±Ú¸s¬°¦ó¤£¦A°µ¥t¤@Ó¤T´Á¥hÅçÃÒ¡H¤p§Ì¤£¬O±M·~¡A¤£´±ÀH«K¤UÂ_»y¡C©Î³\Merck¦Û¤v²M·¡¥¦ªºÃIJz¾÷¨î¬O¤£©ú½Tªº¡A¤]©Î³\¥LÌ»{¬°³oÓ¯S©wÀøªkªº¦³®Ä©Ê¤£¨¬¥H§Î¦¨È±o°µÁ{§Éªº·sÀøªk¡CÁ`¤§¡A¨S¦³¸g¹L¤@Ópriori±ø¥óÅçÃÒªºpost-hoc finding¡A¤£¥u®³ÃÄÃÒ¬O¦³°ÝÃDªº¡A¬Æ¦Ü©ó³s¬ì¾Ç»ùȳ£¤£½T©w¡C ¦ý¬O¡A822©Ò§ä¨ìªº³oÓ 1:160 ªº«ü¼Ð¡A¦ü¥G¯à¦b³\¦h¥æ¤e¤ÀªR·í¤¤³£¬Ý¨ì¤@P©Êªº¦³®ÄÁͶաC°ò¥»¤W¡A³o´N°ª«×±Æ°£¤F¥¦¥u¬O¡y½M¿ß¸I¤W¦º¯Ó¤l¡z¦¡ªºÀH¾÷«ü¼Ð¡C¥ÎÃþ¦üªº«ü¼Ð¦A°µ¤T´ÁÁ{§É®É¡A´N¦¨¬° a priori¡A¥B¦¨¥\¥i´Á¡C ¥xÁÞ¤j¡A ¤p§Ì¦³¤@ÂI¦a¤è¤£¦P·N±zªºpºâ¡C822¥Ø«e¦b°µªº¬O¥þ²yÁ{§É¤G´Á¡A¦Ó¦b¥xÆWFDA«h¬O¦P·NÁ{§É¤G¤T´Á¦X¨Ö°µ¡C©Ò¥H822¦Ü¤µ¨Ã¨S¦³³q¹L¥ô¦ó¤@ÓÁ{§É¤G´Á¸ÕÅç¡C¯E¤Í̦U¤H¹ï822ªºÁ{§É¼Æ¾Ú¬O§_¦³«H¤ß¬O¤@¦^¨Æ¡A¦ý¬OMOA»Pproof of concept¬O§_¯àÅýFDAÂIÀY¡AÁÙn´XÓ¤ë¤~ª¾¹D¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/16 ¤U¤È 11:00:17²Ä 2038 ½g¦^À³
|
©l®Æ¥¼¤Î¡A¦³´X¦ì¤j¤j¹ï½²¸³ªºµû½×¬Ot±ªº¡AÓ¤H¨Ã¤£¦p¦¹»{¬°¡F§Ú¤£»{¬°¥L¦b§åµû¬Æ¦Ü¼J¯º¯E¹©¸Ñª¼ªºµ²ªG¡AY¬O§åµû¡A¨º§Ú·|¤£®h¤@ÅU¡A§ó§O»¡ÁÙ¶K¤W¨Óµ¹¤j®a°Ñ¦Ò¡C §ÚËı±o¬O´i´i¬Û±¤§a¡I¥L̨â¦ì¦U©~¤@¤è¡A¦³¦U¦Ûªº²£·~n¾Ä°«¡A«o¦³µÛ¬Û¦Pªº¥Ø¼Ð¡X«÷FDAªºÃÄÃÒ¡A¤]«÷¥xÆW¤§¥ú¡F¹³¬O¨â¦ì³Ç¥Xªº¿ï¤â¡A¤@¦b¥Ð¤@¦b®|¡A¦ý¬O³£§Æ±æ½l³y¦nªº¦¨ÁZ¡A©¼¦¹¤§¶¡¨Ã¨S¦³Ävª§ªº°ÝÃD¡A¤Ï˦b©¼¦¹ªº°V½mijÃD¤W¥i¥H¥æ´«¤ß±o¡C¨Ã¤£¬O½Ön¥h§åµû½Ö©Î¬O«ü¾É½Öªº°ÝÃD¡C §Ú¬O¬Ý¨ì½²¸³¦b»PFDA¥æ¤âªº¹Lµ{¤¤¡A¹Á¸ÕºN¯ÁFDAªº¤ß«ä¤W¦³ÂI¸gÅç¡A¤~·Q¨ì¥LªºÆ[ÂI©Î³\¥i¥H·í§@°Ñ¦Ò¡AÓ¤H»{¬°¥L©Ò´£¨ìªº¬O¤jªºÁ{§É¸ÕÅçÆ[©Àªº¼h¦¸¡A¦Ó«D°Q½×Àù¯g¥ÎÃĪº¤p½d³òªº¼h¦¸»â°ì¦Ó¤w¡C¦Ü©ón¤£n¬Ý½²¸³¦Û®aªº·sÃįण¯àÅã²{¦]ªGÃö«Y¦A¨Óµû¦ô½²¸³ªºµo¨¥¦³¨S¦³»ùÈ¡K¡K¡A¥i¥Hµ¥¤j¤j̬ã¨s¹LNMDARªº¾÷Âध«á¡A¤p§ÌÄ@¦b¤ß®®ª©®¥Ô¤j¾r¡K¡K¡A³o¬O¦h»ò¨S¦³¥²nªº¯U¹iÆ[ÂI¡I¥t¡A¦b¤HÅéÃÒ¹êGlobo H seriesªºMOA¡A¬OOPT-822-001ªº«n¥ô°È¤§¤@¡A¥H«e²Ö¿nªº¸gÅç»PÃҾڨëDª½±µ¨Ó¦Û¤HÅé¡A³o¦¸ªºÁ{§É¸ÕÅç¤~º¦¸¦b¤HÅé¤W¦³ÅçÃÒªº¾÷·|¡A³o¤@ÂIAmy¸g²z¤w¸g´£¹L¡C °ò¥»¤W§Ú¤£·|¦]¬°½²¸³ªº¤@½gµû½×ªº¤å³¹´NÅ嬰¤Ñ¤H¡AÓ¤H»{¬°¨â¦ì¸³¨Æªø³£¨ã³Æ¤@©wªº¤ß¯Ý»P¾ú½m¡A¤£¹L¨CÓ¤H¹ï½²¡B±i¤G¤Hªº»{ÃѨ䣬ۦP¡A§Ú»P¨ä¥L¤j¤j©Ò¬Ýªº±¦V¤]¥i¯à¤£·|¬Û¦P¡C ¥|®ü¥S¡B¥xÁÞ¥S¤Î½Ñ¦ì¤j¤j¡A·PÁ´£¨Ñ¬Ýªk¡C |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/16 ¤U¤È 10:48:36²Ä 2037 ½g¦^À³
|
¤p©_¤j ·PÁ§Aªº¦^ÂÐ, ¦A¦¸¹ïnumber at risk°µ»¡©ú, (¦pªG¦bÁ{§É«e´N©w¸q¦n²Õ§O¡A¹êÅç²Õ¦³N¤H¡A®É¶¡=0¦P®É¤]¬O¾÷²v=1¡Anumber at risk´N¬O=N¡AµM«áÀHµÛ¥X²{³]¸ê®Æ©ÎOS¨Æ¥óµo¥Í¦Ó³vº¥¤U°¡C) §Ú¹ïnumber of riskªº»{ª¾»P§A¬Û¦P §Ú·Qªí¹Fªº¤ñ¸ûºâ¬O¹ï (¦pªG¬O¹³¯E¹©¿ï¤F§ÜÅé®Ä»ù¡Ù1:160ªº¦¸±Ú¸s¨Ó¤ÀªR¡A´N¨Ì³oӼзǡA¥un¥ô¦ó®É¶¡§ÜÅé®Ä»ù¡Ù1:160ªº±wªÌ´NÂk¤J³oÓ¦¸±Ú¸s¡Apºâ°_¨Ó¦@¦³112¤H¡A©Ò¥H³oÓ§ÜÅé®Ä»ù¡Ù1:160ªº¦¸±Ú¸s¡A·í®É¶¡=0¦P®É¤]¬O¾÷²v=1¡Anumber at risk´N¬O=112) ³oÓ°µªk¦X²z©Êªº½èºÃ Y¬O¥ÎHER2+/-¨Ó¤ÀÃþ, ¹êÅç²Õ¤¤ HER2+¦³35¤H, ·í®É¶¡=0®É¦P®É¤]¬O¾÷²v=1, number of risk¦³35¤H HER2-¦³189¤H, ·í®É¶¡=0®É¦P®É¤]¬O¾÷²v=1, number of risk¦³189¤H ³o¼Ëªº¤ÀÃþªk, ¥i¥Î¨Ó¤ÀªRHER2+/-ªºÀø®Ä®t²§, §Ú¯à²z¸Ñ¤]»{¬°¨S¦³°ÝÃD ²¦³ºHER2+/-, ¬O¤@¶}©l´N¨M©w¦n¤F, ¤£·|¦A¹êÅ礤³~¼W¥[©Î´î¤Ö ¦ý§Ú»{¬°, ¥Î(¥ô¦ó®É¶¡§ÜÅé®Ä»ù¡Ù1:160)·í¼Ð·Ç¨Ó¤À²Õ, µM«á¥Î³Ì«á²Îpªº¤H¼Æ¦^±À·í§@®É¶¡=0®Éªºnumber of risk, ¬O¦³°ÝÃDªº, ¦]¬°²Å¦X³oÓ±ø¥óªº¤H¼Æ¬OÀH®É¶¡Åܲ§ªº §â²Ä8¶g, ²Ä12¶g, ²Ä16©P¤~¶}©l²Å¦X±ø¥óªº¤H¯Ç¤J, ¦^±À¥h·í¦¨®É¶¡=0®Éªºnumber of risk, ¯uªº¦X²z¶Ü? ¦b°ª§ÜÅé¤ÏÀ³²Õ¸Ì, ²Ä8¶g¤~²Å¦X±ø¥ó¯Ç¤Jªº¤H, ¤w¸g½T«O²Ä8¶g¤§«e¨S¦³¨Æ¥óµo¥Í ¬Û¹ïªº, ¥ÎHER2+¤l¸s²Õ¸Ìªº¤H, ¨S¦³«OÃÒþӮɶ¡ÂI«e¤£·|¦³¨Æ¥óµo¥Í ¥Î§ÜÅé°ª/§C¨Ó¤À²Õ, ©M¥ÎHER2+/-¨Ó¤À²Õ, ¬O¤£¬O¥»½è¤W¦³©Ò®t²§©O? n®³¨Ó·í§@¤À²Õªº¼Ð·Ç, À³¸Ónº¡¨¬¤@©wªº±ø¥ó¤~¦æ Á|Ó·¥ºÝªº¨Ò¤l, ¦pªG§Ú¥Î³o¼Ëªº¼Ð·Ç¨Ó¤À²Õ:(¥´º¡¤E°w), ¨º»ò¹êÅç²Õ¤]¥i¥H¤À¦¨¨â²Õ ¥´º¡¤E°w²Õ, ¤H¼Æ104¤H, ®É¶¡=0®É¦P®É¤]¬O¾÷²v=1, number of risk=104 ¥¼º¡¤E°w²Õ, ¤H¼Æ120¤H, ®É¶¡=0®É¦P®É¤]¬O¾÷²v=1, number of risk=120 ³o¨â²Õ¤]¥i¥H®³¥h©M¹ï·Ó²Õ¤ñ¸û, ¶]²Îp, µM«á¨ã¦³²Îp¤WÅãµÛªº®t²§ ¥´º¡¤E°w²Õ¤@©w§¹³Ó¹ï·Ó²Õ, ¥¼º¡¤E°w²Õ¤@©w§¹±Ñ¹ï·Ó²Õ, ¦ý¬O³o¼Ëªº¤À²Õ¤ñ¸û, «Ü©úÅã¬O¤£¤½¥¤]¨S¦³·N¸qªº n¶]²Îp®É, »Ýn½T©w¦³¦h¤Ö¤H ¦ýY¤À²Õªºì«h¥»¨´N¦³°ÝÃD, ¨º¶]¥X¨Óªº²Îp¼Æ¦r, ÁÙ¦³·N¸q¶Ü? ¤£ª¾¹D³o¼Ëªº¸ÑÄÀ»¡±o³q¶Ü? |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/16 ¤U¤È 10:40:26²Ä 2036 ½g¦^À³
|
QQ¤j±z¦n¡G «Ü©êºp ¦]¬°¤p§Ì¦b¦£ ©Ò¥H²{¦b¤~¦^Âбzªº°ÝÃD¡K 1.¤@¯ë¨Ó»¡ ±µºØ¬Ì]©Î§ÜÅé ³Ì±`¨£ªº°Æ§@¥Î ´N¬O¤Þµo¹L±Ó¤ÏÀ³ ¦Ó·|¤£·|¤Þµo¹L±Ó¤ÏÀ³ ´N¸ò±µºØ¬Ì]©Î§ÜÅ骺ÓÅ餧§K¬Ì¤O±j®z¦³Ãö ¬ÛÃö½×z ¥i°Ñ¦Ò¤U¦C²LÅã©öÀ´ªº¹L±Ó¤ÏÀ³¤¶²Ð www.ntuh.gov.tw/derm/healthcareCenter/healthCenter/%E9%81%8E%E6%95%8F%E8%88%87%E5%81%A5%E5%BA%B7.aspx 2.Àù¯g¯f±wªº§K¬Ì¨t²Î ¯S§O¬OÀù¥½¯f¤H ¥»¨Ó´N¸û¥±`¤H®z ©Ò¥H 822n¤Þ°_¹L±Ó¤ÏÀ³²Ä¤T«¬ªº¦å²M¯fªº¾÷²v ·L¥G¨ä·L ¦ý888´N¤£¦P¤F 888¥»½è¬O§ÜÅé ¨ä¤À¤l»·¸û822¨Óªº¤p §Y¨Ï §K¬Ì¤O¦A®z 822´N¹³¦a¤W50¤¸»ÉªO ¦Ó888¬O¤d¤¸¤j¶r n¤£Åý¸ô¹Lªº§K¬Ì¨t²Î¤À¤lª`·N³£Ãø 3.¦]¦¹ ¤p§Ì«e¤å¤~»¡¾á¤ß888ªº°Æ§@¥Î¡]¦p¡G¤ÞµoÄY«¹L±Ó¤ÏÀ³©Î¦å²M¯f¡^ ±©¦^¨ì«e±©Ò»¡ªº ÓÅé§K¬Ì¨t²Î¨S¦³¥\¯à©Î¥¢¥h¥\¯àªº¸Ü ®Ú¥»¤]¤£¥Î¾á¤ß ¬O§_·|¤Þ°_±j¯Pªº°Æ§@¥Î¡]¥B¦ý¦pªG¨S¤Þµo¦å²M¯f·ÀIªº¯f¤H ¨äÀø®Ä¤]¤£¤j---¡Ö¡¨¥B¡¨¬O¥´¿ù¦r¡^ 4.¥Ñ²Ä3ÂI ¤SÃÒ©ú§K¬ÌÀøªkªº¦n³B ¦w¥þ©Ê°ª ¤ÆÀøÃĪ«µL®Ä ¦ýÁÙ¬O¹ï·|¨Åé²£¥Í°Æ§@¥Î¡C ¤p§Ì·N¨£ ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~ ·q½Ð«ü¥¿ |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/16 ¤U¤È 10:27:01²Ä 2035 ½g¦^À³
|
¤p§Ì¦Vª©¥DCliff¤j»¡Án©êºp¡A¤p§ÌÂ÷ÃD¤F¡A ¤p§Ìªº¸Ü´N¦¹¥´¦í¡A©êºp¡I |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/16 ¤U¤È 09:38:04²Ä 2034 ½g¦^À³
|
·x·x¤j¡A±z»¡ªº¦n¡A³o´N¬O°µ¤H³B¨Æªº°ò¥»--------«p¹D¡C ¬ÝÃl¤j¡A±z»¡ªº¤]¦³²z¡A¦ý¦b½²¸³ªº¸Ü»y¤¤¡A¤p§Ì¬Ý¨ì¤F©¶¥~¤§µ¡A ¨º´N¬O--------»¡¨º»ò¦h·F¹À¡I¥Dn«ü¼Ð¨S¹F¨ì¡A´N¨S¹F¨ì¡A»¡¤°»ò¡u«á¨£¤§©ú¡v¡A ÁÙ¥H¥ª¸}Ãö¸`ª¢¨Ó¿Ø¨ë¯E¹©¡C--------¦ýÄ@¬O¤p§Ì·Q¤Ó¦h¡C Äx²y¤§¯«--³Á§J¡D³ì¤¦¡A´¿¸gÂà¶]¹D¡A¥h¥´´Î²y¡CÁöµM³£¬O¹B°Ê¡A¦ýn±N´Î²y¥´ªº¸òÄx²y¤@¼Ë¦n¡A ¨ä¨Å骬ªpªºn¨D¬O§¹¥þ¤£¦Pªº¡A©ó¬O³ì¤¦¥u¯à±q2A¡B3A¥´°_¡Aµ·²@¨S¦³Àu«Ý¡C ¹j¦æ¦p¹j¤s°Ú¡I ¤j®a³£¬O¥xÆW¤H¡A¯Î±Ò´f¦¨¥\¡B¯E¹©¦¨¥\¡A³£¬O¥xÆWªºÅº¶Æ¡C ¤l¤ê¡G¡u§g¤l¦¨¤H¤§¬ü¡A¤£¦¨¤H¤§´c¡C¤p¤H¤Ï¬O¡C¡v |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/16 ¤U¤È 09:31:17²Ä 2033 ½g¦^À³
|
²³¤j¤j Cliff¥S ©ß¥X½²±Ð±Â¬ì¬ãªº¯ª¥À©w«ß ¤Þ°_²³¤j°Q½×! ¥H¤U¬O¤À¨ÉÓ¤H¬Ýªk,ťť´N¦n,¦³¿ù½Ð§ó¥¿ . («nªº¬O¦Û¤vn°ö¾i¿W¥ß«ä¦Ò) 1©â·Ï¤£¤@©w·|±oªÍÀù, ¦ý·|¼W°ª±oªÍÀù·ÀI,¯E¹©¦b«°T´£¨ì§ÜÅé¿@«×¶V°ª¡AÀø®Ä´N¶V¦n¡C³o¬O¥¿¬ÛÃö,¥¼¨Ó¯à²£¥Í¨¬°÷§ÜÅ骺¯f±w¨Ï¥ÎOBI822´N·|¦³«Ü¦nÀø®Ä,¥ý±q¦³¬ÛÃö¤Á¤JÁ{§É¸ÕÅç¤]§ó®e©ö¦¨¥\,³o¬OÁ{§É¸ÕÅç«á¤~µo²{¨ìªº,¬ì¾Ç¬ã¨s¦³½Ö¯à¦ª¾¹D³o¨Çµ²ªG, ¬ì¾Ç¬ã¨s´N¬O®Ú¾Ú¤wª¾,±´°Q¥¼ª¾,¯S§O¬OÀù¯g§K¬ÌÀøªk¥þ¥@¬É³£¦bºN¯Á¬ã¨s,¯E¹©¬ãµo¹Î¶¤¤]¤@¼Ë§V¤O¬ã¨s§ä¥XOBI822ªº¯ª¥À©w«ß (ªÑªF¤]¤@¼Ë¦b¾Ç²ßºN¯Á»P¬ã¨s) 2²Îp¤§¬ü¦b¯à©ó¤@°ï¸ê®Æ¤¤§ä¨ì¬ÛÃö,§ä¨ìÅå©_, §ä¨ì¥¼ª¾,¤£Â_ºë¶i,«P¶i¤HÃþ¤å©ú»P©¯ºÖ.,«Ü©¯¹Bªº¬O¯E¹©§ä¨ì¤F, °£¤F¨ÅÀù¥~¤]§ä¨ì¨ä¥L¤Q¥|ºØÀù¯gªvÀøªº¼ç¤O,¤£¦ý§ä¨ì¤@Ó¹v ,§ó§ä¨ì¨ä¥L¨âÓ¹v,¤£¦ý¯àÄè·ÀÀù²ÓM¤]¯àÄè·ÀÀù·F²ÓM,¤£¶Ë¤Î¥¿±`²ÓM 3½²±Ð±Â:¯ª¥À©w«ßÀ³¥Î¦b¬ì¬ã¤W¡A·N«ü±´°Q¯u²z¹Lµ{Áö¼³®Ò°gÂ÷¡A¤@¥¹¯u¬Û´¦µo¤§«á¡Aµ´¤j³¡¤À²³æªºÃø¥H·Q¹³¡A¨S¦³±M·~°V½mªº¯ª¥À³£¥i¥HÀ´¡C(¯E¹©§ä¨ì¿z¿ï¨ÅÀù¯f±wªºÂ²³æ¤èªk>>¯ª¥À©w«ß) 4¦Ü©ó¦]ªGÃö«Y¯Î°|ªøªºÁ޾Ǭã¨s¤wµoªí¤£¤Ö½g¬ã¨s½×¤å, ½²±Ð±Â¦³ªÅ¥i¦n¦n¬ãŪ¤@µf, ¥t¥~¯E¹©Á{§É¸ÕÅç¤]¯à»¡©úÃĮľ÷¨îMOA ³oÀ³¸Ó´N¬O¦]ªGÃö«Y,(¯E¹©¤wÀò±o4¶µ¬ü°ê±M§Q 14¶µ¥þ²y±M§Q 32¶µ±M§Q«Ý¼f¤¤ Strong worldwide IP protection ) 4¤j®a¤]«Ü´Á«Ý¨ì®ÉԬݬݽ²±Ð±Â¯à¤£¯à»¡©ú¦Û®aÃĪ«ªºÀø®Ä¬O§_¦³¦]ªGÃö«Y©Î ¬O§_¬°¦w¼¢¾¯®ÄÀ³?¬O§_¯à»¡©úÃĮľ÷¨îMOA 5¨Ì¾Ú Clinical Development Success Rates 2006-2015 Psychiatry ¬ãµo¦¨¥\¾÷²v Clinical approval success rate (%) ¥H Phase II to Phase III ¬ãµo¦¨¥\¾÷²v³Ì§C ( p 9 p10 ) Phase I to Phase II 53.9 % Phase II to Phase III 23.7% Phase III to NDA/BLA 55.7% NDA/BLA to Approval 87.9% ±q Phase I ¨ì Approval ¾÷²v ( 53.9 % X 23.7% X 55.7% X 87.9% = 6.25 % ) www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf @@ «Øij²³¤j¤jÀ³³WÁ׳̤jªº¤G´Á·ÀI,¤G´Á³q¹L¤F¦A¥X¤â¤]¤£¿ð 6Àù¯gÃĪ«¬ãµo¦¨¥\Ãø«×¤]«Ü°ª,¯E¹©¨ÅÀùÃĦܤ֤w¸g§¹¦¨¤T´Á ,²æÂ÷¤G´ÁÁ{§É¥¢±Ñ²v³Ì°ªªº·ÀI (oncology: Probability of Phase II Success 25% ) 7¯E¹©¤wªí©ú¤£·|n¨Dקïªk³W: ¹Ãĸp¡G§Úªk³W¤ñ·Ó°ê»Ú½ÃºÖ³¡¹Ãĸp½²§Þ¥¿ªí¥Ü¡A§Ú°ê¹ïÀù¯gÃÄ«~ªºªk³W§¡¤ñ·Ó°ê»Ú¡AµL¸¨«á°ÝÃD¡A¤£·|¦]®×קï¡A¦ý±À´ú·~ªÌ©Ò«ü¨Ã«D¬Oקïªk³W¡AÀ³¬O¬ã¨sµ²ªGÁö¥¼¹F¹w´Á¥Øªº¡A¦ý¥i¯à¹ï©ó¯S©w±Ú¸s¦³ÅãµÛªº²Îp·N¸q¡A¤£±Æ°£·Q¶i¤@¨B×¥¿ì¥ýªº¬ã¨s³]p¡AÂÇ¥H¹F¼Ð¡A©Z¨¥³o½T¹ê¬O¦³¥i°Q½×ªºªÅ¶¡¡C 8¬ü¥x¹ï©ó¬ã¨sµ²ªGÁö¥¼¹F¹w´Á¥Øªº¡A°²³]¦w¥þ©Ê°ª¹ï©ó¯S©w±Ú¸s¤S¦³ÅãµÛªºÀø®Ä»P²Îp·N¸q¤]¬O¥i¥H®ÖãÃÄÃÒ, (¦Ñ¥v¥S¤w´£¨Ñ«Ü¦h§K¬ÌÀøªk¬ÛÃöªk³W¸ê°T) ¸É¥R: ¦w¼¢¾¯®ÄÀ³ placebo effect ¦w¼¢¾¯®ÄÀ³«ü¯f¤HÁöµMÀò±oµL®ÄªºªvÀø¡A¦ý«o¹w®Æ©Î¬Û«HªvÀø¦³®Ä¡A¦ÓÅý¯f±w¯gª¬±o¨ìµÎ½wªº²{¶H¡C Kahn¤½¥¬¤F¤@¶µ¦³Ãö§Ü§íÆ{ÃĪº¾ã¦X¤ÀªR¡]meta-analysis¡^¡Aµo²{ªA¥Î¦w¼¢¾¯ªº¸s²Õ¤¤¥X²{¦Û±þ©Î¥ø¹Ï¦Û±þªº±¡ªp¤U°¤F30%¡A¦ÓªA¥Î§Ü§íÆ{¾¯ªº¸s²Õ«h¤U°40%¡C (¨â²Õ³£·|°) zh.wikipedia.org/wiki/%E5%AE%89%E6%85%B0%E5%8A%91%E6%95%88%E6%87%89 |
|
|
·|û¡G¬ÝÃlµL10141462 µoªí®É¶¡:2016/6/16 ¤U¤È 09:17:24²Ä 2032 ½g¦^À³
|
·x·x¤j~ ¬Oªº¡A§Ú¤]·|³o»ò¹ï¤pªB¤Í~ ¥u¬O¡A¤j®a³£¥XªÀ·|¤F ¡K ¦b¶}·|®É¡A©ÎªÌ¬O¦b½Í¨Æ±¡®É ¡K À³¸Ó¤£·|³o»ò©Mµ½ ............ XD ªp¥B±i¸³¤£¬O¤pªB¤Í°Ú~¥L·d¤£¦n¤ñ½²¸³ÁÙ¦~ªø? ¨ä¹ê§Ú¤]¤£·|ı±o½²¸³»¡ªº¦³¤°»ò¤£¹ï°Ú~ ³oÃþÁo©ú¤H¡A¹ï¤H»Ú¤Wªº³B²z¡A¥»¨Ó´N¤ñ¸û¤£·|×¹¢~ ¯Î°|ªø¤£¤]¤@¼Ë¶Ü ^_^~ ©Ò¥HÅo~~¤£¥Î¤Ó¹L«×¸ÑŪ½²¸³ªº¤f®ð~ «e±c¤j¤]»¡¡A½²¸³ªº½×ÂI©M±i¸³ªº¤è¦V¬Û¦ü¡A¤£´Nµ¥©ó¤]¦³¤HÀ°¦£I®Ñ¤F¶Ü ¡K ©¹¦n³B·Q·Q¡A¤£¤]®¼¦n? |
|
|
·|û¡G·x·x10141215 µoªí®É¶¡:2016/6/16 ¤U¤È 09:03:41²Ä 2031 ½g¦^À³
|
¬ÝÃlµL¤j: ¦pªG¤pªB¤Í°µ¤F«Ü´Îªº¨Æ,§Ú·|§i¶D¥L:§A«Ü´Î!!!~¦pªG¥L°µªº¤£¦n,§Ú·|§i¶D¥L³o¦¸°µ¤£¦n¨SÃö«Y,¥unÄ~Äò°í«ù,·Q·Qþ¸Ì°µ¤£¦n,¤U¦¸¤@©w·|°µ±o§ó¦n,§ó´Î! |
|
|
·|û¡G¬ÝÃlµL10141462 µoªí®É¶¡:2016/6/16 ¤U¤È 07:01:41²Ä 2030 ½g¦^À³
|
Ä~Äò¨Ó«ôŪ¦Ñ¥v¤jªº¤å³¹¡A ªGµMÁÙ¬O¦Ñ¥v¤j¤ñ¸û«ÈÆ[ ¡K ¤£·|¤@¬Nªº¤£¯à±µ¨ü©M¦Û¤v¤£¦PÃ䪺·N¨£¡C |
|
|
·|û¡G¬ÝÃlµL10141462 µoªí®É¶¡:2016/6/16 ¤U¤È 06:55:59²Ä 2029 ½g¦^À³
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/16 ¤U¤È 02:15:16²Ä 2062 ½g¦^À³ ¯E¹©¸Ñª¼¡A¥~°ê¼ö¤£¼ö¤p§Ì¤£ª¾¹D¡A°ê¤º¤@©w«D±`¼ö¡C ³s½²±Ð±Â¤]¨Ó´¡¤@¸}(½²±ÐYÂk¯Ç¬ü°ê¡A¨º¥~°ê¤]«Ü¼ö)¡A¤p§Ì»{¬°°ê»Úºë¯«¬ìÅv«Â¦b´CÅéµoªí¡u¯ª¥À©w«ß¡v¨Ó¸ÑŪ¯E¹© ¬O¦Û°®æ§½¡C ¹j¦æ¦p¹j¤s¡AÁöµM¬ã¨s²Îp¤èªk¬O¤@P³q¥Î¡A¦ý°ÝÃD´N¦b¸~½F±z¤F¸Ñ¦h¤Ö¡HFDA·|¥Îºë¯«¯f¥ÎÃĪº¼Ð·Ç¨Ó¬Ý§K¬ÌÀøªk¡H µS°O±o2¤ë¸Ñª¼«á¡A¤C¼L¤K¦Þ¡A¤°»ò¤H³£¥i¥H´¡¤W¤@¥y¡A56¥x¨H¤j¯¥¡B°êxÐÞªº¤£¤À°Ï¥ß©exx¥Á¡BÁÙ¦³¤°»òºaÁ`xxÂå®v¡A ³oÁÙ³£¬OÂå¾Ç¬ÛÃöªº¤H¡A¤£¬Û¤zªº¤H»¡ªº§ó°_«l¡C¦p¤µ¦w¦b«v¡H ³oÅý¤p§Ì·Q¨ì¡A(¥H¤U±¡¹Ò¬Û«H¤£¤Ö¯E¤Í¤ß¦³±±²j)¡C ¤p§Ì¦³¦¸¦bË©U§£®É¡A¤@¦ì¾F©~°Ý¡A§A±q¨Æ¤°»ò¤u§@¡H¤p§Ì»¡¡AªÑ²¼§ë¸ê¡C¾F©~»¡¡A®@¡Iª±ªÑ²¼³á¡I(¤p§Ì±q¥¼»¡ª±³oÓ¦r) ¤p§Ì©È¥LÅ¥¿ù¡A¤S«ÂФ@¦¸¡A¨Ã§Æ±æ¥L¯à§ì¨ì«ÂI§ë¸ê¨âÓ¦r¡A¤£®Æ¥L¤S¦^»¡¡A§Ú©h©h¥H«eª±ªÑ²¼½ß«Ü¦h¿ú¡A²{¦b¤j½L¤£¿ù §AÀ³¸ÓÁȤ£¤Ö§a¡IÅRÆE°Ô°Õ¤S»¡¤F¤@°ï¡A¤ß·Q¡A¯u«á®¬¸ò§A»¡¨º»ò¦h¡C¤p§Ì¤ß²zÀY¦Ûtªº»¡¡Aµ¥§AªÑ²¼Áȫܦh¿ú«á¦A¨Ó¸ò §Ú»¡ªÑ²¼§a¡I ¤£»¡¸Ü¨S¦³¤H»¡±z¤£À´¡A»¡±o¶V¦h¡A¥u·|¦ÛÃn¨äµu¡C ½Ð°Ý±z·|µ¹¤@Ӻ믫¬ìÂå¥Í¬ÝÀù¯g¯e¯f¶Ü¡H§Y«K¥L¬O¦ìÅv«Â¡C ¤p§Ì¤@ª½Ä±±o¥xÆW¬°¤°»ò·|¦b³o´X¦~¸¨«áÁú°ê¡A¦b«Ü¦h¤è±¡C ¤@Ó«Ü«nªºì¦]¡A°ê¤H¤£¹Îµ²¡A¯Þ»K¦V¥~Ås¡C ´N»¡¥xÆW¤§¥úhtc¦n¤F¡A³\¦h¤H¤£Ä@±·³õ(¤°»òì¦]³£¦³)¡A´N¬O¤£¥Î°ê³f¡C¨ºhtc¤]«Ü©_©Ç¡A¤W¦^ÁÙ§â¦P¤ä¤â¾÷ ³W®æ¸û§Cªº¦b°ê¤º½æ¡A³W®æ¸û°ªªº½æ¨ì¥~°ê¡A¦Û§Ú¬Ý¶S¡C ¤º°««Ü¦æ(¬FÄÒ´c°«)¡A³s¯E¹©¤]¦¨¬°²½«~¡C ¬°¤°»ò´N¤£¯à»¡¥y¦n¸Ü¡H»¡¥y¦n¸Ü¦³³o»òÃø¶Ü¡H»¡¨Ç¹ªÀyªº¸Ü¦³¨º»òÃø¶Ü¡H ¤@©wn»¡ÃøÅ¥ªº¹ê¸Ü¡A¤~¯àÅã¥X¦Û¤vªº°ª¬ñ¶Ü¡H ¹L¥h¤ý«Ø¥Áªº¬v°ò±Ð½m¦«·ç¡A°OªÌ¦Ñ·R°Ý¤ý«Ø¥Á¤µ¤Ñ§ëªº¦n¶Ü¡H¦«·çÁ`¬OÆg¬ü©~¦h¡AÂA¤Ö³dÃø¡A ¨ä¹ê¡A¯u¬Û¬O§ëªº«ÜÁV¡C¬O¦«·ç¨S¬Ý¨ì¦³¦hÁV¶Ü¡HÁV¡A¨p¤UÁ¿´N¦n¡C ¥u¦³½²±Ð±Â¬Ý¨ì¯E¹©¹êÅç³]pªº°ÝÃD¶Ü¡H¦Û°®æ§½¡C ¤¨³Õ¤h¤]»¡¹L¡A¯E¹©¬O¦Û¤v¥XÃD¥Ø¡A¦Û¤v¦Ò®t¤F¡C ²{¦b¯E¹©ªº¬ã¨s¤Hû¦b°ê¥~¶}·|°Q½×¡A¤£´N¦b½Í³o¨Ç¶Ü¡H¦p¦ó§ï¶i¤T´Áªº³]p¡C ¨C¶¡¤½¥q¦³¨C¶¡¤½¥qªº°ÝÃD¡AY¤U¦^´«±i¸³»¡»¡¤ß®®ªºÁ{§É³]pµ²ªG¡A±z»{¬°¦X¾A¶Ü¡H ¯uªº¬OºÞ¤Ó¦h¤F¡I ¤p§Ìn»¡ªº¬O¡A¹ªÀyªº¸ÜY¬O±q½²±Ð»¡¥X¤f¡A¹ï¥Í§Þ·~¤@©w¬O¥¿±¦Vµ½ªº´`Àô¡C ³oªÀ·|±q¤£¯Ê§åµûªº¤H¡C ======================== »¡ªº¯u¦n ............. ©Ò¥H·N«ä´N¬O¥u¯àÆg¡A¤£¯à½| XD |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/16 ¤U¤È 06:25:45²Ä 2028 ½g¦^À³
|
pie¤j¡A number at riskªºÆ[©À¤£¬O³o¼Ë¥Îªº ¦pªG¦bÁ{§É«e´N©w¸q¦n²Õ§O¡A¹êÅç²Õ¦³N¤H¡A®É¶¡=0¦P®É¤]¬O¾÷²v=1¡Anumber at risk´N¬O=N¡AµM«áÀHµÛ¥X²{³]¸ê®Æ©ÎOS¨Æ¥óµo¥Í¦Ó³vº¥¤U°¡C ¦pªG¬O¹³¯E¹©¿ï¤F§ÜÅé®Ä»ù¡Ù1:160ªº¦¸±Ú¸s¨Ó¤ÀªR¡A´N¨Ì³oӼзǡA¥un¥ô¦ó®É¶¡§ÜÅé®Ä»ù¡Ù1:160ªº±wªÌ´NÂk¤J³oÓ¦¸±Ú¸s¡Apºâ°_¨Ó¦@¦³112¤H¡A©Ò¥H³oÓ§ÜÅé®Ä»ù¡Ù1:160ªº¦¸±Ú¸s¡A·í®É¶¡=0¦P®É¤]¬O¾÷²v=1¡Anumber at risk´N¬O=112¡AÀHµÛ®É¶¡±À¶i¡A¦]³]¤H¼Æªº¥X²{¤ÎOS¨Æ¥óªº¥X²{¦Ó»¼´î¡C ¨C¤@²Õªºnumber at risk¡A¦b®É¶¡=0¦P®É¤]¬O¾÷²v=1ªº®ÉÔ¡A¦bn¶]²Îp®É¡A´N¥²¶·½T©w¦³¦h¤Ö¤H¡A¸ò³oÓ¦¸±Ú¸s¬O¤°»ò¼Ëªº¤À²Õì«hµLÃö¡C Ynumber at risk¡A¦b®É¶¡=0¦P®É¤]¬O¾÷²v=1ªº®ÉÔªº¼Æ¦r=N¡A´Nªí¥Ü¦³NÓ¤H±N¶i¤J²Îp¤ÀªR¡A¶]²Îp®É¡A¤£¥ÎºÞ¥¦¬O«ç»ò©w¸qªº¡C |
|
|
·|û¡GBH56710142562 µoªí®É¶¡:2016/6/16 ¤U¤È 05:44:15²Ä 2027 ½g¦^À³
|
¥un²£¥ÍIgM»PIgG¼Æ¶qªºÃöÁp©Ê°ª(¬Ý¥H«á·|¤£·|¤½§G³oÃþ¸ê®Æ), ¨º§Ú·QÀ³¸Ó¥i¥HIgM«e4©P>80 ©Î 8©P>100 ©Î 12©P>120¤§Ãþªº¼Ð·Ç¥h¬D¿ï¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/16 ¤U¤È 05:31:32²Ä 2026 ½g¦^À³
|
½Ð±Ð¹x¥Û¤j IgG titer >= 1:160 ªº¯f¤H³£¥X½u»Ýnªáªñ12Ӥ몺®É¶¡¡C±z¬O¦p¦ó§PÂ_ªº¡H |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/6/16 ¤U¤È 02:21:44²Ä 2025 ½g¦^À³
|
³oªÀ·|±q¤£¯Ê§åµûªº¤H¡C =>ÆgÆgÆg ¥X¼L¦Û¤v °µ¦º§O¤H ·²D «u ´Á«ÝÂI¦n¨Æ ¦nÃøC |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2016/6/16 ¤U¤È 02:15:16²Ä 2024 ½g¦^À³
|
¯E¹©¸Ñª¼¡A¥~°ê¼ö¤£¼ö¤p§Ì¤£ª¾¹D¡A°ê¤º¤@©w«D±`¼ö¡C ³s½²±Ð±Â¤]¨Ó´¡¤@¸}(½²±ÐYÂk¯Ç¬ü°ê¡A¨º¥~°ê¤]«Ü¼ö)¡A¤p§Ì»{¬°°ê»Úºë¯«¬ìÅv«Â¦b´CÅéµoªí¡u¯ª¥À©w«ß¡v¨Ó¸ÑŪ¯E¹© ¬O¦Û°®æ§½¡C ¹j¦æ¦p¹j¤s¡AÁöµM¬ã¨s²Îp¤èªk¬O¤@P³q¥Î¡A¦ý°ÝÃD´N¦b¸~½F±z¤F¸Ñ¦h¤Ö¡HFDA·|¥Îºë¯«¯f¥ÎÃĪº¼Ð·Ç¨Ó¬Ý§K¬ÌÀøªk¡H µS°O±o2¤ë¸Ñª¼«á¡A¤C¼L¤K¦Þ¡A¤°»ò¤H³£¥i¥H´¡¤W¤@¥y¡A56¥x¨H¤j¯¥¡B°êxÐÞªº¤£¤À°Ï¥ß©exx¥Á¡BÁÙ¦³¤°»òºaÁ`xxÂå®v¡A ³oÁÙ³£¬OÂå¾Ç¬ÛÃöªº¤H¡A¤£¬Û¤zªº¤H»¡ªº§ó°_«l¡C¦p¤µ¦w¦b«v¡H ³oÅý¤p§Ì·Q¨ì¡A(¥H¤U±¡¹Ò¬Û«H¤£¤Ö¯E¤Í¤ß¦³±±²j)¡C ¤p§Ì¦³¦¸¦bË©U§£®É¡A¤@¦ì¾F©~°Ý¡A§A±q¨Æ¤°»ò¤u§@¡H¤p§Ì»¡¡AªÑ²¼§ë¸ê¡C¾F©~»¡¡A®@¡Iª±ªÑ²¼³á¡I(¤p§Ì±q¥¼»¡ª±³oÓ¦r) ¤p§Ì©È¥LÅ¥¿ù¡A¤S«ÂФ@¦¸¡A¨Ã§Æ±æ¥L¯à§ì¨ì«ÂI§ë¸ê¨âÓ¦r¡A¤£®Æ¥L¤S¦^»¡¡A§Ú©h©h¥H«eª±ªÑ²¼½ß«Ü¦h¿ú¡A²{¦b¤j½L¤£¿ù §AÀ³¸ÓÁȤ£¤Ö§a¡IÅRÆE°Ô°Õ¤S»¡¤F¤@°ï¡A¤ß·Q¡A¯u«á®¬¸ò§A»¡¨º»ò¦h¡C¤p§Ì¤ß²zÀY¦Ûtªº»¡¡Aµ¥§AªÑ²¼Áȫܦh¿ú«á¦A¨Ó¸ò §Ú»¡ªÑ²¼§a¡I ¤£»¡¸Ü¨S¦³¤H»¡±z¤£À´¡A»¡±o¶V¦h¡A¥u·|¦ÛÃn¨äµu¡C ½Ð°Ý±z·|µ¹¤@Ӻ믫¬ìÂå¥Í¬ÝÀù¯g¯e¯f¶Ü¡H§Y«K¥L¬O¦ìÅv«Â¡C ¤p§Ì¤@ª½Ä±±o¥xÆW¬°¤°»ò·|¦b³o´X¦~¸¨«áÁú°ê¡A¦b«Ü¦h¤è±¡C ¤@Ó«Ü«nªºì¦]¡A°ê¤H¤£¹Îµ²¡A¯Þ»K¦V¥~Ås¡C ´N»¡¥xÆW¤§¥úhtc¦n¤F¡A³\¦h¤H¤£Ä@±·³õ(¤°»òì¦]³£¦³)¡A´N¬O¤£¥Î°ê³f¡C¨ºhtc¤]«Ü©_©Ç¡A¤W¦^ÁÙ§â¦P¤ä¤â¾÷ ³W®æ¸û§Cªº¦b°ê¤º½æ¡A³W®æ¸û°ªªº½æ¨ì¥~°ê¡A¦Û§Ú¬Ý¶S¡C ¤º°««Ü¦æ(¬FÄÒ´c°«)¡A³s¯E¹©¤]¦¨¬°²½«~¡C ¬°¤°»ò´N¤£¯à»¡¥y¦n¸Ü¡H»¡¥y¦n¸Ü¦³³o»òÃø¶Ü¡H»¡¨Ç¹ªÀyªº¸Ü¦³¨º»òÃø¶Ü¡H ¤@©wn»¡ÃøÅ¥ªº¹ê¸Ü¡A¤~¯àÅã¥X¦Û¤vªº°ª¬ñ¶Ü¡H ¹L¥h¤ý«Ø¥Áªº¬v°ò±Ð½m¦«·ç¡A°OªÌ¦Ñ·R°Ý¤ý«Ø¥Á¤µ¤Ñ§ëªº¦n¶Ü¡H¦«·çÁ`¬OÆg¬ü©~¦h¡AÂA¤Ö³dÃø¡A ¨ä¹ê¡A¯u¬Û¬O§ëªº«ÜÁV¡C¬O¦«·ç¨S¬Ý¨ì¦³¦hÁV¶Ü¡HÁV¡A¨p¤UÁ¿´N¦n¡C ¥u¦³½²±Ð±Â¬Ý¨ì¯E¹©¹êÅç³]pªº°ÝÃD¶Ü¡H¦Û°®æ§½¡C ¤¨³Õ¤h¤]»¡¹L¡A¯E¹©¬O¦Û¤v¥XÃD¥Ø¡A¦Û¤v¦Ò®t¤F¡C ²{¦b¯E¹©ªº¬ã¨s¤Hû¦b°ê¥~¶}·|°Q½×¡A¤£´N¦b½Í³o¨Ç¶Ü¡H¦p¦ó§ï¶i¤T´Áªº³]p¡C ¨C¶¡¤½¥q¦³¨C¶¡¤½¥qªº°ÝÃD¡AY¤U¦^´«±i¸³»¡»¡¤ß®®ªºÁ{§É³]pµ²ªG¡A±z»{¬°¦X¾A¶Ü¡H ¯uªº¬OºÞ¤Ó¦h¤F¡I ¤p§Ìn»¡ªº¬O¡A¹ªÀyªº¸ÜY¬O±q½²±Ð»¡¥X¤f¡A¹ï¥Í§Þ·~¤@©w¬O¥¿±¦Vµ½ªº´`Àô¡C ³oªÀ·|±q¤£¯Ê§åµûªº¤H¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/16 ¤U¤È 01:43:51²Ä 2023 ½g¦^À³
|
¥xÁÞ¤j¡A¯E§J¤j¡A IgG titer >= 1:160 ³oÓ¿z¿ï±ø¥ó¡A«ç»ò¬Ý³£¬Opost-hoc¡A¤£·|¬Oa prori¡C ©Ò¥H¡A¦pªG¥Î°ª§K¬Ì¤ÏÀ³²Õ»P¹ï·Ó²Õªº®t²§¼Æ¾Ú¥h¥Ó½ÐÃÄÃÒ¬O»¡¤£¹L¥hªº¡Cµ¥¥þÅé¹êÅç²Õ»P¹ï·Ó²ÕªºOS¹F¨ìÅãµÛ©Ê¦A¥h¥Ó½ÐÃÄÃÒ«h¬O¨S¦³ª§Ä³ªº¡C ¥t¥~¡Anµ¥ IgG titer >= 1:160 ªº¯f¤H³£¥X½u»Ýnªáªñ12Ӥ몺®É¶¡¡C³o¹ï©óµL®Äªº¯f¤H´N¬Oé¹Ü¥L´M¨D¨ä¥LÂåÀø¤è¦¡ªºt±°ÝÃD¡C¦p¦ó¯à¦b4~8¶g¤º§ä¨ì³Ì¥i¯à (©Î´X¥G«OÃÒ) ¹F¨ì³oӼзǪº¯f¤H¸sÅé¡A´Nºâ¿z¿ï²v¤£¨ì¤¦¨¡A¤]¬O¤@ӿﶵ¡C¥Ø«e¤½¥qªº¤½¶}¸ê®ÆÁ٬ݤ£¨ì³oÓµª®×¡C ½²¸³©Ò¨S¦³¦Ò¼{ªº¤@ÂI¡A¬O FDA ¹ï±aÀù¯gÃÄ»P¤@¯ëÃĪ«ªº¼f¬dÅ޿褣¦P¡C¤@¯ëÃĪ«¬O¹ç±þ¤ÅÁa¡A¦ý¬O¹ï©óÀù¯gÃĪ« (¤×¨ä¬O·sÀøªk) «h¤ñ¸û¶É¦V¹çÁa»~±þ¡C ½²¸³»¡¥Î¥D°Ê§K¬Ì¤è¦¡ (¥´888) ¨Ó½T»{ MOA »P®ÄªG¡A³o¨ä¹ê¬O»P´M¨D¥D°Ê§K¬ÌÀøªk§¹¥þ¤Ï¦Vªº§@ªk¡C³Q°Ê§K¬Ì¬O¥´³æ®è§ÜÅé¡A¦]¬°¨ÅéµLªk²£¥Í¥u·|«ùÄò®ø¯Ó¡A©Ò¥H¥²¶·´£°ª¾¯¶q¡A©ö³y¦¨°ªªº°Æ§@¥Î¡C³o»P822ªº§C°Æ§@¥ÎÀu¶Õè¦n¬Û¤Ï¡C¥D°Ê§K¬Ì¤£¬O¤@±ø®e©ö¨«ªº¸ô¡A¹ç¥i¨«ºC¤£¯à¨«§Ã¤F¸ô¡C ³Ì·s¤½¶}ªº¤½¥q²³ø¤¤¡A¨ä¹ê©ú½T«ü¥X¤FÁÞªí²{±j«×ªº°ÝÃDÂI¡C¥Ø«e©Ò¿×ÁÞªí²{±j«×»P822Àø®Ä¨S¦³¬ÛÃö©Êªº¡A«üªº¬OGlobo H³oÓÁÞ¡C¦Ó¦b¤½¥qªº¥¼¨Ó¬ã¨s«ÂI¤¤¡AÁÙ»Ýn¥[ºò¤F¸Ñªº¬OGlobo SeriesÁÞªí²{»PÀø®Ä¤§¶¡ªºÃö«Y¡C ÃĬO¦nªº¡A¦ý¬OÁÙ»Ýnªá®É¶¡§â¤@¨Ç°ÝÃD·d²M·¡¡C |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2016/6/16 ¤U¤È 01:42:35²Ä 2022 ½g¦^À³
|
Hi «ù¤[¤j, §Ú°µ¹Ú·í§Ú¦b¬Ý¹êÅçpµe®É¡A¥¼µo²{¦³´£¨ì§ÜÅé®Ä»ù¤ñ²v¡Ù1:160¡A©Î¬O§ÜÅé®Ä»ù¡Ù160ªº±Ôz¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/16 ¤U¤È 01:33:24²Ä 2021 ½g¦^À³
|
«ù¤[ªº¯E§J¤j¡G ¸ÕÅçpµe¤¤¨Ã¥¼µo²{¦³´£¨ì§ÜÅé®Ä»ù¤ñ²v¡Ù1:160¡A©Î¬O§ÜÅé®Ä»ù¡Ù160ªº±Ôz¡C ¥t¡A³Q°Ê§K¬ÌªvÀøªº³¡¤À¡A§Úı±o¥i¥H¦A¦hŪ´X¦¸¨º¤@¬q±Ôz¡G¡u¡K±Ä¥Î³Q°Ê§K¬Ì¡Aª½±µµ¹¯f¤H¬I¥´¸Ó¯S®í§ÜÅé¡AµL½×§K¬Ì¤O±j®z§¡¦b¦P¤@¤ô¥¤W¤ñ¸û¡A»P¥¼¬I¥´¸Ó§ÜÅéªÌ¤ñ¸û¡C¡K¡v¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/16 ¤U¤È 12:30:43²Ä 2020 ½g¦^À³
|
Cliff¤j ±z´£¨ì: ½²¸³ªº³Ì«á¤@¬q´£¨ìªº¨âºØ§ï¶i¸ÕÅç³]pªº¤èªkªº²Ä¤GºØ¡A»P±i¸³¥ý«e©Ò´£¨ìªº·s¤T´Áªº¸ÕÅç³]pªº²z©À¦³²§¦±¦P¤u¤§³B¡A²{¦b¥Ñ½²¸³ªº¸Ñ»¡«á¦ü¥GÅý¤Hı±o§óÁͪñFDAªº«äºû¡A¦Ó²Ä¤@ºØ¤èªk©O¡Hn¿ï¾Üþ¤@ºØ³Q°Ê§K¬ÌÀøªk¨Ó°µ«e¸m§@·~¡A¬O¤£¬O¤S³y¦¨¤@Ó·sªº§xÂZ¡H Ó¤H¾\Ū«áªº·Pı¬O ¦³Ãö²Ä¤@ºØ¤èªk©O¡Hn¿ï¾Üþ¤@ºØ³Q°Ê§K¬ÌÀøªk¨Ó°µ«e¸m§@·~? ¦ü¥G¤£¬O³o¼Ëªº»y·N ¦Ó¬O¥D°Ê§K¬Ì¹êÅ礣¦n°µ ¦]¬°¦³²V²cÅܶµ¦s¦b«oµLªk¼á²M ¦]¦¹µLªk¦³®Ä¤À²Õ¨Ó«·s¹êÅ窺¸Ü ´NÂà¦V°µ³Q°Ê§K¬ÌªvÀø¹êÅç ¥t¥~§Ú»{¬°½²±Ð±ÂY¨S¦³¬Ý¹L¤G´Á¬ã¨spµe¤º®e ´N»¡ ¤ñ¸û160ºw«×°ª§C¨â²Õªº¤ñ¸û¤£¬Oa priori ¦Ó¬Opost hoc ¥i¯à¹L©óªZÂ_ ¦]¬°¤½¥q¥i¯à¦b¬ã¨spµe¤¤ ¦´N¼g©ú 160ºw«×°ª§C¨â²Õªº°²³]¦ÒÅç ¬O¸Ó¹êÅç¨Æ«e¦ÒÅç»ÝnÅçÃÒªº¤@²Õ°²³]¦ÒÅç ¦Ó«D¨Æ«á¦ÒÅç(¦ý§Ú©Ó»{³o¼Ë¾÷²v¤ñ¸û§C) ½T¹ê ¥¼¨Ó¤T´Á¬ã¨s·|¦p¦ó³]p ¬Û·í¥O¤H¦n©_ |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/16 ¤W¤È 11:50:47²Ä 2019 ½g¦^À³
|
·PÁ¤p©_¤jªº¦n¤å, ¨ü¯q¨}¦h. ¬Ý§¹«á·Q¨ì¥t¤@ÓÆ[ÂI¨Ó¬Ý¸Ñª¼¼Æ¾Ú. ³o¦¸¹êÅçµ²§ô«á, µo²{¦³112¦ì°ª§ÜÅé¤ÏÀ³ªÌ, 112¦ì§C§ÜÅé¤ÏÀ³ªÌ. ³oӼƦr, ¥i¥Hª½±µ®³¨Ó§@¬° number at risk ¤H¼Æ¶Ü? §Ú»{¬°¬O¤£¦æªº. °²³]°ª§ÜÅé¤ÏÀ³ªÌ, ¦b²Ä2¶g®É·s¼W20¦ì, ²Ä4¶g®É·s¼W10¦ì, ²Ä8¶g®É·s¼W10¦ì, ²Ä12¶g®É·s¼W15¦ì, «áÄò¬Ù²¤. ¨º»ò°ª/§C§ÜÅé²Õªº number at risk ¤H¼Æ, ¦b²Ä2¶g«e®ÉÀ³¸Ó¬O 0/224, ²Ä2¶g®ÉÀ³¸Ó¬O 20/204, ²Ä4¶g®ÉÀ³¸Ó¬O 30/194, , ²Ä8¶g®ÉÀ³¸Ó¬O 40/184, ²Ä12¶g®ÉÀ³¸Ó¬O 55/169. ¬°¤F²¤Æ°Q½×, ¥H¤W¥ý©¿²¤PFS/OS¨Æ¥ó. ¦b¹êÅçªì´Á, ¥þ³¡¤H¼Æ³£¬O§C§ÜÅé²Õ. ¨ì²Ä2¶g®É, ¦³20¦ì°»´ú¥X°ª§ÜÅé, Â÷¶}¤F§C§ÜÅé²Õ, À³¸Óµø¬°§C§ÜÅé²Õªº³]¸ê®Æ. ¦P²z, §C§ÜÅé²Õ¤¤, ¨ì²Ä4¶g®É, ¦³10¦ì¹º¬°³]¸ê®Æ, ¨ì²Ä8¶g®É, ¦³10¦ì¹º¬°³]¸ê®Æ, ¨ì²Ä12¶g®É, ¦³15¦ì¹º¬°³]¸ê®Æ. ÀHµÛ¹êÅ窺¹Lµ{, ¤£Â_ªº¦³¤H´ú¥X°ª§ÜÅé¤ÏÀ³, À³¸Óµø¬°Â÷¶}§C§ÜÅé²Õ, ¦¨¬°§C§ÜÅé²Õªº³]¸ê®Æ. ¥H¦¹·§©À, À³¸Ó¥i¥Hµe¥X¤ñ¸û¦X²zªºªº§C§ÜÅé²ÕKM¦±½u. ¦b slide 16¤¤, §C§ÜÅé²ÕY¥H¦¹ªk§@¹Ï, «Ü¥i¯à©M¹ï·Ó²ÕªºPFS·|Åܦ¨¨S¦³²Îp¤WÅãµÛªº®t²§. ¦b slide 17¤¤, §C§ÜÅé²Õ©M¹ï·Ó²ÕªºOS·|Åܦ¨§ó¨S¦³²Îp¤Wªº®t²§. ¦Ü©ó°ª§ÜÅé²Õ, ¥¦ªº number at risk ¤H¼Æ¦b¹êÅçªì´ÁÀ³¸Ó¬O0, ÀHµÛ¤£Â_ÀË´ú¥X°ª§ÜÅé±wªÌ¦Ó¼W¥[. ¦bÀ˵øPFSÀø®Ä®É, ¤@¤è± number at risk ¤H¼Æ¼W¥[, ¤@¤è±PFS¨Æ¥óµo¥Í, ³y¦¨ number at risk ¤H¼Æ¤U°. §Ú¤£¤Ó¯à·Q¹³³o¼Ë¸Ó¦p¦ó¦X²zªº¥h°µKM¦±½u, µû¦ô¨äÀø®Ä. ¦bÀ˵øOSÀø®Ä®É, µ´¤j³¡¤ÀªºOS¨Æ¥ó³£µo¥Í±o°÷±ß, ¦b number at risk ¤H¼Æ¤À°t¤w¸g¤jP©³©w¤§«á. ©Ò¥H±N°ª§ÜÅé²Õªºªì©l number at risk ¤H¼Æª½±µ³]¬° 112 ¤H, »~®t¤ñ¸û¤Ö, À³¸ÓÁÙ¬O¨ã¦³¤@©wªº°Ñ¦Ò»ùÈ. ©Ò¦³ªº¼Æ¾Ú¤¤, §Úı±o³Ì¨S¦³ª§Ä³, ¤S¨ã¦³»¡ªA¤Oªº¬O slide 13, ȱo¦Aµ¥«Ý¤@¨â¦~. ³o¦¸¤½¥q¦b¸Ñª¼¤§«á, ¦A¥Î°ª/§C§ÜÅé²Õ¨Ó¤À¦¸¸s²Õ, l¥Í¤F¤£¤Öªº§xÂZªü. ¤T´Á°È¥²±o·Q¿ìªk¦b¨Æ«e´N¤À¦n²Õ, ¤~¯à§ó«ÈÆ[ªºµû¦ôÀø®Ä, ¥H§ù±y±y¤§¤f. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/16 ¤W¤È 10:33:18²Ä 2018 ½g¦^À³
|
©Ó½²¸³ªº¬ì¬ã¡u¯ª¥À©w«ß¡v¡A«¥Ì¬O§_¤£¸Ó§âslide No.17ªºµ²ªG»{¬°¥i¥Hª½±µ®³¥h¸òFDA½ÍÃÄÃÒ¡H¬O¤£¬OÀ³¸ÓÄ~Äòµ¥«Ý¡Aµ¥¨ìOSªº¥Ê°÷¦¨¼ô¤F¡]No.13¡H¡^¦A¥h½Íxxxxxxx approval¡H¡I¡K¡K¡AˬO¦b³oµ¥«Ýªº®É¶¡ùØ¡A¥ý¥Ó½ÐBTD¬O¤£¬O¤@Ó¸û¦nªº¿ï¾Ü©O¡H®³¸Ñª¼¼Æ¾Ú¥h¥Ó½Ð¡A60¤Ñ¤º´N·|¦³¦^ÂСA·Pı¤W¨S¬Æ»ò·l¥¢ªº¡C FDAn¬Ýªº¬O«e¤©Êªº¸ÕÅç³]pªºµ²ªG¦³¨S¦³Åã¥Ü¥¿±ªºÀø®Ä¡A©Ò¥H¦^ÅU¦¡ªº¤ÀªR·|³´¤JCherry pickingªºbias¡AµLªkÅã²{¦]ªGÃö«Y¡C §_«hBiomiraªºªÑªF´N¤£¥²¦b·t©]¸Ìúª_¡A¦]¬°Theratope¦¦¥i¥H®³Post Hoc Analysis¥h¥Ó½ÐÃÄÃÒ¤F¡C¡]www.ncbi.nlm.nih.gov/pmc/articles/PMC3753533/¡^ ½²¸³ªº³Ì«á¤@¬q´£¨ìªº¨âºØ§ï¶i¸ÕÅç³]pªº¤èªkªº²Ä¤GºØ¡A»P±i¸³¥ý«e©Ò´£¨ìªº·s¤T´Áªº¸ÕÅç³]pªº²z©À¦³²§¦±¦P¤u¤§³B¡A²{¦b¥Ñ½²¸³ªº¸Ñ»¡«á¦ü¥GÅý¤Hı±o§óÁͪñFDAªº«äºû¡A¦Ó²Ä¤@ºØ¤èªk©O¡Hn¿ï¾Üþ¤@ºØ³Q°Ê§K¬ÌÀøªk¨Ó°µ«e¸m§@·~¡A¬O¤£¬O¤S³y¦¨¤@Ó·sªº§xÂZ¡H ´Á¬ß¨Ó¦~¬K·¦A«×©Ø¤WÁyÃe®É¡A·|¦³·sªº·P°Ê¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/16 ¤W¤È 10:12:03²Ä 2017 ½g¦^À³
|
¾\Ū³o½g non-deal road shows ªº¤Q¤j¦n³B ·|¦³¤@¨Ç·§©À TOP 10 BENEFITS OF NON-DEAL ROAD SHOWS westwickepartners.com/2014/02/top-10-benefits-of-non-deal-road-shows/ |
|
|
·|û¡G°Ý°ÝÃD10140527 µoªí®É¶¡:2016/6/16 ¤W¤È 09:22:46²Ä 2016 ½g¦^À³
|
ÁÙ¬O»¡©ú¤@¤U ^^ Non-Deal Roadshow (NDR)ªº¥Øªº, ´N¬O¯Âºé©M§ë¸ê¤H(²{¦b©Î¼ç¦bªº), Åý¥Ļó¤F¸Ñ¤½¥qªºªñªp»Pµo®i. ¥s°µ non-deal, ·N«ä´N¬O¤£¥H¶Ò¸ê¬°¥Øªºªº·N«ä. µ¹¤j®a°Ñ¦Ò¤@¤U. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/16 ¤W¤È 09:19:16²Ä 2015 ½g¦^À³
|
¦³·N«äªº¤@½g¡A¥P«÷¥P¡AÅ¥¦P·~½²±Ð±Â«ç»ò¬Ý822¸Ñª¼¼Æ¾Ú¡C ¡uÆ[©À¥¥x¡Ð¬ì¬ãªº¡u¯ª¥À©w«ß¡v-Ñ¡¯ª¶ý«ç»ò»¡¡H¡v ¡]www.chinatimes.com/newspapers/20160616000072-260202 ¡^ |
|
|
·|û¡GµL¹Ð10141268 µoªí®É¶¡:2016/6/16 ¤W¤È 12:58:00²Ä 2014 ½g¦^À³
|
P16¦³¨ä¥L§Üì»PGLOBH ¨t¦C¨Ã³¯,¥Nªí¥¼¨Ó¦³³\¦h°ê»Ú¤j¼t¦X§@ªºÃD§÷! |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/16 ¤W¤È 12:34:59²Ä 2013 ½g¦^À³
|
¤p©_¤j: ¦³Ãö¡¨s¡¨ ¤Îoverall survival ¤U¤È¤wemailµ¹¤½¥q¤F. ¤è¤~¬Ý¨ì³Ì·sªº¤¤¤åª©§ë¼v¤ù¤w§ó¥¿¤F. ¬Û«H¤½¥q¥i¯à¦´Nª`·N¨ì³o¿ù»~¥B¤w×¥¿¤F. ©È±z±¾¤ß, ¯S¤W¨Ó¸ò±z»¡¤@Án. ¶Â½ü§B: ÁÂÁ±z¥H§K¬Ì¯f²z¨¤«×¨Ó´£¿ô888ªº°Æ§@¥Î. ¯à§_½Ð±Ð¤Uz ¡K {¤ÞµoÄY«¹L±Ó¤ÏÀ³©Î¦å²M¯f, ¥B¦pªG¨S¤Þµo¦å²M¯f·ÀIªº¯f¤H ¨äÀø®Ä¤]¤£¤j} ¡K.. Google¦å²M¯f¬d¨ì: ¡K.. ¡iµo¯f¾÷²z¡j ¦å²M¯f¬O¤@ºØ¨å«¬ªº¢»«¬ÅܺA¤ÏÀ³¡C¾÷Åé¹ï¶i¤JÅ餺ªº²§ºØ¦å²M¦U§Ü즨¤À©Î§@¬°¥b§Ü쪺¬Y¨ÇÃĪ«»PÅ餺³J¥Õµ²¦X§Î¦¨ªº§Üì©Ê½Æ¦X³J¥Õ¡A§¡¥i²£¥Í§ÜÅé¡C·í§Î¦¨ªº§ÜÅé¶q²¤¤Ö©óÅ餺©|®ø¥¢ªº§Üì®É¡A¥i§Î¦¨¨I¿n©ó¦åºÞ¾À¤Wªº§K¬Ì½Æ¦Xª«¡AÄ~¦Ó±Ò°Ê¸ÉÅé¨t²Î¡A¥Í¦¨¦åºÞ©Êª«½è¡B¤¤©Ê²É²ÓMÁͤƦ]¼Æµ¥¡A³y¦¨§½³¡¥R¦å»P¤ô¸~¡A¤¤©Ê²É²ÓMªº®û¼í©M·»酶Å餺³J¥Õ¤À¸Ñ酶ªºÄÀ©ñ¡A¾ÉP²Õ´ªºª¢¯g»P·l¶Ë¡Cºc¦¨¦å²M¯f§K¬Ì½Æ¦Xª«ªº§ÜÅé²y³J¥Õ¥Dn¬OIgG¡A¦ý¦pIgE¸û¦h¡A«hµo¯f®É¦å²M³q³z©Êªº¼W¥[§ó¥[©úÅã¡C¦Ó¥B¥i¦³³ïÀY¤ô¸~¡B§C¦åÀ£¬Æ¦Ü¹L±Ó©Ê¥ð§Jªí²{¡C¤Z§Üì¨ë¿E¤U¸û©ö²£¥ÍIgG»PIgE³o¨âÃþ§ÜÅéªÌ¡A¤]¸û©öµo¥Í¦å²M¯f¡C ¥Ø«eÁ{§É¤W¤Þ°_¦å²M¯fªº¦å²M»s¾¯¥Dn¦³¯}¶Ë·§Ü¬r¯À¡B¥Õ³ï§Ü¬r¯À¡B¦UºØ³D¬r§Ü¬r¯À¥H¤Î§Ü²O¤Ú²ÓM²y³J¥Õ¡]ATG¡^µ¥¡F¤Þ°_¦å²M¯fªºÃĪ«¥Dn¬°«CÅð¯À¡BÃìÅð¯À¡BÁDÓiÃþ¡B¤ô·¨»ÄÆQ¡B«O¤ÓªQ¡Bf§´^¶u¡A¥H¤Î¥k±Û¿}Óþµ¥¥¨¤À¤lÃĪ«¡C ¡K. www.medicchina.com/cmedicchina/daoyitai/changjianjibing/172.htm ¬Ý¤£À´. è¦n³o¦¸³Ì·sªº¤¤¤åª©slide¤¤P.22¤]´£¤ÎPhase I Á{§Éªº¦å²M¤ÏÀ³., ½Ð°Ý¦p822ª`®g«áªº¤j¤ù¬õ¸~¬O§_¤]ÄÝ©ó¦å²M¯fªº§e²{ ? ¯à§_½Ð±z¶i¤@¨BÄÄÄÀ ? ³Â·Ð±z¤F. ·PÁÂ. |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/15 ¤U¤È 11:05:20²Ä 2012 ½g¦^À³
|
§ó¥¿ ADAGLOXAD SIMOLENIN À³¸Ó¬O¾Ç¦W |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/15 ¤U¤È 10:47:55²Ä 2011 ½g¦^À³
|
¤p©_¤j ±z´£¨ì ¤ÏÀ³²Õ°h¥X4¤H ¦º¤`21¤H µL¤ÏÀ³²Õ°h¥X24¤H ¦º¤`29¤H ¹ï·Ó²Õ°h¥X14¤H ¦º¤`35¤H °h¥Xªº4¤H¡B24¤H¡B14¤H¬O«ç»ò§ä¥X¨Ó©Îºâ¥X¨Ó¡H §Ú«á¨Ó·Q·Q §Úªº±À½×¦³°ÝÃD ©Ò¥H´N¤£¦A»¡©ú¤F ©êºpÅý±z¦h¼{Åo ¥t¥~ 822ÃĦW ¬OADAGLOXAD SIMOLENIN ½Ð°Ý¤j®a ³o¬O©Ô¤B¦r«÷µ¶Ü ¥Nªí¬Æ»ò·N«ä? |
|
|
·|û¡Gyuki10141394 µoªí®É¶¡:2016/6/15 ¤U¤È 10:37:29²Ä 2010 ½g¦^À³
|
¯E¹©¬ü°êªk»¡·|¬O¤£¬O¸òµoADR¦³Ãö°Ú¡H¥O¤H´Á«Ý¡K¡K |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/15 ¤U¤È 10:01:09²Ä 2009 ½g¦^À³
|
²³¤j¤j: 105/06/16 ~ 105/06/18 ¥xÆW¯E¹©¨üÁÜ°Ñ¥[·ç¤h«H¶UÁ|¿ì¤§®ü¥~NDR(Non-Deal Roadshow)¡A³ø§i2016 ¦~ ASCO ©Ò´£¥X¤§¬ã¨sµ²ªG¡C ¦aÂI: ¬ü°ê ªi¤h¹y/¯Ã¬ù ¸ê°T ·j´M¸É¥R: non-deal roadshow ¥Øªº: 1¤j³¡¤Àªºnon-deal roadshow ³£¬°¤FÄw¸ê¡A¤ñ¦pµo¦æECB, ADR, GDR®É¡C 2¦³®É¨ü¥~¸ê¨é°ÓªºÁܽСA·í¨S¦³nÄw¸ê®É¡A¤]·|¨ì°ê¥~¦V°ê¥~§ë¸êªk¤H³ø§i¤½¥q³ÌªñªºÀç¹B¤Î°]°Èª¬ªp¡A¨Ã±µ¨ü¨äQ&A¡C 3ÂǾ÷·|±À¾P¤½¥q¡A¥[²`°ê¥~§ë¸ê¤H¹ï¤½¥qªº¦n¦L¶H¡A¨Ãºû«ù»P¥~¸êªº¨}¦n¤¬°ÊÃö«Y¡C ÁÂÁ¯}¸º¤j´£¨Ñªk»¡·|²³øÀÉ «ÂI: A Globo Series ÁÞ¤À¤l¼sªxªí²{©ó15ºØÀù¯g ,«GÂI¬O¦h¤F¦åÀù(Globo H) ¬ãµo¦¨¥\·|¦³§ó¦h¤H±o±Ï Ó¤H¸É¥R: leukemia (¦åÀù) ¬ü°ê New Cases 60,140¤H , Deaths 24,400¤H (2016) ¤¤°ê New Cases 75300¤H , Deaths 53400¤H (2015) ¼Ú¬w New Cases 82300¤H , deaths 53800¤H (2012) ¼Ú¬w 2016 Àù¯g¥þÀù¯g ¦º¤`¼Æ 1 359 500¤H( 753 600 and 605 900 deaths in men and women) www.ncbi.nlm.nih.gov/pubmed/26812903 ¼Ú¤éÁú¬O±ÂÅv°Ï ¼Ú¬w¥«³õ¤]°÷¤j ¥un¥H¼w°ê ªk°ê ¸q¤j§Q ¦è¯Z¤ú ¬°¥D B ¤G/¤T´ÁÁ{§É¸ÕÅçµ²ªG¾ã²z: 1§K¬Ì¤ÏÀ³±µ¨ü¬Ì]ª`®g¥BªvÀø´Á¶¡´¿¥X²{¹ï OPT-822²£¥ÍIgG§ÜÅé®Ä»ù >160¯f±w¡A¨äPFS¤Î´Á¤¤OS©úÅãÀu©ó¦w¼¢¾¯²Õ¤Î¥¼²£¥Í§K¬Ì¤ÏÀ³ªº¯f±w ¡C 2 ¬Û¸û©ó¦w¼¢¾¯²Õ©ÎµL§K¬Ì¤ÏÀ³ªÌ¨ã§K¬Ì¤ÏÀ³¨ü¸ÕªÌ¨äOS´Á¤¤Àò©úÅã§ïµ½ÁÍ¶Õ (¤ÏÀ³ªÌ vs. ¦w¼¢¾¯¤§·ÀI¤ñ 0.57) 3§K¬Ì¤ÏÀ³ªÌ¤ñ¨Ò °ª¹F 50% ¹êÅç²Õ¨ü¸Õ¯f±w²£¥Í©úÅ㪺§ÜÅé¤ÏÀ³(IgG §ÜÅé®Ä»ù≥ 1:160) 4§K¬Ì¤ÏÀ³ªÌ¨ã¸ûÀuªºµL´c¤Æ¦s¬¡´Á (PFS)¥B¤£©ó¸~½F¥Íª«¼Ð°O¨È«¬( ¥]§tHER2 +/-, HR+/-, ¤T³±©Ê¡^ )¤ÎGlobo Hªí²{µ{«× ( HR: Hormone Receptor ¶Pº¸»X¨üÅé)(Ó¤Hµû½×:²×©ó¥¿±ªíz ¯u´Î¤TÃþ¨È«¬¨ÅÀù³£¯à¥Î) 5¾ãÅé PFS ¥DnÀø®Ä«ü¼ÐµL´c¤Æ¦s¬¡´Á (PFS) ¥¼¹FÅãµÛ®t²§ 6´Á¤¤ OS ¨ã§ïµ½ÁÍ¶Õ 7¯f±w§¹¦¨¤E¦¸ª`®gÀøµ{Åã¥Ü¨Ï¥ÎOPT-822/821ªºPFS¨ã§ïµ½ÁÍ¶Õ 8¦w¥þ©Ê @¨ü©Ê°ª¦h¼Æ°Æ§@¥Î¶È¤î©ó²Ä¤@¡B¤G¯Åª`®g³¡¦ì¤ÏÀ³ 9¨ü¸ÕªÌ ¸g²Ä1¡B2½uªvÀøªºÂಾ©Ê C Àù¯gªvÀø«¤jÅܲ §C¾¯¶qMicro doses ¥Ö¤Uª`®gSubcutaneous @¨ü©Ê°ªWell-tolerated ¥ÎÃĦ¸¼Æ¤ÖLess frequent dosing ©µªøªø´Á¦s¬¡ÁÍ¶Õ Trending towards long-term survival Ó¤Hµû½×: ¨ÅÀùOBI 822 ¥H¤WªvÀø«¤jÅܲ³£¨ã³Æ ,¥~¥[°ª¥Í¬¡«~½è »P®aÄÝ·ÓÅU¤è«K, °ª¶Q¤£¶QªºÃÄ»ù D ¥¼¨Óµo®i¨½µ{¸O 1Á{§Éµo®i Clinical Milestones «n°ê»Ú¾Ç³N·|ij±µ¨ü½×¤åµoªí¡C ¦bÀù¯g¥Dn·|ijµoªíÁ{§É¸ÕÅç¼Æ¾Ú¤ÀªR½×¤å¡C ¥ÑÀù¯g¬ÛÃö±M®aµû¼f¤§«¶qÂå¾Ç´Á¥Zµoªí¬ÛÃö¼Æ¾Ú¤Îµ²ªG¡C ¥þ²y©Ê¤T´ÁÁ{§É¸ÕÅç²Ä¤@¦W¯f¤H¦¬®×¡C 2 ªk³W¶i®i Regulatory Milestones »P¥xÆWÂåÃÄ«~¬dÅ礤¤ß(CDE)®i¶}¿Ô°Ó·|ij¡C »P¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)¡N¼Ú·ùÂåÃÄ«~ºÞ²z§½(EMA)¡B¥[®³¤j½Ã¥Í³¡( Health Canada)®i¶}Á{§É¸ÕÅç¤G´Áµ²ªGµû¦ô·|ij(End of Phase 2,EOP2) |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/15 ¤U¤È 08:49:10²Ä 2008 ½g¦^À³
|
Ãø¹D¬°¤FnµoADR§@·Ç³Æ? |
|
|
·|û¡G¸U¸U¨S·Q¨ì10142133 µoªí®É¶¡:2016/6/15 ¤U¤È 08:03:55²Ä 2007 ½g¦^À³
|
¯}¸º¤j¡A·PÁ¤À¨É¡A¤w¬Ý§¹¡AÆgªº! |
|
|
·|û¡G¯}¸ºªº½¹½º10140485 µoªí®É¶¡:2016/6/15 ¤U¤È 07:39:05²Ä 2006 ½g¦^À³
|
mops.twse.com.tw/nas/STR/417420160615M001.pdf |
|
|
·|û¡G12310132455 µoªí®É¶¡:2016/6/15 ¤U¤È 06:35:36²Ä 2005 ½g¦^À³
|
¥»¤½¥q¨üÁÜ°Ñ¥[·ç¤h«H¶UÁ|¿ì¤§®ü¥~NDR(Non-Deal Roadshow)¡A³ø§i2016¦~ASCO©Ò´£¥X¤§¬ã¨sµ²ªG¡C ²Å¦X±ø´Ú ²Ä 12 ´Ú ¨Æ¹êµo¥Í¤é 105/06/16 »¡©ú ²Å¦X±ø´Ú²Ä¥|±ø²ÄXX´Ú¡G12 ¨Æ¹êµo¥Í¤é¡G105/06/16 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G105/06/16 ~ 105/06/18 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G00 ®É 00 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¬ü°ê ªi¤h¹y/¯Ã¬ù 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q¨üÁÜ°Ñ¥[·ç¤h«H¶UÁ|¿ì¤§®ü¥~NDR(Non-Deal Roadshow)¡A³ø§i2016¦~ASCO©Ò´£¥X¤§¬ã¨sµ²ªG¡C 5.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡GµL §¹¾ã°]°È·~°È¸ê°T½Ð¦Ü¤½¶}¸ê°TÆ[´ú¯¸¤§ªk¤H»¡©ú·|¤@Äýªí©Îªk»¡·|¶µ¥Ø¤U¬d¾\¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/15 ¤U¤È 02:53:41²Ä 2004 ½g¦^À³
|
²³¤j¤j §ó¥¿«¶K : ¦³Ãö¤pS ªº¨Æ±¡ ·|¤£·|¬On³o¼Ë¸ÑŪ: 1 p16 OPT-822²£¥ÍIgG§ÜÅé®Ä»ù>=1:160ªº¯f±wp112¦ìresponders,112¤H¬O¦h¼Æ,¥i¥H©M¤pS¦b¤@°_ (¦]¦¹§ë¼v¤ù¦³¥[¤pS ) 2 p16 OPT-822µLªk²£¥ÍIgG§ÜÅé®Ä»ù>=1:160 ªº¯f±wp112¦ìnon-responder, 112¦ì¬Ý°_¨Ó¬O¦h¼Æ,À³¸Ón¥[Ó¤pS,¨ä¹ê¤£µM¦]¬°¯à²£¥ÍIgG§ÜÅé®Ä»ù>= 1:160ªº¯f±wp0¤H,¬JµM¤£¬O¦h¼Æ ,·F¹À©M¤pS ¦b¤@°_(¦]¦¹§ë¼v¤ù¨S¥[¤pS) 3 P17 ¤]¬O¤@¼ËªºÅÞ¿è OPT-822²£¥ÍIgG§ÜÅé®Ä»ù>=1:160 ªº¯f±wp112¦ìresponders, 112¤H¬O¦h¼Æ, ¥i¥H©M¤pS ¦b¤@°_ (¦]¦¹§ë¼v¤ù¦³¥[¤pS) 4 p17 OPT-822µLªk²£¥ÍIgG§ÜÅé®Ä»ù>=1:160 ªº¯f±wp112¦ìnon-responder, 112¦ì¬Ý°_¨Ó¬O¦h¼Æ,À³¸Ón¥[Ó¤pS,¨ä¹ê¤£µM¦]¬°¯à²£¥ÍIgG§ÜÅé®Ä»ù>= 1:160ªº¯f±wp0¤H,¤£¬O¦h¼Æ,·íµM¤£¯à©M¤pS¦b¤@°_(¦]¦¹§ë¼v¤ù¨S¥[¤pS) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/15 ¤U¤È 02:34:41²Ä 2003 ½g¦^À³
|
§ó¥¿: ²£¥ÍIgG§ÜÅé®Ä»ù>1:160 §ó¥¿¬° ²£¥ÍIgG§ÜÅé®Ä»ù > = 1:160 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/15 ¤U¤È 02:29:53²Ä 2002 ½g¦^À³
|
²³¤j¤j ¦³Ãö¤pS ªº¨Æ±¡ ·|¤£·|¬On³o¼Ë¸ÑŪ: 1 p16 OPT-822²£¥ÍIgG§ÜÅé®Ä»ù>1:160 ªº¯f±wp112¤H, 112¤H¬O¦h¼Æ©M¤pS¦b¤@°_ ¦ó¿ù¤§¦³ 2 p16 OPT-822µLªk²£¥ÍIgG§ÜÅé®Ä»ù>1:160 ªº¯f±wp112¤H¬Ý°_¨Ó¬O¦h¼Æ,À³¸Ón¥[Ó¤pS,¨ä¹ê¤£µM ¦]¬°¯à²£¥ÍIgG§ÜÅé®Ä»ù>1:160 ªº¯f±wp0¤H , ¬JµM¤£¬O¦h¼Æ ·F¹À©M¤pS ¦b¤@°_ 3 P17 ¤]¬O¤@¼ËªºÅÞ¿è OPT-822²£¥ÍIgG§ÜÅé®Ä»ù>1:160 ªº¯f±wp112¤H, 112¤H¬O¦h¼Æ¥[Ó¤pS ¦ó¿ù¤§¦³ 4 p17 OPT-822µLªk²£¥ÍIgG§ÜÅé®Ä»ù>1:160 ªº¯f±wp0¤H ·íµM¤£¯à©M¤pS¦b¤@°_ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/15 ¤U¤È 01:54:32²Ä 2001 ½g¦^À³
|
Leo¤j: 6/5 OBI-822 ASCO½×¤åµoªí ¥xÆW¯E¹©ªk¤H»¡©ú·|: www.youtube.com/watch?v=_znW_DxOkRI&feature=youtu.be |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/6/15 ¤U¤È 01:53:18²Ä 2000 ½g¦^À³
|
Leo ¤j ¤½¥qºô¯¸¤W¦³,¥t¦]¬°©ú¤é¤½¥qn°Ñ¥[ªk»¡,©Ò¥H·|¤W¶Ç³Ì·sªºªk»¡·|®Ñ±¸ê®ÆÀÉ!¨Ñ°Ñ! |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/15 ¤U¤È 01:50:17²Ä 1999 ½g¦^À³
|
¤p©_¤j: OK! ¨S±z³o§ä´í¹CÀ¸, §Ú³ºµM³£¨S¦³ª`·N¨ì. ³o¯uªº¬O¡K ü! ¤½¥q·í®É¤]Ãø¬°¤F, ¸I¨ì³oºØ¥xÆWªÑ¥«¦³¥v¥H¨Óªº¯îÂÕ±¡¸`¡K. ¯u¬O¤£§Ô¦h»¡¤°»ò. §Ú¹ï·Ó¤FASCO®ÉDr. Rugoªº§ë¼v¤ù, ¤]¬O¤@¼Ë¡K. ü! ¥t¥~¦Ñ´¤j¦n¹³ÁÙ¦³¤@ÂIn¤À¨É¤£ª¾¬O§_¬ÛÃö, ´Nµ¥¥L¦A¤@°_´£¨Ñµ¹¤½¥q¤F. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/15 ¤U¤È 01:49:31²Ä 1998 ½g¦^À³
|
¤p©_¤j¡A¤£n±¾¤ß¡A¦h¤@ÓSµL¶Ë¤j¶®¡F¦ýY¶b»~´Ó¨Æ¯A¬°¤j¡A¤½¥qÀ³°µ§ó¥¿¡A±z»P¦Ñ´°÷²Ó¤ßȱo¤j®a¾Ç²ß¡A¨ä¥Lªº¤£«n¡C³o¥ó¨Æ´N³o¼Ë¿ì´N¬O¤F¡A¤£¥²¦h³Æ¤@¥÷¡I |
|
|
·|û¡GLeo10142037 µoªí®É¶¡:2016/6/15 ¤U¤È 01:36:33²Ä 1997 ½g¦^À³
|
ªk»¡·|¸ê®Æ¤½¶}¸ê°TÆ[´ú¯¸¤W§ä¤£¨ì¤F ½Ð°Ý¤½¥q¬O¦b§ó·s¶Ü? ¨ºÃä¥i¥H§ä¨ì!!·PÁÂ!! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/15 ¤U¤È 01:00:56²Ä 1996 ½g¦^À³
|
Cliff¤j»P¦Ñ´¤j³£§ä¨ì¡u´í¡v¤F¡I Cliff¤j±z§ä¨ìªº¡us¡v¬O§Ú¤§«e¨Sª`·N¨ìªº ¦Ñ´¤j§ä¨ìy ¶bÀ³¸Ó§ï¬°¡uOverall Survival¡v¬O¤@©wn½Ð¤½¥q§ó¥¿ QQ¤j¬O§_¥i¥H¦A³Â·Ð±z¤@¦¸¡H ¤p§Ì¥u¦³¤@²°»¨m§²° ¤£ª¾n«ç»ò®³µ¹Cliff¤j»P¦Ñ´¤j¨â¦ì¤j¤j¡H ¯E§J¤j¡A ½Ð±Ð¡G ¡u¥t¥~§ó¥¿¤@¤U«ePO¤å¡A¦p¤U: ȱoª`·Nªº¬O17¶ ¤ÏÀ³²Õ°h¥X4¤H ¦º¤`21¤H µL¤ÏÀ³²Õ°h¥X24¤H ¦º¤`29¤H ¹ï·Ó²Õ°h¥X14¤H ¦º¤`35¤H °h¥X¦p¤p©_¤j©Ò»¡drop out¡v ½Ð°Ý°h¥Xªº4¤H¡B24¤H¡B14¤H¬O«ç»ò§ä¥X¨Ó©Îºâ¥X¨Ó¡H |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/15 ¤U¤È 12:14:48²Ä 1995 ½g¦^À³
|
Cliff¤j ¦³Ãöp16-17¨úStratified Cox model°ÝÃD À³¸Ó¬OnÁקK°ò¦¯e¯fª¬ºA»P¶Pº¸»XªvÀø»P§_ ¨âºØ¤zÂZÅܶµ³y¦¨¤T²Õ¤ñ¸û®Éªº®ÄªG²V²c ³o¬O¤@ºØ²Îp±±¨îªº¤èªk ·í§ÚÌÂǥѤÀ¼h¤è¦¡ ¤ñ¸û¥X¤T²Õ¬O§_¥Ñ©ó§K¬Ì¿@«×°ª§C©Î¬O¦³µL¥´822¦Ó±o¨ì¤ñ¸ûªº²b®ÄªG ¦p¦¹¤@¨Ó §Ṳ́ñ¸û¦³«H¤ßªº¹ï¤j®a»¡ ¤ÏÀ³²Õ½T¹ê¤ñ¹ï·Ó²Õ¦³®Ä ¦]¬°¤w¸g±Æ°£°ò¦¯e¯fª¬ºA»P¶Pº¸»XªvÀøªº¼vÅT¤F ©Ò¥H¤]¥i¥H¤£¥Î¤ñ¸û°ò¦¯e¯fª¬ºA»P¶Pº¸»XªvÀø»P§_¦b¤T²Õªº¤À¥¬¤ñ²v ¦Ü©ó¡u¦pªG¹H¤Ï¤F¦¨¤ñ¨Òªº·ÀI°²³]¡A§ÚÌ¥i±N°lÂܤÀ¬°¨âөΧó¦hªº¡y°Ï¶¡¡z¡A¨ä¤¤·ÀI¬O¦¨¤ñ¨Òªº¡C§Ú̱µµÛ¦b¨CӰ϶¡¤À§O¶i¦æCox°jÂk¤ÀªR¡K¡K¡v¡C §Ú¤£½T©w§A»¡ªº¡¦¡¦°Ï¶¡¡¦¡¦¬O¦p¦ó¬É©wªº?¨ä²Îp©w¸q¬°¦ó? ^¤å¦r¬O¤°»ò? ¦ý¬O§Úªºªì²L·Qªk ¬O®É¶¡ªº°Ï¶¡ ¦b¤£¦P®É°Ï ¥[¥H¤À³Î ¨Ã¶i¦æ¦ÒÅç¶Ü? ¨Ò¦p¦b³Âªá±²®É¶¡ÂI¤§«e»P¤§«á¦U¤À¨â¬q ¤À§Oµ¹¤©cox ¦ÒÅç? §Ú¤£ª¾¹D¬O§_¦³³o¼ËÅܳqªº²Îp¤è¦¡?ÁÙn½Õ¬d ¥t¥~ ¡ulog-rank test »PWeighted log-rank test¦³¦ó®t§O¡H¡v §Ú¯uªº¤]¬O²Ä¤@¦¸¤~ª¾¹D ³oÓWLR? »Ýn¦n¦n¬ã¨s¤@¤U è¤U¸üºô¸ô¸ê®Æ ¦ý¬O³£¬O²Îp¨tªº¦r·J ¤@¤U¤l«ÜÃø§l¦¬ ¦³¤ß±o¦A¤À¨É ³Ì«á·PÁ±z¤À¨É³Ì·s¸ê®Æ ¨Ñ¤j®a¦¨ªø ¤×¨ä¬OChen±Ð±Âªº¸ê®Æ ¬OÃĬɻP¾Ç¬Éªº«n°Ñ¦Ò¸ê®Æ ¹x¥Û¤j «áÄòµo¥Í¯f¨Ò¦º¤`®É¬O¤£·|¼vÅT¨ì²Ä15Ó¤ë«eªºOS¦±½u? ¬Oªº ¦ý¬OÀHµÛ®É¶¡±À²¾»P·sªº¦º¤`¯f¨Òªº¥[¤J¡A²Ä15Ó¤ë¨ì²Ä32Ӥ몺OS¦±½u¬O¦³¥i¯à¥X²{¤U²¾ªº¡A¬O³o¼Ë¶Ü¡H ¬Oªº ¤@©w·| ¥t¥~§ó¥¿¤@¤U«ePO¤å¡A¦p¤U: ȱoª`·Nªº¬O17¶ ¤ÏÀ³²Õ°h¥X4¤H ¦º¤`21¤H µL¤ÏÀ³²Õ°h¥X24¤H ¦º¤`29¤H ¹ï·Ó²Õ°h¥X14¤H ¦º¤`35¤H °h¥X¦p¤p©_¤j©Ò»¡drop out ¬°¦óµL¤ÏÀ³²Õ°h¥X24¤H ³o»ò¦h ©úÅã¶W¹L¨ä¥L¨â²Õªº¤ñ¨Ò? µL¤ÏÀ³²Õ¤ñ¤ÏÀ³²Õ°h¥X§ó¦h¡A¬°¦ó°h¥X? ®£©È¸ò°²©ÊPD¦³Ãö¶Ü? ¬O§_¦³¤H¥i¥H¦h±´°Q¤@¤U:§C«×§K¬Ì¤ÏÀ³»P°²©Ê®û¼íªºÃöÁp? |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/15 ¤W¤È 11:48:16²Ä 1994 ½g¦^À³
|
¤p©_¤j:««ª½¶b©Mp-16¤@¼ËPFS, ³£¨S¦³§ï¹L¨Ó, ³oÓpptÁÙ®¼¦h¯}ºìªº, ¦Ñ´ÁÙ¦³¤@ÂIn¤À¨Éªº, ¾ã²z¤@¤U«äºü¦A»¡. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/15 ¤W¤È 11:14:46²Ä 1993 ½g¦^À³
|
¤p©_¤j: Slide No.17¥k°¼ªí¤¤¡A¹êÅç²Õªº¼ÐÃD:OPT-822/821 RESPONDERS, ¬O¤£¬O¦h¤F¤@ÓS? |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/15 ¤W¤È 11:04:27²Ä 1992 ½g¦^À³
|
²³¤j¦n¡A ¤p§Ì27¤éµLªk°Ñ¥[ªÑªF·|¡C¦³Ó°ÝÃD·Q½Ð¯à¥X®uªºªÑªFÀ°¦£°Ý¤@¤U¡A´N¬O²³ø²Ä17¶¨º¤T±ø½u¬°¦ó±q²Ä32Ӥ뤧«á³£¬O¥ªº¡H ÁÙ¦³¡A²Ä32Ӥ뤧«eªºOS¦±½u¬O½T©wªº¶Ü¡H±q2014¦~7¤ë³Ì«á¤@Ó¯f¤H¥[¤J¸ÕÅç¨ì2015¦~10¤ë¼Æ¾Ú¦¬³Î¡A¬O15Ó¤ë¡A©Ò¥H2015¦~10¤ë®É©Ò¦³ÁÙ¬¡µÛªº¯f±wªº¦s¬¡´Á³£¦Ü¤Ö¶W¹L15Ó¤ë¡A¤]´N¬O»¡«áÄòµo¥Í¯f¨Ò¦º¤`®É¬O¤£·|¼vÅT¨ì²Ä15Ó¤ë«eªºOS¦±½uªº¡C¦ý¬OÀHµÛ®É¶¡±À²¾»P·sªº¦º¤`¯f¨Òªº¥[¤J¡A²Ä15Ó¤ë¨ì²Ä32Ӥ몺OS¦±½u¬O¦³¥i¯à¥X²{¤U²¾ªº¡A¬O³o¼Ë¶Ü¡H ¦pªG¬O³o¼Ë¡AM OSªº½T»{¦³¨âÓn¯À¡A¤@¬OOS¬ï¶V50%³o±ø½u¡A¤G¬O³oÓ¬ï¶VÂIªº¤ë¼Æ¥²¶·§C©ó³Ì«á¦¬®×¯f¨Òªº²{¦b¥Í¦s¤ë¼Æ¡C§_«h³oÓM OSªº¼Æ¾Ú´N¬O¤£¦¨¼ôªº¡C ¬O§_¦p¦¹¡H½Ð±Ð¤F¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/15 ¤W¤È 10:06:37²Ä 1991 ½g¦^À³
|
QQ¤j¡A ·PÁ±z¡I ¯E§J¤j¡A ±z´£¨ì ¡uȱoª`·Nªº¬O17¶ ¤ÏÀ³²Õ³]4¤H ¦º¤`21¤H µL¤ÏÀ³²Õ³]24¤H ¦º¤`29¤H ¹ï·Ó²Õ³]14¤H ¦º¤`35¤H¡v ¦º¤`ªº¼Æ¦r¡G21¡B29¡B35¦bp17¤W³£¬Ý±o¨ì ¦ý¡u¤ÏÀ³²Õ³]4¤H¡BµL¤ÏÀ³²Õ³]24¤H¡B¹ï·Ó²Õ³]14¤H¡v ³o¤TӼƦr¦bþ¨à¬Ý¨ìªº¡H ÁÙ¬On³z¹L¤°»ò¤èªkºâ¥X¨Ó¡H ¤ÏÀ³²Õ¦¬112¤H¡A¦º¤`21¤H¡A³]=112-21=91¤H ±z»¡ªº³]4¤H¬O«üdrop out³o¤@Ãþªº³]¦³4¤H¶Ü¡H ³Â·Ð±z¸Ñ»¡¤@¤U ÁÂÁ¡I ¥t¥~ ®ðª^¦n¹³¯uªº¦³ÂI´e ´N¨Óª±¤@Ó¡u¤j®a¨Ó§ä´í¡vªº¹CÀ¸¦n¤F ¦bp17 À³¸Ó¦³¤H¦´N¬Ý¨ì¤F ¤£§ÔV³d¤½¥q ¦]¬°«e¤TÓ¤ën·Ç³ÆASCO¤S³Q¥~¬É·d±oµJÀYÄêÃB ²Ä¤@Ó§ä¨ìªº¤H°e¡uÄõÄR»¨m§²°¡v¤@²Õ ¦ý¤]½Ð³qª¾¤½¥q±Nslideªº¤º®e°µÓ§ó§ï |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/15 ¤W¤È 09:38:19²Ä 1990 ½g¦^À³
|
¤j®a¥i¥H·Q¤@¤U¬°¬Æ»ò·|¦³888³o¼Ëªº§ÜÅé ´N¬Oè¦n¥i¥H¸É±¼¨S¿ìªk¸g¥Ñ822/833¥D°Ê²£¥Í§ÜÅ骺¯f¤H±Ú¸s ¨S¿ìªk¸g¥Ñ·N]²£¥Í§K¬Ì¤ÏÀ³¨º´N¥Î¸É¥Rªº |
|
|
·|û¡G¶Â½ü§B10141808 µoªí®É¶¡:2016/6/15 ¤W¤È 09:36:01²Ä 1989 ½g¦^À³
|
1.¦~³ø³o¥y¸Ü µ¹§Úªº±Ò¥Ü´N¬O ¦pªG¤½¥q¹ï822Àø®Ä¨S«H¤ß ¬°¦ónn´£«e§G§½888¥B¶i¦æ¶q²£¡H 2.´N§K¬Ì¯f²z¨¤«×¨Ó¬Ý ¦ý¤p§Ì»{¬°888ªº°Æ§@¥Î·|¤ñ¸û¤j ¦p¡G¤ÞµoÄY«¹L±Ó¤ÏÀ³©Î¦å²M¯f ¥B¦pªG¨S¤Þµo¦å²M¯f·ÀIªº¯f¤H ¨äÀø®Ä¤]¤£¤j ©Ò¥H ³o¦¸822ªº¹êÅç ¯uªºn¥hÂç²M ¨º¨Ç¨S§K¬Ì¤ÏÀ³ªº¤H ¨ì©³¬O¦³¦h¤Ö¤H¬O¤Þµo§ÜÅé¯à¤O¯Ê¥F ¦³¦h¤Ö¬O§K¬Ì줣¨¬©Î¤ÏÀ³®É¶¡¤£°÷ ³o¹ï888ªº¥¼¨Ó¬O¦³«Ü«nªº«ü¤Þ ³Ì«á·PÁ«ܦh¦p¡GCLIFF ¤p©_ ¦Ñ·¨ ¯E«È¥xÁޤΫӥv¤jµ¥²Îp©Î¨ä¥L¬ÛÃö»â°ì°ª¤â¹ï¥»ª©ªº°^Äm ¤p§Ì¥u¯à³¥¤HÄmÃnªº±q§K¬Ì¯f²z¨¤«×¨Ó´£¨Ñ¤p¤p·N¨£ ¦p¦³¿ù»~·q½Ð«ü¥¿ |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/6/15 ¤W¤È 09:26:46²Ä 1988 ½g¦^À³
|
·PÁ¹x¥Û¤jªº«ü±Ð §Ú·|Ä~Äò§V¤O¸ò¤W¤j®aªº¨B¥ï ¯uªº«ÜÁÂÁ§A |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/15 ¤W¤È 09:23:38²Ä 1987 ½g¦^À³
|
ºÃ´bªÌ¤j¡A 888 ¤£·|¦³¹w¨¾®ÄªG¡C¦]¬°¥~¨Óªº§ÜÅé·|¦bÅ餺¦ÛµM¤À¸Ñ¡A¤£¨ã¦³ªø®Ä©Ê¡C ¥u¦³¦Û¨§K¬Ì¨t²Î»{ÃѧÜì«á¡A¨C¦¸µo²{§Üì´N¥ß§Y²£¥Í§ÜÅé¹ïÀ³¡A³o¤~¨ã¦³ªø®Ä©Ê»P¹w¨¾¥\¯à¡C³o¬O 822 »P 833 ªº¥¼¨Ó«e´º¡C 888 ³oÃþ³æ®è§ÜÅé¥u¦³ªvÀø®ÄªG¡C |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/6/15 ¤W¤È 09:13:12²Ä 1986 ½g¦^À³
|
¦Ñ¥v¤j «_¬N·Q½Ð±Ð±z§Ú³oÆ[©À¹ï¤£¹ï¡H ¦pªG¦³»~ ³Â·Ð±z¤£§[«ü¥¿¤@¤U ·PÁ¤£¤w |
|
|
·|û¡GºÃ´bªÌ10140504 µoªí®É¶¡:2016/6/15 ¤W¤È 09:00:56²Ä 1985 ½g¦^À³
|
¨ä¹ê¬Ý§¹¯E¹©ªº¦~³ø ³ÌÅý§Ú²´·ú¬°¤§¤@«Gªº¬O ¤U±³o¤@¬q¤å¦r ¡§³Ì¥O¤H´Á«Ýªº¬O,±q OBI-822 Á{§É¸ÕÅç©ÒÀò±oªº·§©À©ÊÅçÃÒ±oª¾¯f¤HÁÞ§ÜÅ骺²£¥Í©M §Ü¸~½F¤ÏÀ³¦³«D±`±jªº¥¿ÃöÁp©Ê,¦]¦¹¥xÆW¯E¹©±N¥þ¤Oµo®i³æ®è§ÜÅé OBI-888,´£¨Ñ³Q°Ê §K¬ÌÀøªk,³yºÖµLªk¹ïÁÞ¬Ì]²£¥Í§ÜÅé¤ÏÀ³ªº¯f±w¡C¦¹§ÜÅéÃĪ«°£¤F¤w¥Ó½Ð¦h°ê±M§Q¡B¿n ·¥±M§Q§G§½¤§¥~,¥Ø«e¤w¶i¤JÁ{§É«eÃIJz¬r²z¸ÕÅç¥H¤Î§ÜÅé¶q²£¶}µo,¨Ã¦P®É®i¶}Á{§É¤@ ´Á¸ÕÅ窺³]p¡C¡¨ ¨ÅÀù±wªÌ¤~´X¤Q¸U¤H ¦ý·Q¥´Àù¯g¹w¨¾°wªº¤H¤fÀ³¸Ó¤W»õ¤H§a¡I ©êºp, ¤j®a¦b°Q½×obi-822 ,§Ú«o¦b´£¥i¯à8¦~«á¤~¯à¤W¥«ªºobi-888 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/15 ¤W¤È 12:05:59²Ä 1984 ½g¦^À³
|
¤¤°ê¨ÅÀù2015µo¥Í¤H¼Æ27.24¸U¤H¡A¤ñ¬ü°ê24.92¸U¤H¦h2.32¸U¤H¡A¦ý¬O¦b¦º¤`¤H¼Æ¤W®t²§«Ü¤j¡A¤¤°ê¨ÅÀù2015¦º¤`¤H¼Æ7.04¸U¤H»·¦h©ó¬ü°ê4.08¸U¤H¹F2.96¸U¤H ¡A³oÅã¥Ü¥X¤¤°ê¨ÅÀù°ü¤k·¥»ÝÀò±o§ó¦nªºÂåÀø·ÓÅU¡A¬°¤F¥Í©RµL»ùªº²z¥Ñ¡A¨â©¤À³¥[³t¦X§@¡AÅýOBI822 ¦¤é¦b¤¤°ê¤W¥«¡A¥¼¨Ó¬@±Ï¼Æ¦Ê¸U¤¤°ê¨ÅÀù¯f±w¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/14 ¤U¤È 11:23:40²Ä 1983 ½g¦^À³
|
OS¹³¤@ºØ²¢¥Ê¡Aªø¦b822ªº¾ð¤W¡A¥Ø«e¬Ý¨Ó»á¬°¦n¬Ý¡A¦ý¬O©|¥¼¦¨¼ô¡A±jºK¤U¨Ó²¢«×·|¤£°÷¡C ·|²¢ªº¥Ê¡A¤f·P¤~·|¦n¡A¤]¤~¯à½æ¨ì¦n»ù¿ú¡C ©Î³\©ú¦~¬K·§j°_®É¡A¦¨¼ôªºOS¦ÛµM·|ÄÆ»¡C ¤p©_¤j¡AÁÂÁ±zºë±mªº¤ÀªR¡A¥´¦r¨¯W¤F¡C ¯E§J¥S¡A±zªº°ÝÃD¡G¡uY¤½¥q¨S¦³®Õ¥¿¹LCox model¥H²Å¦X«Dµ¥¤ñ¨Ò·ÀIªv¡²v¼Ò¦¡ ¨º»ò©Ò±oPFS©ÎOS¬O§C¦ôÁÙ¬O°ª¦ô?¡v³oÓ§Ú¤£ª¾¹D¡C §Ú¦Û¤v¬d¨ìªº¬O¡A¶Ç²Îªºµ¥¤ñ¨Ò·ÀI¡]Proportional hazard¡^¬O¥Hlog-rank§@¤ÀªR¡A¥¦ªº¤@Ó°ò¥»ªº°²³]¬O¡u¡K¡Klog-rank test is also based on the assumption of non-informative censoring¡K¡K¡v¡]µù1¡^¡F©Ò¥H¹ï©ó±`¥X²{³]¸ê®Æªº§K¬ÌÀøªk·sÃÄ¡ATai-Tsang Chenªº«Øij¬O±Ä¨ú¡uWeighted log-rank¡v¤ÀªR¡]µù2¡^¡C §ÚªººÃ°Ý¬O¬°¦ó822¦bASCO slide No.16-17³£¬O±Ä¨úStratified Cox model¡H³o¬O²Ä¤@Ó°ÝÃD¡C µM«á®Ñ¤W»¡(µù3)¡G ¡uCox¤ñ¨Ò·ÀI¼Ò«¬¡]Cox proportional hazards model¡^¥i¥Î¨ÓÀË©w¼ÆÓ¸ÑÄÀÅܶµ¹ï©ó·ÀIªº¿W¥ß§@¥Î¡v¡F ¡u¦b¦¹¼Ò«¬¤¤¡A¬Û¹ï·ÀI³Q»{¬°¤£ÀH®É¶¡§ïÅÜ¡A¤]´N¬O¶i¦æ¤ñ¸ûªº±Ú¸sªº·ÀI¬Oµ¥¤ñ¨Òªº¡C¡v¡F ¡u¦pªG¹H¤Ï¤F¦¨¤ñ¨Òªº·ÀI°²³]¡A§ÚÌ¥i±N°lÂܤÀ¬°¨âөΧó¦hªº¡y°Ï¶¡¡z¡A¨ä¤¤·ÀI¬O¦¨¤ñ¨Òªº¡C§Ú̱µµÛ¦b¨CӰ϶¡¤À§O¶i¦æCox°jÂk¤ÀªR¡K¡K¡v¡C §Ú¦b·Q¡A822¦bASCO slide No.13¬O¹êÅç²Õ»P¹ï·Ó²Õ¦³ÃöOSªº´Á¤¤¤ÀªR¡A«e16Ӥ뤺¦³³Âªá²{¶H¡A¸ò16Ó¤ë«á¨â½u¤À¶}ªº±¡§ÎÅã¥Ü¬O¤£µ¥¤ñ¨Ò·ÀIªº¼Ò¦¡¡F¨ì¤FNo.17¡A§ï¥HIgG titer>160ªº¼Ð·Ç¨Ó¤À²Õ¡A°µ¤T²Õªº¤ñ¸û¤ÀªR¡A¬O¤£¬O´N¬O¤W±ªº®Ñ¤W´£¨ìªº¡u¤À¬°¨âөΧó¦hªº¡y°Ï¶¡¡z¡v¨ÓÅý·ÀI²Å¦Xµ¥¤ñ¨Ò·ÀI¡A¨º´N¥i¥H¨Ï¥ÎCox model¨Ó¤ÀªR¤F¡H¡]No.17¸g¹L³o¼Ë¤À°Ï«á¡A³Âªá¤j¬°´î¤Ö¡F¦ý¦¹»¡ªk¥Î¦bNo.16¦ü¥GÁÙ¬O¤£³q¡I¡^ ·Q½Ð±Ð±zªº²Ä¤GÓ°ÝÃD¬O¡G¡ulog-rank test »PWeighted log-rank test¦³¦ó®t§O¡H¡v µù¡G 1.¡uDOES LOG-RANK TEST GIVE SATISFACTORY RESULTS?¡v¡]www.jaqm.ro/issues/volume-7,issue-1/pdfs/1_zaman_pfeiffer.pdf ¡^ 2.¡uStudy Design and Analysis in Late-Stage Cancer Immunotherapy Trials¡vSlide No.13¡]www.ema.europa.eu/docs/en_GB/document_library/Presentation/2016/04/WC500204595.pdf ¡^³o¤@½gȱo¤@¬Ý¡AÁöµM«Ü¦hŪ¤£À´¡C 3.¡uMedical statistics at a glance¡v¡FWiley-Blackwell¡A2009¡C |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/14 ¤U¤È 11:23:13²Ä 1982 ½g¦^À³
|
¤p©_¤j: ¤w±N±zªº´£°Ý±Hµ¹¤½¥q¤F. ªÑªF·|®É¤]·|follow up ³s¦P¦Ñ´¤j¤Î¯E§J¤jªº£¸¨Ö´£¥X. ¦ý¾á¤ß§Ú¦b³o¤@¤è±µ{«×¤Ó®t, ¦pªG¤½¥qªº¦^µª¤¤¦³»Ýn¸ò¶iªº´£°Ý, ®£©È«D§Ú¯à¤O©Ò¤Î. ³oÂI, ÁٽЦU¦ì¤j¤j¨£½Ì. ¬O§_¥¡½Ð·|¥h°Ñ¥[ªÑªF·|ªº²Îp°ª¤â¤j¤j¤@¨Öª`·N´£¥X³o¨Ç°ÝÃD ? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/14 ¤U¤È 10:22:54²Ä 1981 ½g¦^À³
|
ÁÂÁ¯E§J¤j ²q·Q¤j ¤Ñ©R¤j Cliff ¥S ¦Ñ´¥S ¹x¥Û¤j µ¥¦U¸ô°ª¤â ±q¤£¦P¨¤«×¤Á¤J¨Ã²`¤J±´°Q , ¬O¤£¬O¯E¹©n°_¸¤F!!! ¤p©_¤j: Á|¤â¤§³Ò ªá¨Ç®É¶¡¾ã²z ´£¨Ñ¸ê°T¤À¨É¦Ó¤w Cancer statistics in China, 2015 ¥xÆW¯E¹©¥¼¨Ó¦bº¡¨¬¤¤°ê¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D±N§êºt«n¨¤¦â ¨â©¤Á{§É¸ÕÅçÀ³ºÉ§Ö¬Û¤¬©Ó»{, ¬Ù®É¬Ù¿ú, «BÅS§¡ÀL,¤¬»X¨ä§Q 4¡Ï4Á{§É¸ÕÅç¾÷ºc©çªO©w®×¡A¥Ñ¥x¥_ºaÁ`¡B¥x¤j¡B¤TÁ`©MªL¤fªø©°µ¥4®aÂå°|¡AÁÙ¦³4®a¤j³°Âå°|©Ò°õ¦æªºÃĪ«Á{§É¹êÅç¼Æ¾Ú¡A¥i¥Î©ó¤j³°ªºÃÄÃҥӽСA¬°¥xÆW¥Í§Þ·~«n§Q¦h¡C tbsa.org.tw/news/display/264 ( 2016 05 17 ) ¥»¦¸¥xÆW¤T´ÁÁ{§É¸ÕÅç¾÷ºc ¥¿¦n¤]¥]¬A ¥x¥_ºaÁ`¡B¥x¤j¡B¤TÁ`©MªL¤fªø©° ¤¤°êÀù¯g²{ªp 1 2015¦~¦b¤¤°ê¤j¬ù4292000·s¶EÂ_Àù¯f¨Ò¦b¡A¬Û·í©ó¥§¡¨C¤Ñªñ12,000·sªºÀù¯g¶EÂ_®×¨Ò¡C 2¦b¨k©Ê¤¤¤Ó³Ì±`¨£ªºÀù¯g¬O¡GªÍÀù¡AGÀù¡A¹¹DÀù¡A¨xÀù¡Aµ²ª½¸z¦@¦û©Ò¦³Àù¯g¯f¨Ò¬ù¤T¤À¤§¤G¡C¦b¤k©Ê¤¤¡A³Ì±`¨£ªºÀù¯g¬O¨Å¸¢Àù¡AªÍÀù©M¤ä®ðºÞÀù¡AGÀù¡Aµ²¸zª½¸zÀù¡A¹¹DÀù¡A¦û¤Fªñ60¢Hªº®×¥ó¡C 3¨Å¸¢Àù¡A¹wp¦û¤¤°ê°ü¤k©Ò¦³·sµoÀù¯gªº15¢H¡C 4 2015¦~¬ù2814000¤HÀù¯g¯f±w¦º¤`¡A¬Û·í¥§¡¨C¤Ñ¶W¹L7500¤H¡C 5¤¤°ê¨k©Ê©M¤k©Êªº¤Ó¥DnÀù¯g¦º¤`ì¦]¬OªÍ©M¤ä®ðºÞ¡AG¡A¨x¡A¹ºÞ¡Aµ²ª½¸zÀù¡A¦û©Ò¦³Àù¯g¦º¤`ªº¤j¬ù¥|¤À¤§¤T¡C 6§l·Ï¦û¤¤°ê©Ò¦³Àù¯g¦º¤`ªº¤j¬ù¥|¤À¤§¤@;¦b¦¨¦~¤¤°ê¨k¤Hªº¤@¥b¬O§l·ÏªÌ,«C¤Ö¦~©M¦~»´¦¨¦~§l·Ï²vÁÙ¦b¤W¤É¡C 7«Ç¥~ªÅ®ð¦Ã¬V¡A«Ç¤ºªÅ®ð¦Ã¬V³q¹L¥[¼ö©M¨Ï¥Î·Ñ¬´»P¨ä¥L¥Í½è¿U®Æ¡A¤gÄ[¦Ã¬V¡A¤ô¦Ã¬Vµ¥Åý¤¤°êªº¤H¤f¼ÉÅS¦b³\¦hPÀùª«½èÀô¹Ò¤¤¡C ¯E¹©¥¿¬ãµo»P¥¼¨Ó³W¹º¬ãµoªº16ºØÀù¯g (2015¦~¤¤°ê¹w¦ô16ºØÀù¯g µo¥Í¼Æ ¦º¤`¼Æ ) Cancer statistics in China, 2015 ¤¤°ê¹w¦ôÀù¯g -- /µo¥Í¼Æ / ¦º¤`¼Æ / ³æ¦ì: ¤d ¥þÀù¯g All Sites /4291.6 / 2814.2 / ¤fµÄÀù Lip, oral cavity, & pharynx / 48.1 / 22.1 / ¹¹DÀùEsophagus/477.9 / 375 / ¨xÀù Liver /466.1 / 422.1 / ÁxÅnÀùGallbladder/ 52.8 / 40.7 / ¯ØŦÀù Pancreas/90.1 / 79.4 / µÇŦÀùKidney /66.8 / 23.4 / ¨ÅÀùBreast / 272.4/ 70.4 / §Z±_ÀùOvary / 52.1 / 22.5 / ¤j¸zª½¸zÀùColon & rectum /376.3/ 191/ ªÍ»P¤ä®ðºÞÀùLung & bronchus / 733.3/ 610.2 / GÀùStomach / 679.1 / 498 / ¯ØŦÀùPancreas /90.1 / 79.4 / ÄáÅ@¸¢ÀùProstate/60.3 / 26.6 / ¸£Àù Brain & other nervous system/ 101.6 / 61/ ¤l®cÀVÀù uterine cervix /98.9/ 30.5 / ¤l®cÅéÀù Uterine corpus/63.4 / 21.8 / ( ¤l®c¤º½¤Àù) onlinelibrary.wiley.com/doi/10.3322/caac.21338/full Globo¨t¦CÁަܤ֦s¦b©ó14ºØÀù²ÓM(cell culture) ÀùÀù²Ó / Globo H /SSEA-‐3 / SSEA-‐4/ ³Ì°ªªí²{ / ¹¹DÀù / 100% / 0% / 50% / 100% / GÀù / 100% / 50% / 67% / 100% / ¯ØŦÀù/ 75% / 38% / 100% / 100% / «e¦C¸¢Àù/25% / 25% / 100% / 100% / ¨xÀù / 90% / 40% / 60% / 90% / §Z±_Àù/56% / 22% / 89% / 89% / ¤j¸zÀù/86% / 0% / 71% / 86% / µÇŦÀù/86% / 0% / 83% / 86% / ¤fµÄÀù/85% / 15% / 62% / 85% / ®cÀVÀù/25%/ 50% / 75% / 75% / ¨ÅÀù /61% / 26% / 74% / 74% / ¸£Àù /35% / 53% / 71% / 71% / ªÍÀù/ 65% /25% / 65% / 65% / ÁxºÞÀù/60%/20% / 40% / 60% / ¸ê®Æ料»¡說說©ú: (1)Globo¨t¦CÁÞ: GloboH, SSEA4, SSEA3; (2)¥H¬y¦¡²ÓM»ö´ú¶qGlobo¨t¦CÁÞ¡A°»´ú¨ì15%¥H¤W¡A§Y¬É©w¸ÓÃþ²ÓM¦³ Globo¨t¦CÁÞªí²{¡F¨Ó·½:Lou et al.Proc Natl Acad Sci USA.2014 Feb 18;111(7):2482-‐7 ¥H¤W¸ê°T¾ã²z ´£¨Ñ¤À¨É ¦³¿ù½Ð§ó¥¿ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/14 ¤U¤È 09:28:44²Ä 1980 ½g¦^À³
|
¤p©_¤j ±z»¡ªº¬O §ÚÌn¥Î§ó¾U§Q»P§ó¶}Á諸²´¥ú¨Ó¬Ý¨ì¥þ·sªºÁÞ¬Ì]ªºÁ{§É¼Æ¾Ú ¦³¼Æ¾Ú ¤~¦³¯u¬Û ¹x¥Û¤j ±zªº¤ÀªR¤]¬O¦³¹D²z ¹ï·Ó²Õªºªø§À¤ñ¸ûµu ³Ìªø¦s¬¡¯f¤H¤~53©P Åã¥Ü¹ï·Ó²Õ¤£¬Oªø¶]°·±N ȱoª`·Nªº¬O17¶ ¤ÏÀ³²Õ³]4¤H ¦º¤`21¤H µL¤ÏÀ³²Õ³]24¤H ¦º¤`29¤H ¹ï·Ó²Õ³]14¤H ¦º¤`35¤H Åã¥Ü ¹ï·Ó²Õ¤ñ¥t¥~¨â²Õ¥[§Ö¦º¤` ¦ý¬OµL¤ÏÀ³²Õ¦]¬°°²©ÊPD¦Ó°h¥X¹êÅç ´M¨D¨ä¥LªvÀø ¨S¦³Ä~Äò°Ñ»P¹êÅçªÌ ¤]¤£¤Ö ©Ò¥HµLªkÄ~Äò°^ÄmOS |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/14 ¤U¤È 08:48:01²Ä 1979 ½g¦^À³
|
©IÀ³¤p©_¤j¡C¨ä¹ê¤½¥q¹ï©ó¹ï·Ó²Õªº PFS ¦±½u¤]«ÜÅå³Y¡A©Ò¥H¥~¬É½èºÃ¤½¥q¦´Nª¾¹D¸Ñª¼µ²ªG¤£¨Î¦Ó½æ¥X«ùªÑ¡A®Ú¥»¬OµL¤¤¥Í¦³¡C ¦³¹L³o¦¸¸gÅç¡A¯E¤Í¹ï©ó¥¼µo¥Íªº¼Æ¾Ú¯uªº¤£¯à¦A¾Ìª½Ä±¥h²q´ú¡C ¤£ª¾¬°¤£ª¾¡A¬Oª¾¤]¡C ¯u¹ï¤w¸gµo¥Íªº¼Æ¾Ú¨Ó¤ÀªR¡A¤ñ¸û¨S¦³ª§Ä³¡C ¤p§Ìµo²{ p.17 ¦³Ó¯SÂI¡A´N¬O¹ï·Ó²Õªº½u¤ñ¸ûµu¡AÀ³¸Óªí¥Ü³Ì¦¶i¤Jªº¯f¨Ò¤¤¡A¹ï·Ó²Õªº¤w¸g³£¹L¥h¤F¡A¦Ó¹êÅç²Õ (¥]¬A°ª§K¬Ì¤Î§C§K¬Ì¸s) ³£ÁÙ¦³¦s¬¡¯f¨Ò¡C³o¬O¥t¤@Ó¥i¯àªºÀu¶Õ¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/14 ¤U¤È 08:22:25²Ä 1978 ½g¦^À³
|
¥xÁÞ¤j¡A ¤p§Ìº|¤F±zªº¦W¦r°Õ ³o¨â¤T¦~³z¹L±z¨V¨ú¤F«Ü¦h§K¬ÌÀøªkªºª¾ÃÑ ¤£P¤W¤@Án·PÁ ¤ß¸Ì©ñ¤£¤U ÁÙ¦³³\¦hn·PÁªº¤H ´N¤£¤@¤@PÁ¤F ÁÂÁ¤j®a |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/14 ¤U¤È 06:57:50²Ä 1977 ½g¦^À³
|
¯E§J¤j¡A ±zªºÆ[¹î«Ü¥J²Ó p17³Ì¤jªº·N¸q´NÂæb³o¨Ç³]¸ê®Æ¤¤ ¤£¥u¬O¦³¤ÏÀ³²Õªº³]¸ê®Æ¡A¨S¤ÏÀ³²Õªº³]¸ê®Æ¤]³zÅS³\¦h°T®§ ¤w¸g¥P³uªº±wªÌ¤w¸g³y¦¨¤F¾÷²vªº¤U° ¼µ¹L¤@Ó¤£µuªº®É¶¡ÁÙ¬¡µÛªº±wªÌ¥i¯à¤j³¡¤À±N®i²{·¥ªøªº¥Í©R¤O ³Ì«áOS¸ê®Æ¦¨¼ô«á¦¨¬°«Ü«pªº§À³¡ ¦ý ¤p§Ì³o¨â¤T¦~¨Ó±q±qÁ{§É¤@´Áªº¸ê°T¤Îªk»¡¡BªÑªF·|ªº»¡©ú ¤@ª½¥H¬°¹ï·Ó²Õ¬O6Ó¤ë¤W¤UªºM PFS¡A¹êÅç²ÕªÖ©w¦³1XÓ¤ë¥H¤WªºM PFS °µ¹Ú¤]¨S·Q¨ìPFS ªºK-M curve¬Oªø¦¨P12ªº¼Ë¤l ¦ý¬Ý¨ìP17ªºOSªºK-M curve¤S·P¨ìªY¼¢¡A ¤]ºâªø¤Fª¾ÃÑ ¥D°Ê§K¬ÌÀøªkªºª¾ÃÑ ¤£¹L±À½×PFSªº¸gÅç Åý¤p§Ì¨M©wµ¥¨Æ¹ê§i¶D¤F§Ú¬O¨Æ¹ê¤§«á §Ú¦A¨Ó¬Û«H³oÓ¨Æ¹ê ¦pªG©ú¦~¤¤¦]¬°»Ýn¡A¤½¥q¤S°µ¤@ÓOSªº´Á¤¤¤ÀªR ¦³¤ÏÀ³²Õ¤´¦³70%ªº«p§À¡AµL¤ÏÀ³²Õ¤]¤´¦³40%~50%ªº«p§À §Ú±N·|¬Û«H·í5¦~ªºOSÆ[¹î´Áµ²§ô ¦³¤ÏÀ³²Õ±N·|¦³±µªñ70 %ªº«p§À µL¤ÏÀ³²Õ¤´¦³40%¥H¤Wªº«p§À »·»·¶]Ĺ¹ï·Ó²Õ(Cyclophosphamide¤Î²üº¸»XÀøªk¦bMBC)³Ì¥i¯àªº5¦~OSªº20~30%ªº«p§À ¦pªG©ú¦~¤¤¯à¦A¬Ý¤@¦¸OSªºK-M curve ¥B¯uªº¬O¤Wzªº³oÓ¨Æ¹ê ¤p§Ì¥u¯à¥Î¤@¥y¸Ü¨Ó§Î®e ¡u³Ç§J¡A³o¯uªº¬O¤Ó¯«©_¤F¡v ¦bÁÙ¨S¦³¦A¬Ý¨ì¤U¤@±iOSªºK-M curve¤§«e ¥ý¥H¥±`¤ß¨Ó¬Ý Y¨S¦³¦¨¬°³Ç§Jªº¯«©_ªº¨Æ¹ê¡A¤]¬O¤£¿ùªº¨ÅÀùÃÄ ¦¨¬°³Ç§Jªº¯«©_ªº¨Æ¹ê¡A´N·í°µ¬O¤Ñ¤W±¼¤U¨ÓªºÂ§ª« ¦]¬°ÁÙn¸ò¯E¹©©ê«Üªøªº®É¶¡ Ä~Äò¸ò¤½¥q¡Bcliff¤j¡B²q·Q¤j¡B¦Ñ¥v¤j¡B¦Ñ´¤j¡B¯E§J¤j±z¤Î²³¤j¤jµ¥¾Ç²ß³Ì·sªº§K¬ÌÀøªkª¾ÃÑ ¨Ó¤é¤èªø ©Ò¥H¨M©w¥Î¤¤©ÊªººA«×¨Ó±¹ïP17¥Ø«e©Ò§e²{ªº¨Æ¹ê ¨S¦³n¼vÅT¥ô¦ó¤H ¤j®a½Ð¨Ì¦Û¤vªº²ßºD¨Ó¬Ý«ÝP17ªº°T®§ ¾Ç·|«ç»ò¬Ý³Ì«n ¥i¥H¼ÖÆ[¤@ÂI¤]¥i¥H«O¦u¤@ÂI¹w´Á¤´¦b¶i¦æ¤¤ªºÃĮĵo®i¶i«× ¥H¤W¬O¤p§Ìªº·P·Q¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/14 ¤U¤È 05:40:25²Ä 1976 ½g¦^À³
|
¤p©_¤j §O¤¶·N §Ú¤]¬OºCºC¦b¾Ç²ßCox model. ¤j®a¤@°_¦¨ªø »{¦P§Aªº¹w¦ô ¦w¼¢¾¯²Õ km¦±½u À³¸Ó«Ü§Ö±×²v¦V¤U ¦ý¬O¤ÏÀ³²Õ¥i¯à¤£·|¤F®@ ½Ð¬Ýp.17. 29¤ë¥H«eªþªñ¦±½u ¤@°ï³]¸ê®Æ Åã¥Ü¤ñ¸û«á´Á¦¬®×ªº¯f¤HÁÙ¨S¦º¤` «Ü¥i¯à«p§À´N°±¦b 70%®@ ¬Ý¹Ï¸Ó²Õ¦³¤@Ó¯f¤H 56¤ë ¨âÓ53-54¤ë ¤w¸g¹w§i ¦³¤ÏÀ³²Õ ¬¡«Ü¤[. µL¤ÏÀ³²Õ¬ù¦b20-28¤ë¨ºÃä ¤]¬O¤@°ï³]¸ê®Æ ¦pªG¤£¬Odropout ¨º´N¬O¤ñ¸û«á´Á¦¬®×ªº¯f¤H «Ü¥i¯àÄ~Äò°^Äm§óªøªºOS. ¥H§Úµe½u©Ê¦^Âkª½½u¨Ó¬Ý ¬ù¬O44¤ë ¤ñ¹ï·Ó²Õ40¤ë ¦h ¯uªº¬O°¨©ÔªQ¤ñÁÉ «á¨Ó¤W Åã¥Ü822©µÄò¤ÏÀ³»Pªv¡®ÄªG |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/14 ¤U¤È 02:36:35²Ä 1975 ½g¦^À³
|
¯E§J¤j¡A ¤p§Ì¤O¦³¥¼¶e¡ACox Model¯uªº¬Ý¤£À´°Õ¡I ¦pªGp17´N¬O³Ì²×¦¨¼ôªºOS¹Ïªº¸Ü¡A¨ºµL¤ÏÀ³²Õªº4¦~¦s¬¡²v=52.99%¡A52Ӥ몺¦s¬¡²v¤]¬O52.99%¡A56Ӥ몺¦s¬¡²v¤]¬O52.99%¡C §C¤ÏÀ³²Õ¦b¤£»·ªº30Ó¤ë®É¤´¦³¤j¬ù65%ªº¦s¬¡¾÷²v¡A¦ý¦b¤@¹L¤F32Ó¤ë¤j¬ù33Ӥ몺®É¶¡¡A´N¤w¸g°¨ì52.99%¡A¯u¹êªº±¡ªp´N¬O¦³¼ÆÓ¦¦¬®×ªº±wªÌ²£¥Í¤F30~33Ӥ몺OS¦º¤`¨Æ¥ó¡A¦pªG³o´XÓ±wªÌ¬O¦b2013/1~2013/6¤j¶q¦¬®×®É¶i¨Óªº(¤£¤@©w¨C¤@Ó³£¬O)¡A¨º¥L̵o¥Í¦º¤`¨Æ¥ó´N¬O¦b2015/10 data lock¨S¦h¤[¥H«eµo¥Í¡CnÆ[¹î¨ì4¦~ªº¦s¬¡®É¶¡¡A¦Ü¤Ö®É¶¡¶bÁÙn©¹«á±À1¦~¥b¨ì2¦~¡A¦b³o¬q³o»òªøªº®É¶¡¡A¥un¦³±wªÌ¦º¤`¡A´N·|³y¦¨¦b°O¿ýªºOS¤ë¥÷ªº¾÷²v¤U°¡AK-M curve¤£¥i¯àºû«ù¥X¥Ø«eªºª¬ºA¡A²{¦b32Ӥ몺¦s¬¡¾÷²v¬O52.99%¡A¦A¹L¤@¦~¥b¨ì2¦~¡A²{¦b¬¡µÛªº³£¤@©w¬¡µÛ¡AÁöµM»¡¥¼µo¥Íªº¨Æ±¡¤£¤@©w´N¤£·|µo¥Í¡A¦ý¥H¤p§Ìªº²z¸Ñ¤O¡A¥Ø«e¨S¦³¿ìªk·Q¹³¡C ¤Ï¥¿6/27ªÑªF·|§Ö¨ì¤F¡AP17ªº°ÝÃD¥i¥H°Ý¤½¥q¡C ´N½ÐQQ¤j¶¶«KÀ°§Ṵ́ݤ@¤U¡A¦h¤@¨Ç¤H°Ý¤~¤ñ¸û½T«O¥i¥H±o¨ì¦^µª¡C °ÝÃD¡G¥Ø«eP17ªº¹Ï«¬¤W¬Ý¡A¹ï·Ó²Õ4¦~¦s¬¡²v=60.51%¡A½Ð°ÝOS¼Æ¾Ú¦¨¼ô¤§«á¡A¦³«Ü¤jªº¾÷·|¡A¹ï·Ó²Õªº4¦~ªº¦s¬¡²v=60.51%¶Ü¡H ¦A³Â·ÐQQ¤jÀ°§Ṳ́@°_§e¤W°ÝÃD ÁÂÁ¡I |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2016/6/14 ¤U¤È 02:09:46²Ä 1974 ½g¦^À³
|
·PÁÂcliff/¤p©_/¯E§J/²q·Q/¦Ñ´/¤Ñ©R...µ¥¤j¤j©^Äm¤ß¤O±´¯Á¥v¤W³Ì°¶¤jªºÁÞÃÄ ¤p§Ì¦bASCO«á±À¦ô°ª§ÜÅ骺M OS¬ù¦b60mªþªñ¡A¹ï·Ó²ÕªºM OS¬ù¦b40mªþªñ¡A»P¤p©_¤j,¤Ñ©R¤jªº±À¦ô³£®t¤£¦h «á§À¤@©w·|©ì«Üªø¡A¤×¨äY¤½¥q¥uÆ[¹îM OS¨ì60m¡A Y°ª§ÜÅé²Õ¶W¹L60mªº50%(¹w¦ô¤H¼Æ¤ñ¨Ò)±µ¤U¥h°ò¥»¤W¦³«Ü¦hÀ³¸Ó¬O¤w¸g±µªñ²¬Â¡ªº±¡§Î ²{¦b¥~¸ê¤w¸g¶}©lª`·N³sÄò¶R¶i¡A¦ýÁÙ¥u¬O¤p¶R¡AY©¡®É¨ìM OS>60®É±N·|¤Þ°_¥þ²yÃöª` ³o¥i»Ýn®É¶¡µ¥«Ý¡A¦ôp»Ýn¨â¦~~¤T¦~¥ª¥k ¦ý¥unÆ[¹î¹ï·Ó²ÕM OS=40, À³¸Ó¤µ¦~´N¬Ý±o¨ì¡A¦pªG°ª§ÜÅéÁÙ°±¦b70%¥H¤W¡A ©¡®É±N¦¹K-M¦±½uª½±µ¦V¬ü°êFDA¥Ó½Ð¬ð¯}©ÊÀøªk¡A´N·|«Ü§Ö³q¹L ©Ò¥H³Ì§Ö©ú¦~´N·|®³¨ì¬ü°êFDAÃÄÃÒ¡A ¤]©IÀ³¨ì¬°¦ó±i¸³¶ÀÁ`©ó2/19¸Ñª¼«áªºªk»¡·|¤W»¡ªk·|«Ü¼ÖÆ[ªºì¦] ³o¨â¤Ñ«Ü©úÅã¬Ý¨ì¥D¤O¦b¬~Äw½X, 488, 489°ª±¾100±i³æÀ~´²¤á ¤]¯uªºÀ~¤F¤£¤Ö´²¤á¡A¥D°Ê±N¤â¤WªºªÑ²¼©^°e¥X¨Ó ³Ì«á§À½L¦A±N³o¨Ç´²¤áªÑ²¼¦¬¤JÃh¤¤ ¥Øªº´N¬Onµ¥6/27ªk»¡·|¤½¥q«Å¥¬«¤j§Q¦h®ÉÁȤ@ªi ¤d¸U¤£¯àÅý¥D¤O§âªÑ²¼³£§l¨« ¥D¤O¤w¸g¦Y©w7000±i¨éªÅ³æ©¡®É¦^¸Éªº¹ÇªÅ¦æ±¡¡A«ç»ò©Ô³£¦³«îµL®£ ¤d¨½¸ô·|¤£·|¦b¤U¥b¦~¥X²{? ¨CÓ¤H¤ß¤¤³£À³¸Ó«Ü²M·¡¤F |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/14 ¤U¤È 01:38:49²Ä 1973 ½g¦^À³
|
Cliff¤j¡A ¤p§Ì¦]¤u§@¦]¯À¡A¤£¤è«K»P±z¸I±¡A¦ý±z¬O¤p§Ì¤ß¤¤¥Ã»·ªº±aÀY¤jô¡I ±z´£¥X¨Óªº¨âÓÂI¡A¤p§Ìªº¬Ýªk»P±z§¹¥þ¬Û¦P¡A ¤@ÓÂI¬O¦]¬°¶}¤F¤@Ó¤pª±¯º¡A¨S¦³¸ÑÄÀ²M·¡ ¤@ÓÂI¬O¦]¬°¥u¥Î¤å¦r¡u¤j³¡¤À¡v¡A¨S¦³¥Î¼Æ¦r¶i¤@¨BÄÄÄÀ¡A©Ò¥H¤]¤£²M·¡ ¤£¹L¦]¦¹¤Þ¥X±zªº¤å³¹¡AÅý²³¯E¤Í¨ü´f ©Ò¥H´N¡K ²Ä¤@ÓÂI¡A¡u¥ý½Í¤@¤U«ç»ò¬ÝK-M curve¡H¡K¡K¥unÆ[¹îªº®É¶¡°÷ªø¡A©Ò¦³±wªÌ³£·|¦º¤`¡A¦]¦¹¦s¬¡¾÷²v³Ì«á·|Áͪñ©ó0¡C¡v ¤p§Ì¶}¤F¤@Ó¤pª±¯º¡A³Í®¦´µªº¡uin the long run we are all dead¡v¡÷¡u¥unÆ[¹îªº®É¶¡°÷ªø¡A©Ò¦³±wªÌ³£·|¦º¤`¡v ·íµM¡A¨S¦³¤@ÓÁ{§É¹êÅ窺Æ[¹î´Á¬O¡uin the long run¡v ¦¹Á{§É¹êÅçOS°lÂÜ5¦~¡A©¡®É¤½¥¬ªº¦¨¼ô¹Ï«¬¤@©w·|¦³«p§À²{¶H¡A ¥H2015/10 data lock ªºP17¨Ó¬Ý¡A°ª¤ÏÀ³²Õ¦b30Ӥ뤧«á´N¥X²{´X¥G¬O¤ô¥½u¡A¥B§À¤Ú«p¨ì78.05%¡F¹ï·Ó²Õ¦b32Ӥ뤧«á´N¥X²{´X¥G¬O¤ô¥½u¡A¥B§À¤Ú«p¨ì60.51%¡C°ª¤ÏÀ³²Õ¬O³Ì·sªº§K¬ÌÀøªk¡A5¦~ªºOS°lÂܵ²§ô·|¦³¦h«p¨S¤Hª¾¹D¡A¦ý78%³o»ò«p¡A¤p§Ì¥Ø«e¯uªº¤£´±·Q¹³¡A°£«D°²³]©ú¦~¤S¬Ý¨ì¤@¦¸OS´Á¤¤¤ÀªR¹Ï¡A°ª¤ÏÀ³²Õ¤´µM¦³±µªñ78%«pªº¤ô¥½u¡A¨º¤p§Ì¨C±ß°µ¹Ú³£·|¯º¡A¨º±N¬O¥D°Ê§K¬ÌÀøªkªº¸ó¥@¥Nªº¦¨´N¡I ¤£¹LY¬O¹ï·Ó²Õ¨Ó¬Ý¡Anºû«ù60.5%ªº«p§À¦A¤@¦~¦A2¦~(Áô§tµÛ¡AY¯à¬¡¶W¹L32Ó¨S¦³¦º¤`ªº±wªÌ¡A´N¥i¥H¥þ³¡¦A¤@¦~¦A2¦~³£¤£·|¦º¤`)¡A¤p§Ì¬O¤£¥i¯à¬Û«H¡A¬ÝP17ªº¹Ï«¬¡A¦b32Ó¤ë¥H«á¦¨¬°60.51%ªº¤ô¥½u¡A¦ý¤]´N¦b¤£»·ªº30Ó¤ë®ÉÁÙ¦³65%¥ª¥kªº¾÷²v¡A´N¦b³o30~32Ó¤ë³o¨âÓ¤ëµuµuªº®É¶¡°Ï¬q¡A¦³2~3¦ì±wªÌµo¥Í¦º¤`¨Æ¥ó¡AÅý¦s¬¡¾÷²v±q65%°¨ì60%¡A³o¨âÓ±wªÌ¤@©w¬O¨Ó¦Û2013/6¥H«e¦¬®×ªº±wªÌ¡A¦pªGdata lockªº®É¶¡±q2015/10©¹«e´£¦2~3Ó¤ë¡A©Î³\³o2~3¦ì¦b30~32Ӥ몺OSªº±wªÌ¡A§ÚÌ´N¬Ý¤£¨ì¦º¤`ªºµo¥Í¡A¦¹¨Ò¤l¤U(data lockªº®É¶¡±q2015/10©¹«e´£¦2~3Ó¤ë)³Q§Ú̬ݨ쪺¹ï·Ó²Õªº¹Ï«¬±N¦¨¬°¦b28Ó¤ë«á«O«ù¦b65%ªº¤ô¥½u¡A¡y¦ý¬Ý¤£¨ì¤£ªí¥Ü¤£·|µo¥Í¡z¡A¥u¬O¦]¬°Æ[¹î®É¶¡¤£°÷ªø¡AÅý§Ú̼ȮɥH¬°¥¦¨S¦³µo¥Í¡C¦P²z¥i±À¡A2015/10 data lock¤§«áªº³o´XÓ¤ë¡AÀHµÛ®É¶¡ªº±À¶i¡A2013/6¥H«á±ß¦¬®×ªº±wªÌ¤]·|Ä~Äòµo¥Í¦º¤`¨Æ¥ó¡A¥Ø«e¹ï·Ó²Õ¦b28Ӥ릳38¦ìªºnumber at riskªº±wªÌ·íµM¤]·|Ä~Äòµo¥Í¦º¤`¨Æ¥ó¡A¤@µo¥Í¦º¤`¨Æ¥ó¡A´N·|¦bµn°Oªº¨ºÓOS¤ë¥÷Åý¾÷²vȤU°¡A¦p¦¹¤U¥h¡A³]¸ê®Æº¥º¥ÂରOS¸ê®Æ¡A¹Ï«¬¤]¤£Â_©¹¤U°¡Aª½¨ì¥i¥H¬¡¶W¹L5¦~ªº±wªÌ³£³QÆ[¹î¥X¨Ó¡A´N¦¨¬°5¦~OS°lÂÜ´Áªº«p§À¾÷²v¡A¤p§Ì²q¥u¥´¤FCyclophosphamide¤Î¨Ï¥Î²üº¸»XÀøªkªº¹ï·Ó²Õ¡A5¦~ªº«p§À¦³20~30%À³¸Ó´N¤£®t°Õ¡C ¥t¤@ÓÂI¡A¡G¡u²Ä¤GÃþªº³]¸ê®Æ¬OÁ{§É¹êÅçÆ[¹îªº®É¶¡¤£°÷ªø¡A2013/7~2014/8¥H«á¦¬®×ªº¤j¬ù148¤H¡A³o148¤H±q¶i¤JÁ{§É¨ì2015/10 data lock©Ò¸g¾úªºÁ{§É®É¶¡¤j·§¦b28~14Ӥ뤧¶¡¡A¦]¬°°ª§K¬Ì¤ÏÀ³¡BµL§K¬Ì¤ÏÀ³¡B¹ï·Ó²Õ³o¤T²ÕªºM OS³£¤j©ó32Ó¤ë(«á±¦A°µ»¡©ú)¡A¦]¦¹³o«á¦¬®×ªº148¤H©Ò¸g¾úªº®É¶¡¦b14~28Ó¤ë¡A³o148¤H¤j³¡¤ÀÆ[¹îªº®É¶¡¤£°÷¤[¡A©Ò¥H¤j³¡¥÷¤£·|¥X²{¦º¤`¨Æ¥ó¡A¡K¡K¡v ¡u¤j³¡¤À¡v³o¤TÓ¦r¤£°÷ºë½T¡A§Ú¥Î¼Æ¦r¨Óªí¹F¡CÁ|°ª¤ÏÀ³²Õ¬°¨Ò¡A28Ӥ몺number at risk=53¤H¡A§Ú¥ý°²³]³o¤@²Õ¨S¦³drop outªº¦¦Â÷¶}³]¸ê®Æ¡A³o¼Ë¤l¸ÑÄÀªº¼Æ¦r¤è«K§¹¥þ¹ï±o°_¨Ó¡C°²³]2013/6¥H«e°ª¤ÏÀ³²Õ¦¬70¤H¡A70-53=17¡A¦ý°ª¤ÏÀ³²ÕÁ`¦@¦³21Ó¦º¤`¨Æ¥ó¡A¬JµM¦³17Ó¦º¤`¬O¨Ó¦Û©ó2013/6¥H«eªº¦¦¬®×¡A¨º´Nªí¥Ü¦³21-17=4Ó¬O¨Ó¦Û©ó2013/6¥H«á±ß¦¬®×ªº±wªÌ¡A¦]¬°¦º¤`¨Æ¥ó¦@21Ó¡A17Ó¨Ó¦Û¦¦¬®×¡A4Ó¨Ó¦Û©ó©Ò¸g¾úªºÁ{§É®É¶¡¦b28~14Ӥ뤧¶¡ªº±ß¦¬®×¡A17¡G4¡A¦]¦¹¥Î¤F¡u¤j³¡¤À¡v³o¤TÓ¦r¨Ó´yz¡C ¨ä¹ê°ª¤ÏÀ³²Õªº28Ó¤ënumber at risk=53¤H¤¤¡A¦³¤@Ó¦b29Ó¤ë®Éµo¥Í¦º¤`¨Æ¥óÅý¾÷²v¤U°(¨£p17)¡A¦]¦¹¤Wzªºpºân×¥¿¬°¡A70-53=17¡A¦³17¦ì¦¦¬®×ªº¶]¨ì«e±°Ï¬q¦¨¬°OS¸ê®Æ¡A29Ó¤ë¤]µo¥Í¤@ÓOS¡A¦]¦¹±ß¦¬®×¦ÓOSªº¦³21-17-1=3¡C ¦A¥Î¤@Ӥ覡¨Ó¸ÑÄÀ¡A ¡u§Y¨Ï³o148¦ìªºmOS>32Ó¤ë¡A§Ú»{¬°¦b³Q°lÂܪº14~28Ӥ뤺¡A¤´¦³³°Äò¥X²{¦º¤`ªºÓ®×¡A¥u¬O¨ì¤F¬ù32Ó¤ëªþªñ¡A±N²Ö¿n¤Fªñ¤@¥bªºÓ®×¦º¤`¡C³o¼Ë¤l»¡·|¤£·|¤ñ¸û¦X¥G¹ê»Úªºª¬ªp¡H¡v±z»¡ªº§¹¥þ¥¿½T¡A¤@Ó¥»¨Ó¸Ó¦b18Ó¤ë¥X²{OSªº±wªÌ¡A¦pªG¥L¬O¦b2013/6¥H«e¦¬®×¡A¨º¥L¤@©w¥X²{¦bOS=18Ӥ몺®É¶¡°Ï¬q¡A¦]¬°¸g¾ú®É¶¡°÷ªø¡F¦ý¦pªG¥L«ê¥©¬O¦b2014/7¤~¦¬®×¡AÁöµM¥L±ß¤@ÂI¤]·|¥X²{OS=18ªº¦º¤`¨Æ¥ó¡A¦ý¨ì2015/10ªºdata lock¡A¥L¸g¾ú®É¶¡¥u¦³15Ó¤ë¡A©Ò¥H¼È®É¦¨¬°³]¸ê®Æ¡A¨ä¾l´N¨Ì¦¹Ãþ±À¡C©Ò¥H±ß¦¬®×ªº±wªÌ¦bp17¤´¥X²{¤ñ¸û¤Öªº¦º¤`¨Æ¥ó¡A¬O¦]¬°Æ[¹î®É¶¡¤£°÷¤[¡A¦]¦¹¤j³¡¤À¼È®É¥H³]¸ê®Æªº¼Æ¾Ú«¬ºA¤£ªí¹FOSªº¯u¹ê±¡ªp¡A¦Ó¥Ñ¦¦¬®×ªº200¤H¨Óªí¹F¡A¦ýY©â¼Ë¯uªº¨¬°÷ªí¹F¥ÀÅé¡A¦¦¬®×©Î±ß¦¬®×ªº±wªÌ³£¤@¼Ë±µªñ§¹¾ãªí¹F¥ÀÅ骺OS±¡ªp¡A¨º²{¦bÆ[¹î¨ìªºM OS²¤¤j©ó32Ó¤ë(¥H§C¤ÏÀ³²Õ¬°¨Ò)¥Dn¬O¥Ñ¦¦¬®×ªº±wªÌ©Òªí¹F¥X¨Óªº¡AÀHµÛÆ[¹î®É¶¡©Ôªø¡A¦b³Q°lÂܪº14~28Ӥ뤺ªº±ß¦¬®×±wªÌ¡A¤´¦³³°Äò¥X²{¦º¤`ªºÓ®×¡A¤]±Nªí¹F¥Xªñ¦ü©ó¦¦¬®×±wªÌªºOS±¡ªp¡A³Ì«áOS¼Æ¾Ú¦¨¼ô®É¡A§Ú̬ݨ쪺M OS¬O¥Ñ¦?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/14 ¤W¤È 10:51:23²Ä 1972 ½g¦^À³
|
·PÁ¯E§J¤j, Cliff¤j, ¦Ñ´¤jµ¥¤j¤j¹ïslideªº¶i¤@¨B¸ÑªR., ¤]·PÁ¦ѥv¤j µL¨pªº¤À¨É! ²q·Q¤j: + 1 ±z±N§Úªº·PÁ§¹¾ãªºªí¹F¥X¨Ó¤F !! ¦Ñ´¤j: ¨S°ÝÃD! ªÑªF·|¤W·|´£¥X. ®Ú¾Ú¸gÅç, ¤£¬O¨CÓ°ÝÃD¤½¥q³£·|¦³®É¶¡¨Ó±o¤ÎµªÂÐ. ©Ò¥H¤@¯ë, ·U¦h¤H°Ýªº°ÝÃD, ¤½¥qªº¦^µª·|¤ñ¸û§¹¾ã. §Æ±æ³oÓ°ÝÃD, ¤]¦³¨ä¥Lªº¯E¤ÍªÑªF¨ó§U¤@¦P´£¥X. ³o¼Ë¤½¥q·|µªÂÐ, ±o¨ì§¹¾ãµª®×ªº¾÷²v·|¤j´T´£°ª. §Ú·|¦bªÑªF·|«e±N´£°Ý¥ý¥He-mail°eµ¹¤½¥q, ¬O§_¦P¼Ë·Qª¾¹Dµª®×ªº¤j¤jÌ¥i¥H¥ý¥He-mail¤ÏÀ³, Åý¤½¥q¦³·Ç³Æªº®É¶¡, ©¡®É§Æ±æ¯à±o¨ì§¹¾ãªº¦^µª. |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/14 ¤W¤È 10:29:05²Ä 1971 ½g¦^À³
|
¯E§J¤j,·PÁÂ! ±z¯u¬O¦ò¤ß¨ÓµÛ,À°§ë¸ê¤j²³°Ý³o¨Ç°ÝÃD... *¤@©wn°Ý¤½¥q 6/5²Îp¸ê®Æ¬O§_¦³®Õ¥¿¹LCox model¥H²Å¦X«Dµ¥¤ñ¨Ò·ÀIªv¡²v¼Ò¦¡!* *¦³¥i¯à§C¦ô,¤]¦³¥i¯à°ª¦ô* ¤ñ¦p»¡,¦pªG¤T³±©Ê,age,ECOG....ªº, responder ¦³ÅãµÛ> placebo----²n! hormone therapy, responder ¦³ÅãµÛ< placebo----²n! ¦Ñ´¬Ýppt.,À³¸Ó¬O¨S¦³®Õ¥¿¹L,·Ó±`³W¨Ó»¡¦pªG¦³®Õ¥¿¹L,¦bp-16,p-17ªºKM¤U¤è¤@©w·|Åã¥Ü,¥H¤W µ²ªG¬Oadjust¤F¨º¤@¨ÇÅܶµ¤§Ãþªº¸Ü! ¦AªÌ,COX regression¨Ã¨S¦³¿ìªkµe¥Xp-18³oºØ¹Ï,³oºØ¹³´ËªL¹Ïforest plot,¥u¬O¨S¦³¹³¥Î¨Ópºâ²Î¦X¤ÀªR ªºµ{¦¡Review manager¸ÌªºÁÙ·|§e²{Weight,Heterogenity,I2.......µ¥«Ü§¹¾ãªº¸ê°T. ©Ò¥H¥Lªº³oӹϥu§e²{«Ü²³æªºªF¦è,¦n¹³¬Onµ¹¦Ñ¦Ê©m¬Ýªº. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2016/6/14 ¤W¤È 08:19:08²Ä 1970 ½g¦^À³
|
¤p©_¤j¤j ¯E§J¤j¤j Cliff ¤j®¦®v ¦Ñ´¤j±Ð±Â ¦Ñ¥v¤j¤j ...... ÁÂÁ±z̧â¤@´T´TÃøÀ´ªº¹Ïªí¤ÎÁôÂé󤺪ºÄ²[ @¤ß¦aåªRµ¹¤j¹Ù©ú¥Õ ¦³¤F±z̪¾ÃѪº«OÅ@ Åý¤j®a°í©w¦a¨«¹L·«B º¡º¡ªº·PÁ¤¤ ±aµÛ¿@¿@ªº©¯ºÖ·P ¯uÁÂÁ±z̵L¨pªº¥I¥X©M¤À¨É ¤p§Ì¤Åé§ë¦a ÁÂÁ¤j®a! |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/14 ¤W¤È 08:19:05²Ä 1969 ½g¦^À³
|
Statistical issues and challenges in immuno-oncology §@ªÌTai-Tsang Chen ¨Ó¾ú¤£¤p³á The author is director in oncology biostatistics and the lead biostatistician of Yervoy (Ipilimumab) at Bristol-Myers Squibb. He is also an Adjunct Assistant Professor of Biostatistics at Columbia University, New York, NY, USA. Cliff¤j´£¨Ñªº¤åÄm ¦p¤U³sµ² ½Ð¤j®a¦n¦n¾\Ū ¤£µM¦Ü¤Ö¦L¤U¥Lªºµo¨¥ ¦n¦n¾\Ū ¥H«á«Ü¦h¦a¤è ³£ÁÙn¥Î¨ì www.ncbi.nlm.nih.gov/pmc/articles/PMC4019889/pdf/2051-1426-1-18.pdf ·PÁÂCliff¤j¦Ñ®v ´£¨Ñ³o»ò¦nªº¤å³¹ ¬O§_ §Ú̦bªÑªF·|¤]n°Ý¤½¥q 6/5²Îp¸ê®Æ¬O§_¦³®Õ¥¿¹LCox model¥H²Å¦X«Dµ¥¤ñ¨Ò·ÀIªv¡²v¼Ò¦¡? ½Ð°ÝCliff¤j¦Ñ®v Y¤½¥q¨S¦³®Õ¥¿¹LCox model¥H²Å¦X«Dµ¥¤ñ¨Ò·ÀIªv¡²v¼Ò¦¡ ¨º»ò©Ò±oPFS©ÎOS¬O§C¦ôÁÙ¬O°ª¦ô? |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2016/6/14 ¤W¤È 06:49:07²Ä 1968 ½g¦^À³
|
·PÁ©_¤jªº¤j§@,Àò¯q¨}¦h~~ ¹ï·Ó²ÕªºM OS¦b36Ó¤ë¤W¤U¡A¦]¬°¦³67.8%ªº¦¬®×³£¬OER+¡BPR+ªº±wªÌ¡A¥Bµ´¤j¦h¼Æ³£¦³«ùÄò²üº¸»XÀøªk¡A ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ ¥t¥~cyclo¤]µo´§¤F³¡¤ÀÀø®Ä¡A©Ò¥H¹ï·Ó²Õ»PIbranceªº¯Â²üº¸»XÀøªkªº¹êÅç²Õ»P¹ï·Ó²ÕªºM OS=37.5Ó¤ë ¥H¤Î33.3Ó¤ë«Ü±µªñ¡C¦Ó§C¤ÏÀ³²Õ¦¬®×¤¤¤ñ¸ûÃøªvªº¤T³±©Ê¦û16¦ì¡BHER+¦û24¦ì¡A¦@¦û¤F(16+24)/112=35.7% ªº¤ñ¨Ò¡A²¤°ª©ó¹ï·Ó²Õªº(17+23)/124=32.2%ªº¤ñ¨Ò(¨£ P18)¡A¦¹¥i¯à¬OOSªºK-M curve¤W¦b«e¬qªº°Ï¶¡ ²¤¿éµ¹¹ï·Ó²Õªºì¦]¡C ¦Ñ´´£¥X´XÂI¬Ýªk~~ ®Ú¾ÚP-11-¹êÅç²Õ224&¹ï·Ó²Õ124ªº²üº¸»XÀøªk¨â²Õ¨Ã¨S¦³®t²§(p=0.82,ªþ±a¤@´£,P-11³ºµM¤Öºâ³oÓP-value, ³o¬O¦Ñ´ºâªº,°ê»Ú©ÊªººtÁ¿,¦³ÂI¤£¤jÄYÂÔ) ¥t¥~, Placebo vs. non-responder- ER+¡BPR+ (p=0.57), ¤T³±©Ê&HER+ (p=0.58),¨â²Õ¤]¨S¦³®t²§©Ê,©Ò¥H non-responderªºOS K-M curve¤W¦b«e¬qªº°Ï¶¡²¤¿éµ¹¹ï·Ó²Õªºì¦]-----¥i¯à©Ê¤£·|¤Ó¤j. ***responder&non-responder¬O¬G·N¬D¥X¨Óªº,¤£¬O©â¥X¨Óªº***³o´N¬OsubgroupÅý¤H¸á¯fªº¦a¤è! ¦Ñ´ÁÙ¬O¨º´XÓ°ÝÃD-½ÐQQ¤jÀ°¦£°Ý: 1. Placebo, non-responder, responderªº²üº¸»XÀøªk, age, ECOG....ªº¤H¼Æ 2. °w¹ïp-16ªºPFS°µ¤F¤@±ip-18, ¬°¤°»ò¤£°w¹ïp-17ªºinterim OS¤]°µ¤@±ip-18ªº¹Ï?¥Dn¤£¬O¬Ý¹Ï,ÁÙ¬O·Qª¾ ¹D¤H¼Æ!¹Ï¬O¥i¥HÄF¤Hªº,³oºØ¹Ï¦bRevman©Ô¤j©Ô¤p¤@ÂI´N¥i¥HÅý¥L¦b¥ªÃä©Î¥kÃä,³Ì¦n¬O¦³¨C¤@Ó²Ó¶µªº HR(95%CI)----¼Æ¦r¤~¤£®e©öÄF¤H. ~~¦Ñ´¬Û«H¤½¥q,¬Û«H822ªºOS,¥u·Q¬Ý¬Ý¦U²Õ¶¡ªº¤H¼Æ¦³¨S¦³®t²§,´N³o»ò¤@Ó¤p¤pªº°ÝÃD¦Ó¤w~~ P.S.·PÁÂcliff¤j,it¡¦s globo H, not global H----------§Æ±æ822¥H«á¥i¥Hglobal^^ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/13 ¤U¤È 11:19:28²Ä 1967 ½g¦^À³
|
·PÁ¤p©_¤jªº¥Î¤ß¡A±zªº±À²z¤@¦V¥O¤H¿E½à¡AWµ¥¤£¨ì±zªº¶K¤å¡A6/5¤S¥¢¤§¥æÁu¡AªGµM±zÄ~Äò¦b®Iº§V¤O¡A¯u¥O¤H·P°Ê¡I¥H¤U§Úªº¨£¸Ñ¤£¤@©w¹ï¡A¥u·Q»P±z¤Á½R¡C ¦b¡uªí®æ¤¤¦³4¦~¦s¬¡²v¡A³o¼Æ¦r¤d¸U¤£n®³¨Ó¥Î¡vªº¬q¸¨ªñ§À¡A´£¨ì¡u§C¤ÏÀ³²Õªº¤ô¥½u¡K¡K¡AX®É¶¡¶bÄ~Äò©¹«á¨«¡A¦ýY¶b¤WªºOS³ºµM¨S¦³ÅܤơA2015/10¤´¬¡µÛªº±wªÌ¡A¦A¸g¹L2¦~ªºÆ[¹î¡A³ºµM¥þ³¡³£¤´¬O¬¡µÛªº³]¸ê®Æ¡A¤ô¥½u¨Ì¡A³o¬O¤£¥i¯àªº¨Æ¡K¡K¡v¡A¨ä¹ê¤£n»¡§C¤ÏÀ³²Õªº¦s¬¡¾÷·|¡A¦b¤T²Õ·í¤¤¡A²z½×¤WÀ³¸Ó¬O¹ï·Ó²Õ³ÌÁV¿|§a¡H¦]¬°¥u¥´Cyclophosphamide¡Aµ¥©ó©ñ¤û¦Y¯ó¡AÅ¥¤Ñ¥Ñ©R¡A¨º¡A¦pªG³Ì«á¥þ³¡Ó®×°lÂÜOS¦Ü5¦~µ²§ô®É¡A¹ï·Ó²Õ¥X²{¤FNEDªºÓ®×¡A¨º¡A«ç¿ì¡H ©Ò¥H¤Þ¥X¤F¤@Ó¤j«e´£ªº°ÝÃD¡A¦b¤å³¹¶}ÀYªº²Ä¤T¬q¡A¤]´N¬O¡u¥ý½Í¤@¤U«ç»ò¬ÝK-M curve¡H¡K¡K¥unÆ[¹îªº®É¶¡°÷ªø¡A©Ò¦³±wªÌ³£·|¦º¤`¡A¦]¦¹¦s¬¡¾÷²v³Ì«á·|Áͪñ©ó0¡C¡v ³o¨ä¹ê¬O¤@Ó°²³]¡A¦Ó¥B¬OÄÝ©ó¦´Á¥Î©ó¤ÆÀøÃĪvÀùªº¤@Ó°ò¥»°²³]¡A³o¼Ëªº°²³]·N¨ýµÛ¹êÅç²Õvs¹ï·Ó²ÕªºÁ{§É®ÄªG(Clinical effect)¦bK-M¦s¬¡¦±½u¤W±q¶}©l¨ìµ²§ô³£¥H©T©w¤ñ¨Òªº¤è¦¡¼vÅTµÛ¨â²Õªº¦s¬¡¦±½u¡C³o¼Ë¤@¸ô°O¿ý¤U¨Ó³Ì«á¨â²Õªº¦s¬¡Ó®×¼Æ³£±N°¬°¹s(zero survival probability)¡C °Ñ¬ÝFig.1¡G¡uwww.ncbi.nlm.nih.gov/pmc/articles/PMC4019889/figure/F1/¡v ì¤å¥þ¤å¡G¡uStatistical issues and challenges in immuno-oncology¡v J Immunother Cancer. 2013; 1: 18.¡G(www.ncbi.nlm.nih.gov/pmc/articles/PMC4019889/) §Ú¥ý¤@¦¸Á¿§¹¦A´£§Úªº°ÝÃD¦n¤F¡C Fig.1A¤¤¬õ½uªº¹êÅç²Õ»P¶Â¦âªº¹ï·Ó²Õ¦U¦³¦Û¤vªº©T©wªº·ÀI²v¡]constant Hazard rate¡^¡A¤@¶}©l¨â²Õªº¦s¬¡¦±½u¤U°´T«×¦]¨â²Õ¶¡¦U¦Û·ÀI¤ñ¨Ò¤£¦P¦Ó¦³®t²§¡A¹êÅç²Õ¦]¬°¹êÅçÃĪ«ªºÀø®Ä¨Ï¦s¬¡²v/¦s¬¡¤H¼Æ°ª©ó¹ï·Ó²Õ¡A¨â²Õ¡u¦s¬¡¼Æ¡vÀH®É¶¡ºt¶i¦Ó®t¶ZÂX¤j¡A¨ì40³æ¦ì®É¶¡«á¶}©l³vº¥¾aªñ¡A60³æ¦ì®É¶¡«á¨â²Õº¥ÁÍ©ó¹s¡C µM¦Ó¤@¯ë¦Ó¨¥³o¼Ëªº°²³]¬O¤£¦X²zªº¡C §K¬ÌÀøªk¦s¦³¨âÓ°¾®t¦]¯À¡G 1.ªø´Á¶¡¦s¬¡(Long term survival)¡G·|³y¦¨¹ï¸ÕÅç©Ò»Ý®Éµ{©ö³Q§C¦ô(Underestimation of study duration) 2.©µ¿ð©ÊÁ{§É¤ÏÀ³(Delayed clinical effect)¡GpÈ·|¤W¤É¡A³à¥¢²Îp®Ä¤O(loss of statistical power)¡C 1.ªø´Á¶¡¦s¬¡(Long term survival) ¦]¬°·sªñÀù¯gªvÀøªº¶i¨B¨Ï±o¦³¤@³¡¤ÀªºÀù¯g±wªÌ¥i¯à¥X²{ªv¡(cured)¡A¦]¦¹¹ïªvÀø¤£¦A¨ã¦³·P¨ü©Ê¡F§Ynon-susceptible(Fig.1B & D)¡A¹³Mrs. SerenityªºNED¡C¹ï¬Y¨Ç¯e¯f¦Ó¨¥¡A¸g¹Lªø´Á°lÂܤU¨Ó¥iºû«ù¦s¬¡(alive)©ÎµL¯e¯fª¬ºA(disease-free)¡A³oºØ²{¶H¦bK-M¹Ï¤W¥i¥H¬Ý¨ì¡u«D¹sµ²§À¾÷²v¡v(non-zero probability)¡C ¦ý¬O¦]¬°¨S¦³¤H¯à¯u¥¿²¬Â¡(cure)¡A³oºØcure©Ò«ü¬O³o¦ì±wªÌ¤w¤£¦AÁͪñ©ó§ÚÌ©Òn°lÂܪº¨Æ¥ó(´c¤Æ©Î¦º¤`)©ÎªÌ»¡¦o¯àºû«ù½w¸Ñ(remission)¡A¦b¦X²zªº°lÂÜ´Á¤º(¥H822¦Ó¨¥¡AOSn°lÂÜ5¦~)¤£¦A»ÝnªvÀøªº·N«ä¡A¤]ºÙ¬°¥\¯à©Ê²¬Â¡(functional cure)¡C Fig.1B©Ò¥Ü´N¬O¨â²Õ¨ã¦³µ¥¤ñ¨Ò·ÀI¡A¦ý³Ì«á¦³¬Û·í¼Æ¶qªº¨ü¸ÕªÌ¡A¥iºû«ù¦s¬¡©ÎµL¯e¯fª¬ºA¡A¤]´N¬O¨ì¤F«á¬q¡A¹êÅç²Õªº¦s¬¡¼Æ°ª©ó¹ï·Ó²Õ¡A¹³¬O§Î¦¨«p«pªº§À¤Ú¤@¼Ëªº¡u«p§À¡v²{¶H¡]´¿¬Ý¹L¤å³¹¥H¡ulong ¡¥tail¡¦¡vªø§À¨Ó§Î®e¡^¡FÄÝ©ó¡uµ¥¤ñ¨Ò·ÀIªv¡²v¡v¼Ò¦¡(Proportional hazards cure rate model¡FPHCRM)¡C ·í¨ü¸Õ¸sÅ餤¥]§t¤F¹ï¸ÕÅçÃĪ«©Î¤èªk¡u¦³·P¨ü©Ê¡v(susceptible)»P¡uµL·P¨ü©Ê¡v(non-susceptible)ªº¨ü¸Õ±wªÌ®É¡A³B©ó´c¤Æ©Î¦º¤`·ÀIªº¤H¼Æ´NÅܤp¡C³o·N¨ýµÛn¹F¨ì§ÚÌ·QÆ[¹îªº´c¤Æ©Î¦º¤`ªº¹w©w¤H¼Æ¡A»Ýn§ó¤[ªº®É¶¡¡C¦]¬°¥u¦³¡u¦³·P¨ü©Ê¡vªº¨ü¸ÕªÌ¤~¥i¯à¦b¥¼¨Ó°lÂܪº¤é¤lùØ°µ¥X°^Äm¡A¦Ó¡uµL·P¨ü©Ê¡vªÌ³£¦¨¤F³]¸ê®Æ(censored)¡C 2.©µ¿ð©ÊÁ{§É¤ÏÀ³(Delayed clinical effect) ·Ó²z»¡¦³®Äªº¤ÆÀøÃĪ«´N¬O¦³®Ä¡A±q¤@¥ÎÃĶ}©l¡A¹êÅç²Õªº´c¤Æ©Î¦º¤`¤H¼Æ´N¶}©l¦³©Ò®t§O¡C ¦ý¦b¤j¦h¼Æªº§K¬ÌÀøªk¸ÕÅ礤©ÒÆ[¹î¨ìªº¡AK-M¹Ï¤¤¨â²Õ¦s¬¡¦±½u«o¬O©µ«á¤À¶}¡C(Fig.1C & D)¡C ¥i¯à¦bÀH¾÷¤À°t¼ÆÓ¤ë«á¤~¥X²{¨â²Õ¦±½u¤À¶}¡A³oºØ©µ¿ðªº²{¶H¹H¤Ï¤F¤å³¹³Ì¶}ÀYªºÁ{§É¸ÕÅç¡uµ¥¤ñ¨Ò·ÀI¡vªº°ò¥»°²³]¡C³Ì²×µ²ªG´N¦³¥i¯à³y¦¨²Îp®Ä¤O³à¥¢(loss of statistical power)¦ÓÃø¥H®i²{¹êÅç²Õ»P¹ï·Ó²Õ¤§¶¡ªº®t²§¡C¦bªÈµ²³Âªáªº¨º¤@¬q¡A¨â²ÕªºÀø®ÄµL¤À°a¸þ¡A¤]´N¬O¨â²Õªº·ÀI¤ñÈHR¡]Hazard Ratio¡^±µªñ1¡]¦b1ªº¤W¤Uªþªñ¡^¡A·N«ä¬O³oÓ«e¬qªº®É¶¡ùØ¡A¹êÅç²Õ¨Ã¥¼¦]¬°¥Î¤F¯uÃĦӤñ¹ï·Ó²Õ°§C¤F´c¤Æ©Î¦º¤`ªº·ÀI¡C¦b¤À¶}ÂI¤§«á¡A¨â²Õªº·ÀI¤ñÈHR¡]Hazard Ratio¡^³vº¥¤p©ó1¡A¤]´N¬O»¡¦b«á¬q®É¶¡ùØ¡A¹êÅç²Õ©Ò¥Îªº¯uÃĵo´§¤FÀø®Ä¡A©Ò¥H¤ñ¹ï·Ó²Õ°§C¤F´c¤Æ©Î¦º¤`ªº·ÀI¡CFig.1C©Ò¥Ü´N¬O¡u«Dµ¥¤ñ¨Ò·ÀI¡v¼Ò¦¡(Nonproportional hazards model¡FNPHM)¡C©Ò¥H¦b³oºØ¼Ò¦¡¤U¨â²Õpºâ¥X¨ÓªºHR¬O¤@Ó¥Nªíªº¥§¡È¡C Fig.1A¥i¥H¬OFig.1Cªº¤@Ó¯S¨Ò¡AYFig.1C¡]NPHM¡^ªº¨â²Õ¦U¦Ûªº·ÀI²v¦¨©T©wÈ¡A¥B«e¬q®É¶¡»P«á¬q®É¶¡ªºHR¤]¬Û¦P®É¡A´N·|Åܦ¨Fig.1A¡]PHM¡^¡C ¦pªGݨã¤Fªø´Á¶¡¦s¬¡»P©µ¿ð©ÊÁ{§É¤ÏÀ³ªº¸Ü¡A´N¦p¦P |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2016/6/13 ¤U¤È 11:02:20²Ä 1966 ½g¦^À³
|
¤p©_¤j ¥ý¸ò±zP·q ±zªºªø½g¤j§@ ¥Î¤ß²`»· ¨Ã¥B«Ü»{¦P±zªº³Ì«áµ²½× ¥u¬O¥H¤U½Ð±Ð»P«ü¥¿ ªí®æ¤¤¦³4¦~¦s¬¡²v¡A³o¼Æ¦r¤d¸U¤£n®³¨Ó¥Î¡A32Ó¤ë¥H«áªºK-M curve§e²{¤ô¥½u¡Anumber at riskÀHµÛ¨C4Ӥ몺°Ï¬q¡A¤H¼Æ¤j¤j°§C¡AÆ[¹î®É¶¡¦b48Ó¤ë¤]´N¬O4¦~ªºnumber at risk¤À§O¥u¦³6¤H¡B2¤H¡B4¤H¡A³o»ò¤Öªº¤H¼Æ¦p¦ó¯à´£¨Ñ¦s¬¡²vªº°Ñ¦Ò©O¡H¥B¥H§C¤ÏÀ³²Õªº¤ô¥½u»P48Ӥ몺³sµ²=52.99%¦s¬¡¾÷²v¨Ó¬Ý¡A¬OÁô§tµÛ¦A¸g¹L2¦~ªºÆ[¹î´Á¡AX®É¶¡¶bÄ~Äò©¹«á¨«¡A¦ýY¶b¤WªºOS³ºµM¨S¦³ÅܤơA2015/10¤´¬¡µÛªº±wªÌ¡A¦A¸g¹L2¦~ªºÆ[¹î¡A³ºµM¥þ³¡³£¤´¬O¬¡µÛªº³]¸ê®Æ¡A¤ô¥½u¨Ì¡A³o¬O¤£¥i¯àªº¨Æ¡A©Ò¥H4¦~¦s¬¡²vªº¾÷²v¤£n®³¨Ó¥Î¡C ¤W¬q±zªº»¡ªk ©TµM¥i¥H°Ñ¦Ò ²¦³º¯u¹êªº¦s¬¡¼Æ¾Ú¤£µ¥©ó²q´úªº¾÷²v ¦ý¬O ¤½¥q½Ðªº¥Íª«²Îp±M®a¤]¤£¬OÄF¦YÄF³Üªº ©Ò¥H°ÝÃD¨Ó¤F °ÝÃD:4¦~¦s¬¡²vªº¾÷²v¬O«ç»òºâ¨Óªº?¥Íª«²Îp±M®a¥Î¦ó¤è¦¡¨Ó¦ôp? Á٫ܦh¤H°Ñ¥[¹êÅç¨S¨ì¥|¦~ KM¦±½uÁÙ¬O«ù¥³]¤¤ ¤½¥qµ¹³o¥|¦~¦s¬¡²vªº¾÷²vªº¥Î·N? ¦]¬°²Îpªí®æ¤Wªº¼Æ¦r¤£·|ÀH«K®³¥X¨Ó¥Îªº¡A¥|¦~¦s¬¡²vªº¾÷²vªº¥i«H«×¦p¦ó?¦p¦ó¥Î¨Ó¸ÑÄÀMOS©O?(½Ð«ä¦Ò«á ¦A©¹¤U¬Ý) °Ñ¦Ò:4¦~¦s¬¡²vªº¾÷²v¬O²Îp±M®a¨Ì¾ÚCox Model¦ôºâ¥X¨Óªº¡ACox Model°ò¥»¤W¬O¤@ÓµL¥À¼Æªº°jÂk¼Ò¦¡¡A¤£¦P©ó¹L¥h§Ú̦b²Îp³Ì±`¾Ç¨ìªº½u©Ê°jÂk¡A¦ý¬Oì²zÃþ¦ü¡C¥Ñ©óCox Model¬O®É¶¡¹ïÀ³¦s¬¡²vªº¶¥±è¨ç¼ÆÃö«Y¡A¦¹KM¦±½uªºÁͶլO¨ã¦³¹w´ú©Ê¡A©Ò¥H²Îp±M®a¦bX¶b§ì¥|¦~ªº®É¶¡ÂI¡A¶i¦Ó´£¨Ñ¤F4¦~¦s¬¡²vªº¾÷²v¹w´úÈ¡A¨ä¤¤ªí®æ¤º(95%CI)´N¬O95%«H¿à°Ï¶¡¡A¦Ó¥Ç¿ùªº¾÷²vp¬O0.05¡A¥HµL¤ÏÀ³²Õ¬°¨Ò¡A4¦~¦s¬¡²vªº¾÷²v52.99%¡A¦ý¬O«H¿à°Ï¶¡¬O32.9-69.6%¡A´«¥y¸Ü»¡¡A4¦~¦s¬¡²vªº¾÷²v¤ñ¸û¥i¯àªº½d³ò´N¬O¡A§@¤@¦Ê¦¸¹êÅç¬ù¦³95¦¸ªº4¦~¦s¬¡²v³£¬O¸¨¦b32.9-69.6%¤§¶¡¡CY¥H¦¹¼Æ¾Ú¡A»¡µL¤ÏÀ³²ÕMOS±µªñ4¦~/48¤ë¡A¬O¬Û·í¦X²zªº¡C¦ý¬O°ÝÃD¨Ó¤F¡A¦³¤ÏÀ³²ÕMOS©O?¥Ø«e¸Ó²Õ4¦~¦s¬¡²v78.05%¡A95%«H¿à°Ï¶¡ÁÙ¨S¸I¨ì50%¡A©Ò¥H¥i¥H«D±`¦³«H¤ßªº»¡ «D±`°ªªº¾÷²v¬O¤ÏÀ³²ÕMOS»·¤j©ó48 ¦Ü©ó¹w´ú¦~¤ë ¦³ªÅ½Ð¤j®a¦Û¦æ±Àºâ§a ¤½¥q¨ä¹ê¤]¬O¥i¥H½Ð²Îp±M®a¥Î°jÂk¼Ò¦¡¹w´ú¦s¬¡²v50%®É¡A¤j¬ù¬O´X¦~´X¤ë¡A¦ý¬O¨S¦³¡A³o¤]¬O¤½¥q¤ñ¸û«O¦uÂÔ·Vªº¦a¤è§a PS1.±ø¤jªº°jÂkª½½uµe¹Ïªk »á±µªñ¤Wz§t·N ¥u¬O¹w´ú¤W ¦]¬°Ó¤Hµe½u¤è¦¡¤£¦P ¹w¦ôÈÃø§K¤£¦P Áö¤èªk²³æ ¦ýµLªk»¡©ú¥i«H¿à½d³ò¤Î¿ù»~¾÷²v PS2.¤Ñ©R¤j ½Ð±Ð±z MOS/PFSªº¤èªk ¬O±qþ¸Ì¬Ý¨ì?¦³¬Æ»ò®Ú¾Ú¶Ü? |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/13 ¤U¤È 10:56:57²Ä 1965 ½g¦^À³
|
·PÁ¤p©_¤j«e½úªº¨¯W»P·ÓÅU¤j®a¡A¦bÃöÁäÃú·Ù·Ùªº®É¨è¡A¦³½Ñ¦h«e½ú̪º«ü¤Þ¡A¯uªº¬O¯E¤Í̪ººÖ®ð¡C ¨Æ¹ê¤WÁ{§ÉÃÒ©ú{¬Ì]ªº¦³®Ä©Ê}¤w¸g¬O©_ÂÝ...¤]¬O¯E¹©¥¼¨Óªº«e³~¬O¥i¥H¬è«ÝªºÃÒ¾Ú¡C......³oÀ³¸Ó¬Oªø´ÁªÑªF³Ì¦w¤ßªº±¡¹Ò¡C ¨Ì¾Ú³o¦¸Á{§É¤Wªº¸gÅç¡A§ï¶i¥¼¨Ó¨ä¥L¾AÀ³¯gªºÁ{§É³]p¡A±Û«a¤j«e½ú©Ò¨¥¥¼¨Ó¤£¥²¦Aªá¤ß«ä¿ïªÑ¯uªº¬O«D±`¡A«D±`´Îªº«Øij¡C ·PÁ±z¤p©_¤j«e½ú¡C |
|
|
·|û¡G561910141205 µoªí®É¶¡:2016/6/13 ¤U¤È 10:51:38²Ä 1964 ½g¦^À³
|
¸U¤À·PÁ¤p©_¤jªº¸Ô²Ó¸Ñ説¡A¤p§Ì¦¬Ã¬·¥¤j¡C¤p©_¤jªº¼ö¤ß»Pµ½¤ß¡A¥O¤H·P¨Ø¡C¤p§Ì¤T«ôÁ¡C |
|
|
·|û¡G§d½n¶¯10142119 µoªí®É¶¡:2016/6/13 ¤U¤È 10:40:48²Ä 1963 ½g¦^À³
|
·PÁ¤p©_¤j¡B¥xÁÞ¤j¡B¤Ñ©R¤jªº±M·~¡BµL¨p¤À¨É¡A ÁöµM§Ú²Îp¾Ç¤W¹L¨â¾Ç´Á¡]²Ä¤@¦¸¥þ¯Z³Q·í16Ó¡Aè¦^°êªº±Ð±Â¥Î«¢¦òªº½Ò¥»¡A¯u¬Oxxxxx¡^¡A¤]³£¬O20¦~«eªº¨Æ¤F¡K¤u§@¥Î¤£¨ì¡A¦§Ñ±o®t¤£¦h¤F¡C©ñ²´¥xªÑ¡AÁÙ¦³¨º¤@ÀɪѲ¼ªºªÑªF¯à¦³³oºØ±MÄݪº¸Ñ»¡¡A¯u¬O¯E¤Í¤§ºÖ¡C ¦p¦P¶ÀÁ`¡B±i¸³»¡ªº¡A³o¦¸822ªºÁ{§É¹êÅçÄÂäFÄ_ÂáA¦¬Ã¬º¡º¡¡A¬Û«H¦b³oÓ°ò¦¤W¡A¥[¤W°ê»ÚÂå¾Ç±M®aªº¨ó§U¡A¯E¹©¹ï§ÜÀù¯g±N¦³§ó§Ö¡B§ó©ú«Gªº¥¼¨Ó¡C ¯E¹©¥[ªo¡I¡I¤jÁÞÄ¥¶¤¦¤é¦¨x¡C |
|
|
·|û¡G¶Â³Ç§J10142064 µoªí®É¶¡:2016/6/13 ¤U¤È 09:08:59²Ä 1962 ½g¦^À³
|
¤¸¦Ñ«e½ú´N¬O¯à®i²{¯Eª©ºë¯« , ¸U¤À·PÁ¤p©_¤j»P±Û«a¤j !! |
|
|
·|û¡G»¨10136549 µoªí®É¶¡:2016/6/13 ¤U¤È 08:50:38²Ä 1961 ½g¦^À³
|
·PÁ¤p©_¤j~ ±z¬O¯Eª©ªº¤¤¬y¯¡¬W ¥»½g¤å³¹¯u¬O»ùȳs«° |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2016/6/13 ¤U¤È 07:58:02²Ä 1960 ½g¦^À³
|
·P®¦¤p©_¤j¨¯W§V¤Oªº¥I¥X¡A¸ÑŪK-M curveªºÁô§t¼Æ¾Ú¯u¥¿·N¸q¡A¬Ý§¹©ç®×¥sµ´¡A¤]¸¨¹ê¤ß¤¤ªºÁr´ú¡A¹ï·Ó²ÕªºMOS¹ê»Ú¤W¤w¸g©ÎÁͪñ¦¨¼ô¡A°ª§ÜÅé±Ú¸sªº¦s¬¡²v°ª¼Ð¥H¤W¡AMOSªº¥X²{ÁÙ¦³ªºµ¥¡C822ªºMOA½T¥ß¡AªÅ¤èºò¨nPFS¥¼¨ãÅãµÛ·N¸q¤£¦A¬O°ÝÃD¡A©Î¬O¨è·N¸Ø¤j822ÃĮĦM®`§C§ÜÅé±Ú¸s¡A¬Ý¨Ó³£ÄÝ°¾»áÆ[ÂI¡C ¥¼¨Ó¡A®Ú¾Ú³Ì·s¥XÄlªº¦~³ø¡A822¤µ¦~±N®i¶}¥|¶µ¨ä¥L¾AÀ³¯gªºÁ{§É¡A¥]¬AªÍÀù¡AGÀù¡A¤j¸zª½¸zÀù¡A¨xÀù(º«×¥X²{¦b822)µ¥¤G´ÁÁ{§É¸ÕÅç¡A·¥¥i¯à¬O»P¸ó°ê¤½¥q¦X§@ªº¼Ò¦¡¡A¨Ã±N«e¶i¤¤°ê¤j³°®i¶}¤T´ÁÁ{§Ép¹º¡C 833·~¤w¦b¥xÆW©M¬ü°ê®i¶}¤@´ÁÁ{§É¡A¥]¬AªÍÀù¡AGÀù¡A¤j¸zª½¸zÀù¡A¨ÅÀùµ¥¤wÂಾªº¯f±w¡AÁÙ¦³888³Q°Ê§K¬ÌÀøªk¡A³yºÖµLªk¹ï¬Ì]²£¥Í§ÜÅ骺¯f±w¡C§Ú·Q¡A©Î³\¥i¥H¤£¥Î¦Aªá¤ß«ä¿ïªÑ¤F¡A«ùÁZÃöª`¶i«×§Y¥i¡C |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2016/6/13 ¤U¤È 07:35:08²Ä 1959 ½g¦^À³
|
¤p©_¤j¤j§A¦n, ÁÂÁ§A |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/13 ¤U¤È 07:30:00²Ä 1958 ½g¦^À³
|
¤Ñ©R¤j¡A ¯uªº«Ü¤£¦n·N«ä ¤p§Ì¥i¥Hµ¹±z¤@Ó«Øij¶Ü¡H §Ú¨S¦³°µ¤°»ò±À½× ¥u¬O®Ú¾ÚK-M curveªº²z½×¤Înumber at riskªº¼Æ¦r ¼g¥Xp17¥i¥Hµ¹§Ú̪º°T®§ MOS/MPFS ¿¼Æ¤@ÂI¹D²z³£¨S¦³ °ª§ÜÅé¤ÏÀ³ªº²Ä¤@Ó¦¬®×ªº±wªÌ¨ì2015/10¤]¥u¦³Æ[¹î¤F57©Î58Ó¤ë(¹Ï¤£²M·¡) 6/5ªº¹Ï¦p¦ó¯à±À¨ì°ª§ÜÅé²ÕªºM OS¹F¨ìªñ60Ó¤ë©O¡H ÁÙ¬O§âM OS¥æµ¹±wªÌ¥»¨ªº¦s¬¡±¡ªp¨Ó¨M©w§a ±z¤ßùØ¥i¥H³o¼Ë²q¡A ¤p§Ì¤]«Ü§Æ±æ¬O³o¼Ë¡A¬Æ¦Ü§Æ±æº¡5¦~ªºÆ[¹î´Á¤´¦³60%¥H¤Wªº°ª§ÜÅé²Õ¬¡µÛ ¦ý§Æ±æÂk§Æ±æ ¨Æ¹êÁÙ¬O¥æ¥Ñ¨Æ¹ê¨Ó¨M©w§a §Ú¦b±À°ª§ÜÅé²Õ¨ì2017/6Y¦³°µOS´Á¤¤¤ÀªR¡A´N¥i¥H½T©wªÖ©w¦³48Ӥ몺M OS¡A¤w¸g¦b°µ¤jÁx¹w´ú¤F ¦ý¨º¤´¬O¦³¼Æ¦r°µ°ò¦ªº¹w´ú ¥ÎMOS/MPFS¿¼Æ¨Ó°µ±À½×¯uªº¤@ÂI¹D²z³£¨S¦³ ¤£§Æ±æ¦³¤H¬Ý¤F¥H¬°²{¦bªº¸ê®Æ´N¥i¥H±À¥X°ª§ÜÅé²ÕªºM OS¦³ªñ60Ó¤ë ¦Ó¹ïªÑ»ù¤Ó¿³¾Ä µ¥¤U¦¸¦³OSªº´Á¤¤¤ÀªR¼Æ¾Ú¡A §Ú̽T©wnumber at risk¦b48Ӥ몺¦a¤è¤´¦³¤j©ó60%¥H¤Wªº±wªÌ¦s¬¡ §Ú̦A¨Ó±À½×M OS±N©¹60Ó¤ë±À¶i¦n¶Ü¡H ¤p§Ì±o¸o¤F¡I |
|
|
·|û¡Gªü¤å10138375 µoªí®É¶¡:2016/6/13 ¤U¤È 07:23:55²Ä 1957 ½g¦^À³
|
ÁÂÁ¤p©_¤j «Ü¸ÔºÉ¦Ó¥B«D±`«ÈÆ[ªº¤ÀªR,¤]¸Ñ¤F§Ú¹ï"4¦~¦s¬¡²vxx%"ªººÃ´b |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/13 ¤U¤È 06:53:04²Ä 1956 ½g¦^À³
|
¤p©_¤j ÁÂÁ¤p©_¤j, ºë±måªR, ¤K±Æ[¹î¡A¨£·Lª¾µÛ¡A¬}¹î¥ý¾÷, ÁÙ¨S«ôŪ§¹,´N¤w©ç®×¥sµ´,¤µ±ßn±M§ð¤p©_¤j³o½g: 822¦b¦¹348¤HªºMBCÁ{§É¹êÅç¨ì©³ÃĮĦp¦ó¡H ¥ý»¡Án¹DÁ¤F! |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2016/6/13 ¤U¤È 06:49:31²Ä 1955 ½g¦^À³
|
·PÁ¤p©_¤jªº¤j§@~~~ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/13 ¤U¤È 06:38:51²Ä 1954 ½g¦^À³
|
¤p©_¤j: ¹ê¦b¤Ó·P®¦¤F !! ÁöÁÙ¥¼§¹¥þ«ôŪ§¹, ¦ý¥ú¬Ý³o¥÷¶q´Nª¾±zªº»{¯u»P©Ò§ë¤Jªº¤ß¦å. ¤Ó·PÁ¤F, ¦hÁÂ±Ð¾É !!! §Ú·|§V¤O¥h¬ãŪ²z¸Ñ, ¦A»¡¤@¦¸, ·PÁÂ°Ú ! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2016/6/13 ¤U¤È 05:54:50²Ä 1953 ½g¦^À³
|
822¦b¦¹348¤HªºMBCÁ{§É¹êÅç¨ì©³ÃĮĦp¦ó¡H ¦p¦ó¸ÑŪ6/5ªk»¡·|ªºK-M curve©Ò§e²{ªº·N¸q¡H ¥H¤U¤p§Ì¹Á¸Õ³æ¯Â¥Ñ¹Ï«¬»P¼Æ¦r¨Ó¸ÑŪ822¦b¦¹Á{§É¹êÅ窺ÃĮġA¦Ü©ó§e²{¨ì¥Ø«e©Ò¬Ý¨ìªºÃĮĨä¾Ç²z¤Wªº¸ÑÄÀ¡A´N¥Ñ¤½¥q¥¼¨Óªº¶i¤@¨B¤ÀªR»P¸ÑÄÀ¡A¤j®a¦AºCºC¨Ó¬ã¨s¡C (QQ¤j¡B¥xÁÞ¤j¡A±zÌ·Qª¾¹Dªº¤]¦b¥H¤Uªº¸Ñ»¡¤¤) ¥ý½Í¤@¤U«ç»ò¬ÝK-M curve¡Hy¶b¬O±wªÌ¦s¬¡ÀHµÛ®É¶¡©Ôªøªº¾÷²v¡A¦b®É¶¡=0ªº®ÉÔ¡A©Ò¦³¤H³£¬¡µÛ¡A©Ò¥H¦s¬¡ªº¾÷²v¬O100%¡F¥unÆ[¹îªº®É¶¡°÷ªø¡A©Ò¦³±wªÌ³£·|¦º¤`¡A¦]¦¹¦s¬¡¾÷²v³Ì«á·|Áͪñ©ó0¡CX¶b¬O®É¶¡¶b¡A®É¶¡©³¤Uªº¤H¼Æ«h¬Onumber at risk¡A°O¿ýµÛ¤@ÓÓ±wªÌ¦b¦¹Á{§É¹êÅ窺°^Äm¡C K-M curve³ÌÃøÀ´ªº³¡¤À´N¬Ocensored data(³]¸ê®Æ)¡A¥H¤Înumber at risk¡A³o¬O¦b¨ä¥¦¾Ç¬ì¤£®e©ö¨£¨ìªºÆ[©À¡A¤£§â³o¨âÓÆ[©À§ËÀ´¡A´N«ÜÃø¬ÝÀ´K-M curve¡CÁ|p17ªº¹Ï«¬¨Ó»¡©ú¡A³]¸ê®Æ¤À¤TºØÃþ¡A¤@ºØ¬Odrou out¡A¦b¶i¤JÁ{§É¤@¬q®É¶¡«á¡A±wªÌ©Úµ´¦A±µ¨ü¥ô¦ó°lÂÜ¡A¦¨¬°¥Ã»·ªº³]¸ê®Æ¡A³oÃþ¥Ã»·Â÷¶}ªº³]¸ê®Æ¡A³q±`¦b¶i¤JÁ{§É¨S¦³«Üªøªº®É¶¡µo¥Í¡A¥i¯à¬O±wªÌ¬ð¯}«á®¬¤F¡A¥i¯à¬O±wªÌ¦Û¤v§PÂ_¨S¦³¥´¨ì¹êÅç²ÕªºÃÄ¡A¤Ï¥¿´N¬OÂ÷¶}Á{§É¤F¡A³oÃþ³]¸ê®Æµo¥Í®É´N°é¤@ÓÂI¦bK-M curve¤W¡A¦bµo¥Í·í®É¹ïK-M curve¤£·|³y¦¨¾÷²v¤U°(¾÷²v°¨ì0.5´N¬OM OS¥X²{¡A´N¬O¤¤¦ì¼Æ¥X²{¡A¤]´N¬O¥Nªí³oÓ¹êÅç²Õ©Î¹ï·Ó²ÕªºªºÃĮġA©Ò¥H¾÷²v«ç»ò¤U°¡A°±o§Ö©ÎºC¬O«Ü«nªº)¡A¦ý¬O³oÓ³]¸ê®Æ§âªí¹FÃĮĪºÅv§Q¥æµ¹«á±µo¥Í¦º¤`¨Æ¥óªº±wªÌ¡A«á±¨C¤@Ó¦º¤`¨Æ¥óªº±wªÌªº¾÷²v¤U°³t«×·|¥[§Ö¡CÁ|¤@Ó²³æ¨Ò¤l¡A¦³¤@ÓN=100ªº¹êÅç²Õ¡A¹Ï«¬±q®É¶¡=0¶}©l³£¨S¦³³]¸ê®Æ¡A±µ¤U¨Óµo¥Í10Ó¦º¤`¨Æ¥ó¡A¨º»ò¨CÓ¦º¤`¨Æ¥ó·|Åý¾÷²v¤U°1/100=0.01¡A10Ó¦º¤`¨Æ¥óµo¥Í¤§«á¡AK-M curve°¨ì¤F0.9¡F¥t¤@ÓN=100ªº²Õ§O¡A¦b10Ó¦º¤`¨Æ¥óµo¥Í«e¦³10Ódrou outªº³]¸ê®Æ¡A¦]¦¹¨C¤@Ó¦º¤`¨Æ¥óªº¾÷²v¤U°=1/90=0.011¡Aµo¥Í¤F10Ó¦º¤`¨Æ¥ó¤§«á¡A¾÷²v°¨ì0.89¡A³o10Ódrou outªº³]¸ê®Æ±N·|¤@ª½¼vÅT«á±ªº¨C¤@Ó¦º¤`¨Æ¥óªº¤U°¾÷²vÈ¡C ²Ä¤GÃþªº³]¸ê®Æ¬OÁ{§É¹êÅçÆ[¹îªº®É¶¡¤£°÷ªø¡A¥H822¦¹Á{§É¬°¨Ò¡A2013/6¥H«e¦¬®×ªº¤j¬ù200¤H¡A2013/7~2014/8¥H«á¦¬®×ªº¤j¬ù148¤H¡A³o148¤H±q¶i¤JÁ{§É¨ì2015/10 data lock©Ò¸g¾úªºÁ{§É®É¶¡¤j·§¦b28~14Ӥ뤧¶¡¡A¦]¬°°ª§K¬Ì¤ÏÀ³¡BµL§K¬Ì¤ÏÀ³¡B¹ï·Ó²Õ³o¤T²ÕªºM OS³£¤j©ó32Ó¤ë(«á±¦A°µ»¡©ú)¡A¦]¦¹³o«á¦¬®×ªº148¤H©Ò¸g¾úªº®É¶¡¦b14~28Ó¤ë¡A³o148¤H¤j³¡¤ÀÆ[¹îªº®É¶¡¤£°÷¤[¡A©Ò¥H¤j³¡¥÷¤£·|¥X²{¦º¤`¨Æ¥ó¡A¦]¦¹³o¨ÇÆ[¹î®É¶¡¤£°÷¤[¥B¨S¦³¦º¤`ªº¤j¶q³]¸ê®Æ¡A¤À§O°é¤@ÓÓÂIÂI¦bp17ªº14~24Ó¤ë¤W±ªºK-M curve¤W¡A³o¨Ç14~28Ӥ몺³]¸ê®Æ¤£·|¥X²{¦b14Ӥ뤧«e¡A¤]¤£·|¥X²{¦b28Ӥ뤧«á¡A¦]¬°³o148¤HªºÆ[¹î®É¶¡³Ìªø¬O28Ó¤ë¡A³Ìµu¬O14Ó¤ë¡C ²Ä¤TÃþ³]¸ê®Æ¬OÆ[¹î®É¶¡°÷ªø¥B¤]¥¼µo¥Í¦º¤`¨Æ¥óªº±wªÌ¡A³oÃþ±wªÌ¬OÅý K-M curveªº¾÷²vȦó®É¤U°¨ì0.5Ó³ÌÃöÁä¦]¯À¡A¦pªG¹êÅç²Õªº°ª±¬Ì¤ÏÀ³²Õªº¦¦¬®×ªº±wªÌ(¦b2013/6~2011/1¦¬®×ªº¤j¬ù200¤H¡A¥L̸g¾úªº®É¶¡¦b58~28Ó¤ë)¤@ª½¦³50%¥H¤Wªº±wªÌ¨S¦³µo¥Í¦º¤`¨Æ¥ó¡A¥BY¹êÅç²Õ±ß¦¬®×ªº±wªÌªº¦s¬¡ª¬ªp»P¦¦¬®×ªº±wªÌ¦s¬¡ª¬ªpÃþ¦ü¡A¨º»òK-M curveªº¾÷²v¤U°´N¤@ª½·|¦Q¦b0.5¥H¤W¡AM OSÁÙ¥¼¥X²{¡A¤]´N¬OÃĮĪº¥NªíÈ-----¤¤¦ì¼Æ¦s¬¡®É¶¡¤´¦b«ùÄò±À¶i¤¤¡C ·íµM¡A¦¦¬®×ªº±wªÌ(¦¹¶K¤å³£¥H2013/6¤ë©³¬°¬É¡A¤]´N¬O¨ì¥H¨ì2015/10 data lock=28Ӥ묰¬É)¡AYµo¥Í¤F¦º¤`¨Æ¥ó¡A´N·|¨Ì¥L̹ê»Úµo¥Í¦º¤`¨Æ¥óªº¤ë¥÷°O¿ý¦bK-M curve ¤W¡A¤@¦ì2013/2¦¬®×¦b2014/9¦º¤`ªº±wªÌ¡A¥LªºOS=19¡A¤@¦ì2012/10¦¬®×¦b2014/5¦º¤`ªº±wªÌ¡A¥LªºOS¤]¬O=19¡A³o¨â¦ì±wªÌ³£·|¥X²{¦bP17ªºK-M curve¤¤ªºnumber at risk¼Æ¦r¤¤ªº16~20Ó¤ë³o¤@ӰϬqªº²Îp¼Æ¦r¡A¦pªG¥L¬O°ª¤ÏÀ³²Õ¡A¥L´N¬O94~81ùتº¤@¦ì¡A¦pªG¥L¬O§C¤ÏÀ³²Õ¡A¥L´N¬O69~52ùتº¤@¦ì¡A¦pªG¥L¬O¹ï·Ó²Õ¡A¥L´N¬O92~70ùتº¤@¦ì¡C¦³¨S¦³µo²{¡A³ºµM¦P¼Ë4Ӥ몺°Ï¬q¡A¤T²Õªºnumber at risk¤H¼Æ³£¤£¤@¼Ë¡A°ª¤ÏÀ³²Õ¦³13¤H¡A§C¤ÏÀ³²Õ¦³17¤H¡A¹ï·Ó²Õ¦³22¤H¡AWHY? ÁÙ°O±o¶Ü¡H16~20Ó¤ë³oӰϬqÁÙ¥]¬A¤FÆ[¹î®É¶¡¤£°÷ªøªº±ß¦¬®×¥B¥¼¦º¤`ªº³]¸ê®Æ¡A¤]´N¬O2014/2~2014/6¦¬®×¥B¥¼¦º¤`ªº±wªÌ³£·|¥X²{¦b³o16~20Ӥ몺°Ï¬q¡A¦¨¬°number at riskªº¤@û¡A¤T²ÕªºÁ`¦¬®×¤H¼Æ¤À§O¬O112¡B112¡B124¡A¤À§O¬O32%¡B32%¡B36%ªº¤ñ¨Ò¡A²z½×¤W³oӰϬq¤T²Õªºnumber at riskÀ³¸Ó¬Û·í±µªñ¡A«ç»ò·|¬O13¡B17¡A22¤Hªº®t§O©O¡Hì¨Ó16~20Ӥ몺number at risk¤]¥]¬A¤F¦¦¬®×¦Ó¦º¤`¨Æ¥óµn¿ý¬°OS=16~20Ӥ몺±wªÌ¡A¥i¥H¬O2012¦~¡B2013¦~¡B2014¦~ªº±wªÌ¡A¥un¦º¤`ªºOS=16~20Ӥ볣¬O³o°Ï¬qªºnumber at riskªº¤@û¡A·íµMªº¡A¥H¾÷²v¨ÓÁ¿¬O2013/6¥H«e¦¦¬®×ªº±wªÌ¬°¥D¡CY°²³]³o16~20Ӥ몺°Ï¬q¤¤¤w¸g¨S¦³drou outªº³]¸ê®Æ(·|¨M©wdrou out¤j©³¦b16Ó¤ë¥H«e´N¨M©wÂ÷¶}¤F)¡A¨º³oӰϬqªºnumber at risk´N¬O¥Ñ¦¦¬®×¥BOS=16~20ªº¤ëªº±wªÌ¡A¥H¤Î2014/2~2014/6¦¬®×¥B¥¼¦º¤`ªº³]¸ê®Æ©Òºc¦¨¡A¦]¬°¤T²ÕªºM OS¬Ò¤j©ó32Ó?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/12 ¤U¤È 05:15:31²Ä 1952 ½g¦^À³
|
·PÁ¦ѥv¤j¡B¥xÁÞ¤j¡B¤Ñ©R¤j©Ò´£¨Ñªº»¡©ú¡C ¯u©Ò¿×¡y¦³½Õ¬d¤~¦³µo¨¥Åv¡z¡C«ç»ò´CÅé´N¤£¨Ó§Û§Û³o¨Ç¡A¥u·|Âà¶K¤@¨Ç¤ù±¡B°¾»áªº¿ù»~¸ê°T¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/12 ¤U¤È 03:28:22²Ä 1951 ½g¦^À³
|
www.mohw.gov.tw/news/571553648 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/12 ¤U¤È 01:50:45²Ä 1950 ½g¦^À³
|
1 ·sÃĬdÅçµn°O¥[³t®Öã¾÷¨î (Accelerated Approval, AA) www.fda.gov.tw/upload/133/Content/2014033109025666118.pdf 2 104年度·sÃĬdÅçµn°O¼f¬d¦¨ªG¦^ÅU :¥xÆWTFDA ¼fÃĨî«×¤w°ê»Ú¤Æ,Àu¥ý¼f¬d®×¥ó¡A¼f¬d®É¶¡¤j´TÁY´î¦Ü171¤Ñ §Ú°ê¥h¦~¥ç¥[³t®Öã2¶µ·sÃĤW¥«¡AÅã¥Ü¹Ãĸp¿n·¥¬°¨üÄY«©Î«Â¯Ù¥Í©R¯e¯f¯f¤H¿Ñ¨D·sªvÀø¿ï¾Ü¡C ¬°¥[³t¦UÃþÂåÀø¢¤Á»Ý¨D¤§·sÃļf¬d¡A¹Ãĸp¤½§i×¥¿¡u·sÃĬdÅçµn°OÀu¥ý¼f¬d¾÷¨î¡v¤Î¡u·sÃĬdÅçµn°O¥[³t®Öã¾÷¨î¡v¡AÂX¤jì¾A¥Î¡u·s¦¨¤À·sÃÄ¡v¬°²[»\¦ÜÃĨƪk²Ä¤C±ø·sÃÄ(§Y·s¦¨¤À¡B·sÀø®Ä½Æ¤è¡B·s¨Ï¥Î³~®|)¡C104¦~«×§¹¦¨15¥óÀu¥ý¼f¬d®×¥ó¡A¼f¬d®É¶¡¤j´TÁY´î¦Ü171¤Ñ(¤¤¦ì¼Æ)¡C¦¹¥~¡A¹ï©ó§Ú°ê¦Û¦æ¬ãµo·s¿oÃÄ«~¡A¦Û¬ãµo¶¥¬q§Y´£¨Ñªk³W¿Ô¸ß»²¾É¡AÅýÃÄ«~¤Î¦¤W¥«¹Å´f¯f¤H¡A¨Ã«P¶i§Ú°ê·sÃĬãµo²£·~¡C www.fda.gov.tw/pda/page02Content.aspx?id=19542&chk=c237e72b-14e9-4a66-964e-5ce2937c0042¶m=&pn=4 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/12 ¤U¤È 12:28:23²Ä 1949 ½g¦^À³
|
¦Ñ¥v¥S: 2¤ë22¤éªk»¡·|¤½¥q´£¨ìªº¥þ²y¤T´ÁÁ{§É¶i¦æ¨ì¤@¥b ¬ü°êFDA¦Aµ¹»PÃÄÃÒ®Öã,³o¬O«Ü¼Ð·ÇªºAAª¬ªp ÁÂÁ¦ѥv¥S ªº»¡©ú ¦Ñ¥v¥S´£¨ìªºAA: ¥[³t®Öã¾÷¨î¡]Accelerated Approval¡^ ¨Ì¾Ú±´°Q¬ü°êÄY«¯e¯f¥ÎÃÄ«P¶ipµe²²¤»¡©ú¦p¤U: 1992¦~¬ü°êFDA¦bCFR 21 part314»Ppart 601ªk®×¤¤q©w¤F¥[³t®Öã(Accelerated approval)¨î«×¡C¥Ó½Ð¥[³t®Ö㪺·sÃÄ¥²¶·¦³¤ä«ù¨ä¹ïÄY«©Î¦M¤Î¥Í©Rªº¯e¯f¨ã¦³Àø®Ä»P¦w¥þ©Ê¡A¥B¥i´£¨Ñ±wªÌÀu©ó²{¦æÀøªkªº®Ä¯q¡C ¥[³t®Öã¾÷¨î¨ä¯S¦â¦³¥|¡A¤À§O¬° a¥H´À¥NÀø®Ä«ü¼Ð¥N´ÀÁ{§ÉÀø®Ä«ü¼Ð b»Ý©ó¤W¥««áÄ~Äò°õ¦æ½T»{©ÊÁ{§É¸ÕÅç (¤@¯ëÃĪ«¤W¥«³£·|Ä~Äò°õ¦æ½T»{©ÊÁ{§É¸ÕÅç Phase 4) c¨î³B¤è:¸g¥Ñ¥[³t®Öã¨î«×¤W¥««á¡A¬°¤FÝÅU¨äÀø®Ä¤Î¯f±w¦w¥þ»Ý¸g¥Ñ¯S®íÂåÀø¬yµ{,¯S©wÂåÀø°|©Ò¨ã¯S®í¸ê®æªºÂå®v¤~¯à¶}¥ß³B¤è (Àù¯g¯f±w·íµM·|¦b¯S©wÂåÀø°|©Ò¨ã¯S®í¸ê®æªºÂå®v¤~¯à¶}¥ß³B¤è) d¦³ÃÄÃÒ³QºM¾Pªº¥i¯à©Ê:¤W¥««áÁ{§É¸ÕÅçµLªkÃÒ¹êÃÄ«~¤§Á{§ÉÀø®Ä»P¦w¥þ©Ê,¥¼°õ¦æ¬ü°êFDAn¨D¤§¤W¥««áÁ{§É¸ÕÅç ,¥¼¿í¦u³B¤è¨î±¹¬I©Î«Å¶Ç¸ê°T»~¾É¥Á²³(¤@¯ëÃĪ«¤W¥«³£·|Ä~ÄòÆ[¹îÀø®Ä»P¦w¥þ©Êµû¦ô,·íµM¤]¤£¯à«Å¶Ç¸ê°T»~¾É¥Á²³) ¤£¹L¨ì2008¦~¬°¤î¡A¬ü°ê©|¥¼¥X²{¨Ì¥[³t®Öã¨î«×¨ú±oÃÄÃÒ«á³QºM¾PªºÃÄ«~¡C |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/6/12 ¤W¤È 10:59:28²Ä 1948 ½g¦^À³
|
¥xÁÞ¥S 1.¡u¥þ²y¤T´ÁÁ{§É¶i¦æ¨ì¤@¥b ¬ü°êFDA¦Aµ¹»PÃÄÃÒ®Öã¡v¡A³o¬O«Ü¼Ð·ÇªºAAª¬ªp 2.ˤ]¤£¬O¬°¤Fµ¥¥xÆW¤T´ÁªºMOS¡AÀ³¸Ó»¡¡AFDA¥»¨Ó´N·|°w¹ïÃļt´£¥Xªº¼Æ¾Ú¸Ô²ÓÀˬd¡A´£¥X½èºÃ»P«Øij¡A¥ú³oÓ¹Lµ{´N«Ü¤[¤F¡A©Ò¥H¦³®ÉÔ§Ú̬ݨìFDA³Ì«á½T»{ªº¼Æ¾Ú¡A»PÃļt¤@¶}©l´£¥Xªº¼Æ¾Ú¬O¤£¦Pªº¡AT-VecªºMOS´N¬O«Ü¦nªº¨Ò¤l(Opdivo¡BIbrance¤]¬O)¡C¦Ó»PFDA©¹¨Ó·¾³q¼Æ¾Úªº´Á¶¡¡A¦pªG¨ä¥L¼Æ¾Ú¦¨¼ô±o¥H´£¨Ñ·íµM§ó¦n¡A§Ú°O±oKeytruda¤@¶}©lEOP1®É¥u´£¥X10mg²Õ80¤Hªº¼Æ¾Ú¡A¦ý³Ì«á¤S¼W´£2mg²Õªº¼Æ¾Ú¡A¨â²Õ¤@¦@173¤H¡C©Ò¥H±z»¡¡uµ¥¥xÆW¤T´ÁªºMOS¡v¡A¤ñ¸û¦X¾Aªº»¡ªk¬O¡u·¾³q´Á¶¡¦pªG¥xÆW¤T´ÁªºMOS¦¨¼ô¤F¡A§ó¦³¥»¿ú»PFDA·¾³q¡v 3. ¥xÆW¤T´ÁÁ`¦s¬¡´ÁnÆ[¹î¨ì¦ó¦~¦ó¤ë¡H³o§Ú¤£´±»¡¡AÁ|OpdivoµÇ²ÓMÀù»PÀYÀVÀùÁ{§É¬°¨Ò¡A¥DnÁ{§Éendpoint¬OOS¡G¥h¦~7¤ë20¤éBMSµo·s»D½Z²×¤îÁ{§É¡Aan open-label, randomized Phase III study evaluating Opdivo versus everolimus in previously-treated patients with advanced or metastatic renal cell carcinoma (RCC) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm¡A¹F¨ìendpoint´N²×¤î¡A¦P®É±Nµ¹¹ï·Ó²Õ¾A¦Xªº¯f¤H¨Ï¥ÎOpdivo¡C independent Data Monitoring Committee (DMC)´£¦³Û°±ªº®Ú¾Ú¬O§_¬OPȹF¨ì0.05¥H¤U¡H§Ú¤£ª¾¹D¡A¥æµ¹±M®a̧a ¤µ¦~1¤ë28¤é«Å¥¬ÀYÀVÀù´£¦µ²§ôBMS today announced that a randomized Phase 3 study evaluating Opdivo versus investigator¡¦s choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. independent Data Monitoring Committee (DMC)´£¦³Û°±ªº®Ú¾Ú¬O§_¬OPȹF¨ì0.05¥H¤U¡H§Ú¤]¤£ª¾¹D.... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/12 ¤W¤È 09:50:02²Ä 1947 ½g¦^À³
|
¦Ñ¥v¥S ´Nºâ¯E¹©¥Ó½ÐFDAÁ{§É¤T´Á¨ÃÀòã°õ¦æ¡A¤]¤£¥Nªí¥¦ªº¤G´Á¼Æ¾ÚµLªk¨ú±oÃÄÃÒ¡H µª®×¬OYES (¦^µª¹x¥Û¥S) ½Ð°Ý 1³o·|¤£·|´N¬O¤G2¤ë22¤éªk»¡·|¤½¥q´£¨ìªº¥þ²y¤T´ÁÁ{§É¶i¦æ¨ì¤@¥b ¬ü°êFDA¦Aµ¹»PÃÄÃÒ®Öã? ¤½¥q»{¬°ÃÄÃÒ®ÖãÅv¦bFDA,¤£´±¥ý¹w´úµ²ªG,¥u´£¨ìOBI822¤TºØ¥i¯àµ²ªG : 1 conditional approval 2 ¥þ²y¤T´ÁÁ{§É¶i¦æ¨ì¤@¥b ¬ü°êFDA¦Aµ¹»PÃÄÃÒ®Öã 3 ±qÀY°µ¨ì§À 2¥þ²y¤T´ÁÁ{§É¶i¦æ¨ì¤@¥b ¬ü°êFDA¦Aµ¹»PÃÄÃÒ®Öã? ·|¤£·|¬O¦Aµ¥¥xÆW¤T´ÁÁ`¦s¬¡´ÁMOS ? ¥xÆW¤T´ÁÁ`¦s¬¡´ÁnÆ[¹î¨ì¦ó¦~¦ó¤ë? §Ú»{¬° Kaplan-Meier curve ¦s¬¡¦±½u¥u»ÝÆ[¹î¬ù¤@¥bªº¹êÅç²Õ¤H¼Æ ´N¥i¬Ý¥XÁÍ¶Õ ¹ï¶Ü? ¥H¤W°ÝÃD½Ð±Ð ÁÂÁ |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/6/12 ¤W¤È 08:29:13²Ä 1946 ½g¦^À³
|
¹x¥Û¤jô ´Nºâ¯E¹©¥Ó½ÐFDAÁ{§É¤T´Á¨ÃÀòã°õ¦æ¡A¤]¤£¥Nªí¥¦ªº¤G´Á¼Æ¾ÚµLªk¨ú±oÃÄÃÒ¡H µª®×¬OYES ¥i¥H°Ñ¦ÒKeytruda¡BOpdivoªºmedical review¡Bsummary review¡A¥i¥H§ä¨ì¸òFDA©¹¨Ó·¾³q°Q½×ªº°O¸ü¡A±q¶}©l¸òFDA·¾³qAA¨ì¨ú±oAA¶O®É¬Æ¤[¡A©Ò¥H¦P¨B¶i¦æ¤T´Á¬O«D±`¦X²zªº¡A¤Ï¥¿¤T´Á¬O¤@©wn°µªº¡Cmedical review¡Bsummary review³£¬O¦Ê¨Ó¶ªº^¤åªZ¾Ç¯µÓD¡AŪ§¹¥i¥H´£¤É¤@¥Ò¤l¥\¤O¡A§Ú¥\¤O¤£°÷¥u½¤F´X¶´N¸g¯ß§Ã¹D¡B®ð¦åªmÄË¡K¡K Keytruda 2012.8/21 EOP1(End of phase1) meeting¡A°Q½×´£¥æªºPN001ªºÁ{§É¼Æ¾Ú¥H¤ä«ù½Ð¨Daccelerated approval¡AMerck³¯z³oӥӽбN¥H80¦ìYervoyÃøªv«¬ªº¬°°ò¦¡Aªì¦ô¦¹°ª¾¯¶q²ÕªºORR¬°30%(¨C3¶g10mg/kg)¡AÁ{§É®Ä¯qÃÒ©ú±N°ò©óPN002¡BPN006ªºÁ{§Éµ²ªG¡AFDA»¡©úMerck¥²¶·³]p¨¬°÷ªº¡B¾A·íªº¡A±±¨î¨}¦nªºÁ{§É¡Adetect a response rate of sufficient magnitude and duration to be reasonably likely to predict clinical benefit¡C 2013.1/11 Pre-Phase3 meeting¡G1.¦^ÀYÀË´úPN001¤¤Ipilimumab-Refractory±Ú¸sªºPD-L1ªí²{²v¡A¥H§@¬°³z¹LAAÃĪ«¤W¥«¼f®Öªº¤ä«ùÃÒ¾Ú¡A2.¦pªGAA³Q®Ö¥iªº¸Ü¡APN006´N¬On¥Î¨ÓÃÒ©ú¨äÁ{§É®Ä¯qªº¸ÕÅç¡A3.FDA»Ý»PMerck´£¥XªºCMC¦³¤@P¬Ýªk 2013.1/17¨ú±oBTD 2013.4/2 CMC meeting 2013.4/22 Type B meeting 2013.8/23 CMC meeting 2013.10/3 ¥¿¦¡©w¦W¬°Keytruda¡K¡K¡K«á±¹Lµ{Á٫ܤ¾ªø 2014.9/4 Accelerated approval FDA·s»D½Z»¡±o«Ü²M·¡¡AThe FDA action was taken under the agency¡¦s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials. An improvement in survival or disease-related symptoms has not yet been established. ±q°Q½×AA¨ì¥¿¦¡¨ú±oAA¤@¦@ªá¤F¨â¦~®É¶¡¡A©Ò¥H¤T´ÁÁ{§É¤@©wn¦P®É¶i¦æ Opdivo 2012.7/17 an End of Phase 1 (EOP1)/pre-Phase 3 meeting was held with the Appli-cant to provide feedback on the preliminary data from the ongoing Phase 1 study (CA209003) for advanced, unresectable, or metastatic melanoma, and discuss the po-tential for accelerated approval based on study CA209003. Study CA209037 was planned as an open-label, multicenter, randomized (2:1), active-controlled study BMS¤ñMerckÁÙ¦¤@Ó¤ë¶}EOP1¡A¦Ó¥B³spre-Phase 3¤]¦P¤@¤Ñ¤@¨Ö¶}¡AFDA¦P·N«D±`¦hBMS©Ò´£¥Xªº¨Æ¶µ¡C¤§«áBMS»PFDA¤]¶}¤F«D±`¦h·|¡A½Õ¾ã¼Æ¾Ú¡An¨DªFn¨D¦è¡A2013.1.23´£¥XBTD³Q©Úµ´¡A2014.7.18¤S¥H¨ä¥L¶i¦æ¤¤ªºÁ{§É´£¥XBTD¤~Àò±o¤¹³\¡A2014.12.22¤ñKeytruda±ß¤TÓ¦h¤ë¤~¨ú±oÃÄÃÒ 1.¦pªGÁÙ¦³¤H»¡¤@©wn°µ§¹¤T´Á¤~¯à¥Ó½ÐÃÄÃÒ¡A¨º¬O¨SŪ®Ñ 2.¦pªG¦³¤H»¡¯E¹©¼Ë¥»¼Æ¤Ó¤Ö¡AKeytruda¤@¶}©l¥u´£80¤H¡AOpdivo¥u¥Î120¤H´Á¤¤¤ÀªR¼Æ¾Ú¡K¡K¡A¯E¹©¦³¸ê®æ´£¡A±µ¤£±µ¨ü¬OFDA¡A§Oµ¹¤½¥qÀ£¤O 3.¹ñ·sªº§K¬ÌÃĪ«±q°Q½×AA¨ì¥¿¦¡¨ú±oAAnªá«Ü¤[®É¶¡¡A¤j¼t³£¦p¦¹¤F¡A¯E¹©¤j·§¤]§K¤£¤F¡A¦ý¥unFDAÄ@·N°Q½×AA¡A¬YºØµ{«×¤WÁô§tµÛFDA»{¦PÁ{§É¼Æ¾Ú¡A¥un¶]§¹¸Ó¶i¦æªº¬yµ{¡K¡K¡C¸ê¥»¥«³õ·|´£«e¤ÏÀ³°Q½×AAªº§Q¦h¡AÁÙ¬Oµ¥¨ì¥¿¦¡¨ú±oAA¤~¤ÏÀ³§Q¦h¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/11 ¤U¤È 06:02:55²Ä 1945 ½g¦^À³
|
·PÁ¹x¥Û¤j¸ÔºÉªº¸É¥R ²³¤j¤j 1 °¨°º¬ö©ÀÂå°|¥Ñ°ê¬ì·|°ê®a«¬¬ì§Þpµe¸É§Uªº¬ã¨spµe¡A¨â¦~«e§Yµo²{¡A¦Ü¤Ö¦³70¡ã80%¯f¤Hªº§Z±_Àù²ÓM¡A¦s¦b¦³Globo H ¤Î¨ä«eÁÍÁޯ׽誺§Üì¦ì¸m¡C§Q¥ÎÁޤƪ«§Ç¦C´¹¤ù´ú©w¤]µo²{¡A¦³¤£¤Ö§Z±_Àù¯f¤H¦å²M¤¤¥i¥H§ä¨ì¹ï§ÜGlobo H©Î¨ä«eÁÍÁޯ׽誺¦Ûµo©Ê§ÜÅé¡AÃÒ¹êGlobo Hªº½T¥i¥H¤Þµo§Z±_Àù¯f¤Hªº§K¬Ì¤ÏÀ³¡C www.mmh.org.tw/info-news-detail.asp?id=1675 2¥HGlobo H-KLH + QS21¥Î©óµL¯e¯f¶i®iªº§Z±_¤W¥ÖÀù¡B¿é§ZºÞÀù©Îìµo¸¡½¤Àù±wªÌªº¬ã¨s2014¦~11¤ë¬ã¨s³ø§i µ²ªG¡G33¦ì§Z±_Àù¡B¿é§ZºÞÀù©Î¸¡½¤Àù±wªÌ±µ¨ü´î¿n¤â³N¤Î¹`°ò¤ÆÀøÃĪvÀø«á¡C°lÂܤ¤¦ì¼Æ¬°4Ó¤ë ±µ¨ü¦Ü¤Ö¥|°wªº¯f±w¤¤¦³88¢M IgM ¿@«×¤W¤É¡A43¢M IgG ¿@«×¤W¤É¡C¨S¦³«¤jªº°Æ§@¥Î (¥u¦³¤@¨Çµu¼È§C·Åµo¿N¤Î§½³¡¥Ö½§¤ÏÀ³) ¥u´ú33¦ì ,¥Ø«e¤w¦¬77¦ì (µ¥¥¼¨Ó¼Æ¾Ú¦¨¼ô¤½§GÀø®Ä) ÁöµM¥Ø¼Ð¦¬110¦ì , ¤G´Á¬O§_»Ýn¦¬¨º»ò¦h¤H? °O±o¨ÅÀù¤G´Á¥u¦¬45¤H¥ª¥k 3 822 833 ¥¿¦b¬ãµo»P³W¹º¬ãµo¤¤¥H¨ÅÀù ªÍÀù ¤j¸zÀù ¬O¤jÃÄ ¯ØŦÀù¦b¬ü°êµo¥Í¤H¼Æ¤]¤£¤Ö ÄáÅ@¸¢Àù¦bMSKCC¦³§¹¦¨¤@´ÁÁ{§É ¥xÆW¯E¹©¥¼¨Ó¦bº¡¨¬¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D¼ç¤OµL½a ¨Ì¾Ú Cancer Facts & Figures 2016 ¬ü°ê¹w¦ôÀù¯g --/µo¥Í¼Æ / ¦º¤`¼Æ All Sites /1,685,210/595,690 ¨ÅÀùBreast/249,260/40,890 §Z±_ÀùOvary/ 22,280/14,240 ¤j¸zª½¸zÀùColon & rectum /13490/63670 ªÍ»P¤ä®ðºÞÀùLung & bronchus / 224,390/ 158,080 GÀùStomach/ 26,370 / 10,730 ¯ØŦÀùPancreas /53,070 / 41,780 ÄáÅ@¸¢ÀùProstate/180890/26120 ¸£Àù Brain & other nervous system/23770/16050 ¤l®cÀVÀù uterine cervix /12900/4120 ¤l®cÅéÀù Uterine corpus/60050/10470 ( ¤SºÙ¤l®c¤º½¤Àù) 4¯E¹©¬ãµoªºÃĦpªG¦b¤G´Á¬Ý¥XÃĮĤ]¦³¥i¯àÀò±o©t¨àÃĸê®æ¥[³tÃÄÃÒ¨ú±o (§Z±_Àù.¯ØŦÀù,¸£Àù GÀù ¤l®cÀVÀù ¤l®c¤º½¤Àù ¿©¯f¤H¼Æ¤Ö©ó20¸U¤H ) ©t¨àÃÄ«üªº¬O¨u¨£¯e¯f¥ÎÃÄ¡A¬ü°ê©w¸q¬°°ê¤º¿©¯f¤H¼Æ¤Ö©ó20¸U¤H¡A¼Ú¬w©w¸q¯e¯f¿©±w²v§C©ó¸U¤À¤§5¡A¤é¥»©w¸q¿©¯f¤H¼Æ¤Ö©ó5¸U¤H¡A¥xÆW©w¸q¿©±w²v¦b¸U¤À¤§1¥H¤U¬°¨u¨£¯e¯f |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2016/6/11 ¤U¤È 04:57:00²Ä 1944 ½g¦^À³
|
Âà¶K¯E§J¤j¦b¡yÄw½Xª©¡zªº¶K¤å¡A¦p¤U¡C ¼ÒÀÀ¦³Ãö³]¤H¼Æªº¤À¥¬»PKM¶¥±è¨ç¼Æ½u¹ÏªºÅÜ¤Æ Â²n¾ã²z¦p¤U ¼ÒÀÀ¸ê®Æ¦pºô¸ôµwºÐ¸ê®Æ drive.google.com/folderview?id=0B6poLqRh-kUHcmlMRzFXV3FzVzg&usp=sharing 1.°Ñ¦Ò°ò·Ç¼Ë¥»,¦p10ÓOS¡A1-10¦~ªº¥§¡¤À¥¬¡A¨C¦~¦º¤@Ó¡A°Ñ¦Ò10ÓOS¡A°ò·Ç¼Ë¥»KM¹Ï¡CMOS 5¦~ 2.«e³]¬O°²³]³]¤H¼Æµo¥Í¦b®É¶¡¼Ë¥»«e60%¡A¦¹³B¼ÒÀÀ3¦ì¡A°Ñ¦Ò10ÓOS¡A«e3Ó³]¼Ë¥»KM¹Ï¡C¶V¦h«e³]¤H¼Æ(¤´¦s¬¡©ÎDropout)¡A¦bKM¦±½u«á¥b¬q¶V®e©öÅýKM¶¥±è¹³¹q±è¤U°¡A MOS 7¦~->KMªk¹ï©ó«e³]ª¬ªp¡A¦ü¥G¹w¦ôMOS«á©µ 2.«á³]¬O°²³]³]¤H¼Æµo¥Í¦b®É¶¡¼Ë¥»«á60%¡A¦¹³B¼ÒÀÀ3¦ì¡A¶V¦h«á³]¤H¼Æ(¤´¦s¬¡©ÎDropout)¡A¦bKM¦±½u«á¥b¬q¶V®e©öÅýKM¶¥±è¹³¹q±è¤U°¡A°Ñ¦Ò10ÓOS¡A«á3Ó³]¼Ë¥»KM¹Ï¡CMOS 5¦~->KMªk¹ï©ó«á³]ª¬ªp¡A¹w¦ôMOS¤£ÅÜ 3.³Ì«á³]¬O°²³]³]¤H¼Æµo¥Í¦b®É¶¡¼Ë¥»³Ì«á¤À¥¬¡A¦¹³B¼ÒÀÀ3¦ì¡A¶V¦h³Ì«á³]¤H¼Æ(¤´¦s¬¡©ÎDropout)¡A¦bKM¦±½u³Ì«á¤@¬q¶V®e©öÅýKM¶¥±è¹³¤ô¥½u(«p§À)¡A°Ñ¦Ò10ÓOS³Ì«á3Ó³]¼Ë¥»KM¹Ï¡CMOS 5¦~->KMªk¹ï©ó³Ì«á³]ª¬ªp¡A¹w¦ôMOS¤£ÅÜ ¥H¤W¥u¬O¼ÒÀÀ¡Aµ²½×¶È¨Ñ°Ñ¦Ò¡A¤£¦P¦s¬¡®É¶¡¼Ë¥»¤À¥¬¡A¼ÒÀÀµ²ªG¥²µM¤£¦P¡C ¦Ñ¥v¤jªºµo¤åÁ`¬O¤@°w¨£¦å¡C ¤p§Ì¾\ŪFDA³o´Xӽͼf®Ö§ÜÀùÃĪ«ÃÄÃÒªº»¡©ú¤å¥ó¡A¦³³o»ò¤@Ó²³æªºÆ[ÂI¡A½Ð¦U¦ì«ü¥¿¡C ¤p§Ì»{¬°¡G§Ú̦b¦U¾ãÁ{§É¼Æ¾Ú·í¤¤©Ò¬Ý¨ìªº PFS ²Îp¡A¨ä¹ê¥u¬OÓ surrogate endpoint (´À¥N©Ê«ü¼Ð)¡A¯u¥¿ªº«ü¼ÐÁÙ¬OÀ³¸Ó¬O¦s¬¡´Á¡B¦w¥þ©Ê»P¥Í¬¡«~½è¡C¬°¦ón¦³´À¥N«ü¼Ð PFS¡A¬O¦]¬°¦s¬¡´Á OS »Ýn«Üªø®É¶¡¤~¯à½T»{¡A¬°¤F¥[³t®ÖãÀù¯g¥ÎÃÄ¡AÅý¯f¤H¦³·sªºÃĪ«¥i¥H¨Ï¥Î¡A©Ò¥H¥Î¤ñ¸û§Ö³t¯à¨ú±o§¹¾ã¼Æ¾Úªº PFS ¨Ó°µ¬° surrogate endpoint¡C §Ú̦b¥xÆWªº§ë¸ê¤H¥H¤Î²£·~¤ÀªR®v¨Ã¤£¤F¸Ñ³o¨Ç¾ú¥v¡A»~¥H¬° PFS ´N¬O FDA ¼f¬dÃÄÃÒªºÃöÁä«ü¼Ð¡A¤@ª½¦b PFS ¬O§_¹F¼Ð³oÂI¤W¥´Âà¡A®Ú¥»¬O°¾Â÷¤F¥DÃD¡C·íµMÅo¡A½Ö¥s¯E¹©·íªì³]pÁ{§É¸ÕÅç protocol ®É¹ï©ó 822 ªºÁ{§É®ÄªG»{ÃѤ£¨¬¡A¦Û¤v§â PFS ¼g¦¨ primary endpoint¡A¤]©Ç¤£±o¦³¤ß¤H¤@ª½¦b³oÂI¤W½a°l²r¥´¡C ¦^Âk¨ì FDA ¼f¬dÃĬFªº°ò¥»ÅÞ¿è¡A¨ä¹ê´N¬O³Ì§Ö³tªº´£¨ÑÀù¯g¯f¤H§ó¦h¡B§ó¦nªº¿ï¾Ü¡C¹CÀ¸³W«h¬O¥¦©wªº¡A©Ò¥H¥¦µ´¹ï¤£·|§â PFS ¥¼¹FÅãµÛ©Ê·í¦¨§P¨M®Ñ¡C §ó¦óªp¡A FDA ¤å¥ó¤¤¤]´£¨ì¡G Ãļt¥²¶·´£¨Ñ substantial evidence of Efficacy and Safety; °eFDA¥Ó½ÐÃÄÃÒªºÀù¯gÃĪ«¡A¨äÁ{§É¼Æ¾Ú¯S©Ê»P¤@¯ëªº°e¼fÃĪ«¤£¦P¡CÀù¯gÃĪºÁ{§É¹êÅç¼Æ¾Ú°e¼fªº¤º®e©¹©¹¦³¦p¤U±¡§Î¡G 1. ³æ¤@¸ÕÅç¡A¯f¨Ò¼Æ 100~800¡F 2. ¥¼°µÂùª¼¡AµL¦w¼¢¾¯¹ï·Ó²Õ¡F 3. «D§¡½èªº¯f±w±Ú¸s¡F 4. ²ÎpÅãµÛ©Ê§C¡A©¹©¹¥u¦³ 0.03~0.05 ³o¹ïFDAªºÃĪ«¼f¬d«H¤ßµ{«×³y¦¨¦ÒÅç¡C FDA´Á«ÝÀù¯g·sÃÄ©Ò´£¨Ñªº®Ä¯q¡G 1. Live Longer. (³o¸Ì¬Ý¤£¨ì PFS ³o¼Ëªº«ü¼Ð¡AÀ³¸Ó¬O«ü OS.) 2. Live Better (Quality of Life). ¦pªG¬O¥H QOL °µ¬°®Ä¯q«ü¼ÐªºÃĪ«¡A¥²¶·¬O¦³ ¹ï·Ó²Õ+¸Ñª¼¸ÕÅç (¨Ã¥¼»¡¥²¶·Âùª¼) 3. Safer than alternatives, with efficacy. (Benefit / Risk assessment.) ÃĪº®Ä¯q¥²¶·¶W¹L¨ä©Ò±a¨Óªº·ÀI (±q¯e¯f±±¨îªº¨¤«×¨Ó¤ñ¸û¡CFDA¤£ºÞ»ù®æ¦]¯À¡C) ¥[³t¼f¬d (Accelerated Approval, AA) ªºn¥ó¡G¹ï©ó life-threatening ¯e¯f¡A·sÃļf¬d±ø¥ó¥i¥H©ñ¼e¡A 1. ¥²¶·¤ñ²{¦³ªºÀøªk (ÃĪ«) n§ó¦n 2. ¥i¥H±Ä¥Î´À¥N«ü¼Ð (surrogate endpoint)¡A¥H¦X²z¹w¦ô¤WzªºÁ{§É®Ä¯q (¤p§Ìªº¸ÑÄÀ¡G¨Ò¦p¥H PFS ¨Ó¹w´ú OS¡C) 3. n¯àÃÒ©ú®Ä¯qªº¦s¦b¡C ÃöÁä°ÝÃD¡GFDA¨s³ºÃö¤ß²Îp¤WªºÅãµÛ©ÊÁÙ¬OÁ{§É®ÄªGªºÅãµÛ©Ê¡H 1. Y¬O²Îp¤WÅãµÛ¦ý¬OÁ{§É¤W¤£ÅãµÛ ==> ¤£·|µ¹ÃÄÃÒ 2. Y¬OÁ{§É¤WÅãµÛ¦ý¬O²Îp¤W¤£ÅãµÛ ==> ¤]³\·|µ¹nÃÒ (¨Ò¦p·íªìªº²Îp¤èªk³]p¦³°ÝÃD) ²¦³º¡AÃĮĤ~¬O³Ì«nªº¡I ¤p§ÌµL¯à¤O¬ã§P 822 ¬O§_¯à°÷ª½±µ¥Ó½ÐÃÄÃÒ¡C¦ý¬O±q¤W±ªº»¡©ú¥i¥Hµo²{ FDA ¼f¬d·sÃĪº¦Ò¼{¬O¦h±¦Vªº¡Aµ´¤£¹³¥xÆW¬Y¨Ç´CÅé©Î¤ÀªR®v©Ò»¡ªº¡yPFS ³£¨S¹F¼ÐÁÙ¤£©Ó»{¥¢±Ñ¡A¯E¹©¥u·|µw抝¡I¡z ÁÙ¦³¤@ÂI½Ð²³¤j½T»{¡G Keytruda ¦b2014¦~´NÀò±o FDA §åã¥Î©ó¶Â¦â¯À½F¤F¡A¦ý¬O¨ì³o¶gÁÙ¦b¤½¥¬¶Â¦â¯À½FÁ{§É¤T´Áªº³Ì·s¹êÅç¼Æ¾Ú¡C ³o¬O«ç»ò¦^¨Æ¡H ¸ê®ÆÅã¥Ü¡A2014¦~ Keytruda ¥u³Q¤¹³\¥Î©ó¹ï©ó¨ä¥L©Ò¦³ÃĪ«§¡µL¤ÏÀ³ªº¶Â¦â¯À½F±wªÌ¨¤W¡C2015¦~¸Ónªº¾AÀ³¯g¦³©ÒÂX¤j¡C ³o¬O§_¤]ªí¥Ü¡A´Nºâ¯E¹©¥Ó½Ð FDA Á{§É¤T´Á¨ÃÀòã°õ¦æ¡A¤]¤£¥Nªí¥¦ªº¤G´Á¼Æ¾ÚµLªk¨ú±oÃÄÃÒ¡H |
|
|
·|û¡G99910140657 µoªí®É¶¡:2016/6/10 ¤U¤È 01:00:16²Ä 1943 ½g¦^À³
|
¥«³õ¡i¸U¯ë©Ô©ïªÑ»ù¬°¥X³f¡j¡I ¨º¡i¸U¯ë¥´À£¬O¬°¶i³fÁÙ¬O¥X³f¡H¡j¡I ¯E¹©¬O±Ð¥DµLª¾¡H¯Î«e°|ªøµLª¾¡H±i¸³µLª¾¡H ¬O²`¬ã¦h¦~±a»â½Ñ¦h¯E¤Í«i´±«e¶iªº¡A¥xÁÞ¤j«e½ú¡ACliff¤j«e½ú¡A¦Ñ¥v¤j«e½ú¤Îºô¤W¦h¦ì±M¬ãªº«e½úµLª¾¡H ³o¨ÇªºµLª¾¬O¯uªº¶Ü¡H²{¦bªºµLª¾¤w¤S¼W¥[¤F¦h¤Ö¤wª¾¡C ÁÙ¬O´CÅéµLª¾¡AÀ˽յLª¾¡A¥ß©eµLª¾¡AªÀ·|¤j²³µLª¾...¡H ¯Î«e°|ªø«i´±ª½¥Õªº»¡¥X¤F¥ÍºA±Ð¨|¤§¨¥¡G ªÀ·|ÁֽסA¤£¤@©w¬O¹ïªº...¡I ¾Ì¤°»ò¡H ¬O±M·~ÁÙ¬OµLª¾¡H ·q¯¬½Ñµ½¤j¤j¨Î¸`¥¦w¡C ¦b¦¹¨Î¸`¡A¦A¦¸·PÁ½Ѧhµ½¼w±M¬ã¤j¤j¡AµL¨pªº·ÓÅU¤j®a¡C {ºÖ³ø¨Ó¦Û¼w} Ä@ºÖ¥Ã»·»P±z̦P¦b¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/9 ¤U¤È 10:17:06²Ä 1942 ½g¦^À³
|
1ÁÂÁ¦ѥv¥S±qªk³W±¤Á¤J¡A°t¦X¬ü°êFDA¼fÃÄì«h>©µªø¦s¬¡¡A¦w¥þ¡A¥Í¬¡«~½è¡AÁö»¡¬Oì«h ¨ä¹ê¬O¤@ºØ»ùÈ¡C 2Á`¦s¬¡´Áªº¦¨¼ô¦p¦P¥Ê¼ô¸¦¸¨¡A¦p¦P¦Ñ¥v¥S¥mÀ{ªº¤£¯à¾Þ¤§¹L«æ¡A ¡AÓ¤H»{¬°¦hµ¥¤@¨Ç®É¶¡¶H¼x¨ü¸Õ¯à¦³«~½èªº¬¡ªº§ó¤[ 3¬ü°êFDA¼fÃıM®a¬Ý¦s¬¡¦±½u´N¦p¦P¤ßŦ¬ìÂå®v¦b¬Ý¤ß¹q¹Ï¤@¼Ë¡A·¥µu®É¶¡´N¯à¬Ý¥XºÝÙ¡A ¨º¨Ç±M®a³Ìµ½ªø¬ÝÁͶաA¬Ý¥XÁͶաA¼Æ¾ÚÁÙ¨S¦¨¼ô¤]¥i¯à³Û°±¡C |
|
|
·|û¡G³\¤j10137169 µoªí®É¶¡:2016/6/9 ¤U¤È 06:46:14²Ä 1941 ½g¦^À³
|
¦Ñ¥v¤j ¤p§Ì±M·~¦³ ¥ý¤W¨Ó«öÆg¤@¤U! ±z»¡ªº²Ä5ÂIªº³Ì«á¤@¬q¸Ü (¡u¨ÅÀù²{¦b¤w¸g¦³«Ü¦nªºÃĪ«¤F¡v¡A¦b§Ú¬Ý¨Ó¡A·¥«×§N»ÅµL±¡) ¤p§Ì·P¦P¨¨ü ¾ú¾ú¦b¥Ø ¯f¤H½T¹ê»Ýn§ó¦³«~½è¥B¦³´LÄYªº¤è¦¡ªvÀø ¯f¤Hªø´Á°lÂ̩ܳÈÅ¥¨ì¸~½FÂಾ©ÎºÃ¦ü´_µo ¥úÅ¥¨ìºÃ¦ü©Î¥i¯àn¦A¤Á¤ùÀˬd ¥i¯à´N»L³n©Î¤£·Q¬¡¤F ¹L¥hªvÀøªº¾µ¹Ú¦p¼vÀH§Î ´§¤§¤£¥h ©Ò¥H§Ú¯uªºÄ±±oFDA¬O«D±`¦³¤H©Ê»P¼u©Êªº°µÃĪ«¼f¬d»P®Öã. |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2016/6/9 ¤U¤È 06:23:26²Ä 1940 ½g¦^À³
|
1.¬Ý°IªÌªGµM©ß¥XPFS¡BIbrance¡A¦ý§Ú¤w¸g·P¨ü¨ì822¦bOS²Ó¤ôªø¬yªº·¥¤jÀu¶Õ¡A½Ð°O±o±i¸³»¡ªº¸Ü¡u¸~½FÁY¤p¤Sso what¡v¡A¬ãµoÃĪ«ªº²×·¥¥Øªº¬O¦bÅý¯f¤H¦³´LÄY¦³«~½è©µªø¥Í©R¡A¤£¬OÅý¸ê¥»¥«³õ§N»Å¦a®³PFS¨ÓPK¡A¥H¤U¤å¦r¨Ó¦ÛFDAªºJohn R. Johnsonµ¥(End Points and United States Food and Drug Administration Approval of Oncology Drugs)¡AGuidance promulgated in the 1980s indicated that efficacy should be demonstrated by prolongation of life, a better life, or an established surrogate for at least one of these. Drugs must also be safe for their intended use¡CFDAªº°ò¥»¥ß³õ´N¬O©µªø¥Í©R¡B§ó¦nªº¥Í¬¡«~½è¡B¦w¥þ¡A1992¦~Subpart H¼W¥[NDA¥[³t®ÖãAccelerated Approval(AA)ªº³W«h¡Afor diseases that are serious or life-threatening when the new drug appears to provide benefit over available therapy, but under situations when the demonstrated benefit did not yet meet the standard for regular approval¡A¦pªG±qPFS¡BDFS¡BORRµ¥´À¥N«ü¼Ð¥i¥H¹w§P¸ÓÃĪ«¥i¯àÀu©ó²{¦³ªºªvÀø¡A¦³§Q©ó¯f¤H©µªø¥Í©R¡A¾¨ºÞ³oÓÃĪ«©|¥¼¹F¨ìregular approval ªº¼Ð·Ç¡AFDA¤]·|Ä@·N¥[³t®ÖãÃĪ«¤W¥«¡A¦ý®Öã«áÁÙ¬O¥²¶·°µ¤@Ópostmarketing study¡Cregular approvalªº·N«ä´N¬Obased on end points that demonstrate that the drug provides a longer life, a better life, or a favorable effect on an established surrogate for a longer life or a better life¡C¤W¤å§Ú¤£¬Oª½±µÂ½Ä¶¡A§Ú¥Î¤ñ¸û¤f»yªº±Ôz¥H¤è«K¤j®a²z¸Ñ 2.¦pªG¥i¥H±q¯f¤H¨¤«×»{¦P¡u¦³´LÄY¦³«~½è©µªø¥Í©R¡v¤ñ¡u¸~½FÁY¤p¡v§ó¦³·N¸q¡A¦pªG¥i¥H²z¸ÑFDAªº¥ß³õ¡A§Ú̲{¦b¨Ó¬Ý822°ª§ÜÅé¶q²Õ¡AµL½×¬O¦bPFS¥H¤Î§ó«nªºOS³£Àu©ó¹ï·Ó²Õ¡A³oӼ˥»¼Æ¯à¤£¯à¸òFDA·¾³qAA©O¡H¾¨ºÞ¦³ÓT-Vec«e¨Ò¡AOSªºP=0.116¡B278 subjects dropped out of the study¡]63.7%°h¥XÁ{§É¡^¡Bcherry-picking¡A¦ý¯E¹©¤£¬OAmgen¡A¤]¤£¬O¥Î61¤H¼Æ¾Ú´N¸òFDA·¾³qªºMerck¡A§Ṳ́£nµ¹¤½¥q¤Ó¤jÀ£¤O¦n¶Ü¡H¦¹¥~¡A¦pªG®É¶¡©Ôªø¡Aµ¥822¹êÅç²ÕOSªºP値¤p©ó0.05¡A¬O¤£¬O§ó¦³¸ê®æ©MFDA·¾³q¡H 3.PD-1ªºOpdivo¥h¦~11¤ë¨ú±oFDA®Öã¥Î©óªvÀøµÇ²ÓMÀù¡AÁ{§É³ø§iNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma¤]¦b¦P¦~11¤ëµoªí©ó·s^®æÄõÂå¾Ç´Á¥Z¡C½Ð¬Ý1808»P1809¶ªºOS¡BPFS¹Ï¡A¹êÅç²ÕPFS=4.6Ó¤ë¡A¹ï·Ó²ÕPFS=4.4Ó¤ë¡AHR=0.88¡AP=0.11¨S¹LÃö¡F¹êÅç²ÕOS=25Ó¤ë¡A¹ï·Ó²ÕOS=19.6Ó¤ë¡AHR=0.73¡AP=0.002¹LÃö¡C½Ðª`·N¡A³oÓÁ{§É¦¬®×821¤H¡APÈ·|¤ñ¸ûº}«G¡C1811¶¥ª¥b˼Æ17¦æ¡Gthe results of a comparison of progres-sion-free survival between the nivolumab group and the everolimus group suggest that progression-free survival was not a surrogate for overall survival in this study¡A¡u¦b³oÓ¹êÅç¡APFS¨ÃµLªk·í¦¨OSªº´À¥N«ü¼Ð¡v¡C³o¼ËÀ³¸Ó§ó¥i¥H²z¸ÑOS¬°¥»¡APFS¬°´À¥N«ü¼Ðªº·N«ä§a¡AÀ³¸Ó§ó¯àÅé·|¡u¸~½FÁY¤p¤Sso what¡v§a¡C³o½gÁ{§É³ø§iÁÙ¦³«Ü¦h¦nª±ªº¦a¤èµ¥«Ý¤j®a¥h«õ±¸¡A³oÓ¶}©ñ¦¡Á{§É°µ¨ì¤@¥b´N³Qindependent Data Monitoring Committee´£¦³Û°±¡K¡K 4.§ÚÀ°±i¸³¨Ç³\×¥¿¤@¤U¡A¡u¸~½FÁY¤p¤Sso what¡vÁ¿ºë½T¤@ÂIÀ³¸Ó¬O¡u¸~½F¤@¶}©l´NÁY¤p¤Sso what¡v¡A¯à¤£¯àªø¤[±N¸~½FÁY¤p©µªø¥Í©R¤~¬O§Ú̦b·Nªº¡C§Ú¥ÎStable Disease(SD)¨Ó»¡©ú¡A´N²ÓM¬r±þÃĪ«¨Ó»¡¡ASD¬Oµu¼Èªº¡A¤£³Qµø¬°¯u¥¿ªº§Ü¸~½F¤ÏÀ³¡¨With chemotherapy, SD is often transient and therefore not considered indicative of true antitumor activity¡¨¡A¦ý´N§K¬ÌÃĪ«¨Ó»¡¡A¡¨With immunotherapeutic agents, which enhance antitumor immune responses, SD may also be viewed as an indicator of meaningful therapeutic effect¡¨¡C¬°¤°»ò¡H³o´N¬O¤HÅé§K¬Ì¨t²Î¶ø§®ªº¦a¤è¡A¬ü°êNIHÆ[¹î¨Ï¥ÎYERVOY(CTLA-4)6~8¦~«áªº±¡§Îµo²{¡A¦³¨Ç¨S¦³¤ÏÀ³ªº·|Åܦ¨¦³¤ÏÀ³¡A¦³¨ÇPR·|Åܦ¨CR¡¨with long-term follow-up some of the non-responders may become responders, and some PRs may evolve into CRs¡¨¡A³o¨ÇCRªº¯f¤H¥§¡ªá¤F30Ó¤ë¤~¹F¨ìCRªºµ{«×¡A¨ä¤¤¤@Ó¯f¤H¬Æ¦Üªá¤F70Ó¤ë¤~¸Ñ¨M±¼ªÍ³¡ªºÀù²ÓMÅܦ¨CR 5.ÃĮĦnÃa¤£¬O¹³¥xÆW¸ê¥»¥«³õ¥ÎPFS¨ÓPK³o»ò²³æªº¨Æ¡A·q½Ð¯¸¦b¯f¤Hªº¥ß³õ·Q¡A¬Æ»ò¼ËªºªvÀø¤~¯àÅýÀù¥½¯f¤Hºû«ù¥¿±`¤Hªº¥Í¬¡«~½è¡A¦³´LÄYªº©µªø¥Í©R¡A³o¤~¬O¯f¤H©Ò»ÝnªºªvÀø¡A³o¤~¬O·|¤j©ñ²§±mªºªvÀø¡C¬Y®a¨é°Ó´¿»¡¡G¡u¨ÅÀù²{¦b¤w¸g¦³«Ü¦nªºÃĪ«¤F¡v¡A¦b§Ú¬Ý¨Ó¡A·¥«×§N»ÅµL±¡ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/9 ¤U¤È 03:38:26²Ä 1939 ½g¦^À³
|
¤Ñ©R¤j ÁÂÁ´£¨ÑMOS¼ÒÀÀ±À¦ô,§óÁÂÁ´£¨ÑIbrance ªº³Ì·sMOS ¸ê°T ,OBI822¥¼¨Ó¦pªG»PIbranceÁp¦X¥ÎÃÄ,¨äMOS ¤@©wn§¹³ÓIbrance ,§_«h¦p¦ó§l¤Þ½÷·ç»P¯E¹©¦b¥«³õ¤Wµ¦²¤¦X§@? ,¦]¦¹¨ÅÀùOBI822MOS¼ÒÀÀ±À¦ô»PIbrance ªº³Ì·sMOS ¸ê°T´x´¤ §óÅ㨣¨ä«n©Ê!!! ¥t¥~Cliff ¤j¤]´£¨Ñ¥t¤@¼e¼sªº«äºû:822¤£¥²Ãª©ó¨ÅÀùÃþ«¬¡A¤]¤£¥²¹w¥ý¿z¿ïGHªí²{²v¤F¡A¥[¤W¿W¯Sªº§C°Æ§@¥ÎªºÀuÂI¡A¦Ñ¥v¤j¤]Á|¤F«Ü¦hPD-1/PD-L1·sÃĪº¨Ò¤l¡A§Y¨ÏPFS¤£¨Î¡A¬Æ¦Ü PFS¤£¿ù¦ýOSµL¯qªº¡A³£Àò±oFDAÃÄÃÒ¡C³o®É¦A©ëªd©óPFS©Î¬Æ¦ÜOS¼Æ¦rªºPK¡A·|¤£·|¤Ó¦Û¤F¡H³oÓ½×z¤]ȱo¤j®a²`«ä (1)¥¼°Ï¤À¥Íª«¼Ð°O²Õ¤¤ ¹êÅç²Õ(IBRANCE + LETROZOLE)ªºMOS37.5¤ë ©M¹ï·Ó²Õ( LETROZOLE )33.3¤ëµLÅãµÛ®t²§,(¦º¤`²v 47.1%/46.9% ±µªñ¦¨¼ô50%), HR 0.844 ,CI95% (0.417-1.710), P-Value 0.3189 (2)°Ï¤À¥Íª«¼Ð°O²Õ¤¤ ¹êÅç²Õ(IBRANCE + LETROZOLE)©M¹ï·Ó²Õ( LETROZOLE ), µLÅãµÛ®t²§,(¦º¤`²v 28%/32.7% ¥¼¦¨¼ô ), HR 0.783 ,CI95% (0.382-1.606),P-Value 0.2520 www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000SumR.pdf FDA SUMMARY REVIEW---- IBRANCE + LETROZOLE VS. LETROZOLE |
|
|
·|û¡G¦³«í10141521 µoªí®É¶¡:2016/6/9 ¤U¤È 12:06:14²Ä 1938 ½g¦^À³
|
Pie¤j ÁÂÁ±zªº»¡©ú! ¤p§Ì·Q¤j®a¹ï±i¸³¤Î¶ÀÁ`¬Ýªk³£¬O¤@Pªº,¥u¬O¤½¥q¥Ø«e¥¿³B©ó·¼É¤¤¤ß,±¹ï±Ó·Pªº¸ê¥»¥«³õ,¥DºÞ¾÷Ãöªº¥[±jºÊ·þ¡A¤@Á|¤@°Ê³£³Q¥Î©ñ¤jÃèÀ˵ø¡A¹ï¯E¹©³o¼Ë¤p¤½¥q¦Ó¨¥¡A¯uªº¬O·|¯h©ó©b©R¥B°Ê«h±o©S¡A¯uªº¬OÃø¬°¡A¤£¹L¦Ü¤Ö±q³Ìªñ¤½¥q±¹ï¦M¾÷³B²z¤Î¦^À³ªº³t«×³£¦³§óºë·Ç¤Î¥[³t¡A³o¬O¥i³ßªº²{¶H,´Á³\¤½¥q¯à¦A¥[§â«l¡A»°§ÖÅý822¦¤é¤W¥«,³yºÖ¬°Àù©ÒWªº¯f±w¤Î®aÄÝ¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2016/6/9 ¤W¤È 11:10:20²Ä 1937 ½g¦^À³
|
°ò¥»¤W§Úı±o822¯à¤£¯à¨ú±oFDA«C·ý¡A¤£¥²«Ø¥ß¦b¯à¤£¯à¥´±Ñ²{¦³¨ä¥LªºÃĪ«¡C¦pªG±N¨Ó822¬O¯à»P/n»PIbrance°µÁp¦X¥ÎÃĪº¸Ü¡A¨º»PIbranceªºÃö«Y¬O¤Í«D¼Ä¡A¦ó¥²PK±o¦º¥h¬¡¨Ó¡HÀR«Ý»PFDA¶}§¹EOP2·|ij«á¦A²q¤´¤£¿ð¡C ASCO©Ò§e²{ªº³ø§i¤wÅã¥Ü822¤£¥²Ãª©ó¨ÅÀùÃþ«¬¡A¤]¤£¥²¹w¥ý¿z¿ïGHªí²{²v¤F¡A¥[¤W¿W¯Sªº§C°Æ§@¥ÎªºÀuÂI¡A¦Ñ¥v¤j¤]Á|¤F«Ü¦hPD-1/PD-L1·sÃĪº¨Ò¤l¡A§Y¨ÏPFS¤£¨Î¡A¬Æ¦Ü PFS¤£¿ù¦ýOSµL¯qªº¡A³£Àò±oFDAÃÄÃÒ¡C³o®É¦A©ëªd©óPFS©Î¬Æ¦ÜOS¼Æ¦rªºPK¡A·|¤£·|¤Ó¦Û¤F¡HY¬OFDAÄ~ÄòªÃ«ù¥R¹ê½b³Uùئh¼Ë¤Æªº½bªºªì°J¨Ó¬Ý«Ý822¡A¨º¤j®aªº·Qªk¬O¤£¬O¤]¸ÓÅý¦Û¤v¾¨§Ö¸ò¤W¥h¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/9 ¤W¤È 08:48:44²Ä 1936 ½g¦^À³
|
ÁÂÁ¤ѩR¤j¼ÒÀÀ±À¦ô¡A¦³¤@±i«Ü«nªºP17 ¤Ñ©R¤j¿òº|¤F¨S¦³¼ÒÀÀ±À¦ô? |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/6/9 ¤W¤È 02:46:24²Ä 1935 ½g¦^À³
|
©êºp ¤p§Ì¶K¿ùª© ©çÁÂ~ |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2016/6/9 ¤W¤È 02:42:02²Ä 1934 ½g¦^À³
|
¨S¿ù ´Ût¦Ñ¹ê¤H ¯E¹©¸Ü¤Ö¤]¦³¨Æ ¤@¸ÑÄÀ´N³Q¥´¦¨°ª½Õ ¦Ê¦W´N¨Æn¥´ Y´«¦¨³¢¸³ ¥xÆW½Ö´±×²z? ı¤½¥q¤£»Ý²z·| ±Mª`¦b·sÃĬãµo¹ïªÑªF»¡©ú¹ïÂÛ·Ø´I¿A´N¦n §ó¤£¥ÎºÞªÑ»ù ¦ý§Úµ´¤½¥qµo¨¥¤HÀ³¸Ón§ä±j®«¤@ÂI³Ì¦n¬Oªk«ßI´º ¤@Ó¤£¹ï¨ýª½±µ§i ¾ß¥ý¥Í»â¤FÁ~¤ô¿ì¤£¿ì¬O¥L®aªº¨Æ °_½X¦³Ó«Å¥Ü§@¥Î~ |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/6/9 ¤W¤È 01:40:47²Ä 1933 ½g¦^À³
|
§Ú̬O¦P¤@°êªº! ~~~ ¥¿½TµL»~..ÆgÆgÆg Pie¤j..ªº«Øij,¬O«D±`²z©Ê,Å㨣¥L¤]Æ[¹î¤J·L..§Ú«D±`»{¦P.. ¶ÀÁ`,²z©Ê.¦³¤À¤o.¶i°h±o©y,¼ÖÆ[,¿Ë©M¤O«D±`±j,¨C¤@¦¸¬Ýªk»¡·|,³£·|³Q¦oªºÀéÄ꯺®eµ¹¿Ä¤Æ¤F.. ¦Ü©ó±i¸³,¦³®É·|½Ä¹LÀY®É,´N¬O¦]¬°¥L¤Ó¼ö±¡.¼ö¸Û.©Z¸Û¦Óª½¤ß.. §Y¨Ï½Ä¹LÀY¨Ç,§Ú¤]ı±o«Ü´Î..§Ú¤Ó³ßÅw³o¼Ëªº¤H.. µL©`,¥xÆW¥«³õÀô¹Ò«o¬O¦p¦¹ªºVÁ¡.µL±¡.±M¬D¦Ñ¹ê¤H¦¾öG.°µ¤å³¹.. ¨SÃö«Y..«B¹L·|¤Ñ´¸..¾ú¥vªº¸}¨B¤£·|°±·²,¦ý¤½¥q©Ò¨«¹Lªºy¸ñ,¤@©w·|ÃÒ©úªº.. §Ú«D±`ªº°í«H.. ¯E¹©¬O·sÃĪºÀsÀY¡A³o¥«³õ¹ï·sÃIJ£·~ªºµLª¾»P°¾¨£..¯E¹©¬J¬OÀsÀY,´N¥þ³¡¦ª°_¨Ó§a. ¥@¬É¯Åªº¬ì¾Ç¤Hª«,¥@¬É¯Åªº¸gÀç¹Î¶¤,¥@¬É¯Åªº·sÃÄ...±a»â¥xÆW¥´¥@¬ÉªM,¶ø¹BÁÉ.. §Y¨Ï¬O¹p¹q¥æ¥[,¤j·¤j«B,³£¸Ó«i´±ªº¼µ¤U¥h,®É¶¡²fÁåÁö¨¯W,¦ý³Ì«á¹Ü«aªº²¢¬üªG¹ê,±N³yºÖ¤HÃþ,¥B´À°ê®a¼W¥ú. ¸Ü¦h¤F..¤£¦n·N«ä..±ß¦w.. |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2016/6/9 ¤W¤È 01:08:29²Ä 1932 ½g¦^À³
|
¯E§J¤j, ¤Ñ©R¤j: ÁÂÁ¨â¦ìªº¸Ñ»¡¤Î«ü¾É, Á`ºâ¸Ñ´b¤F, ·PÁ !! ¥xÁÞ¤jªº¸ò¶i´£°Ý, Åý§Ú¯à»{ÃѨì§ó¦h²Ó¸`, ¤@¨ÖPÁ ! |
|
|
·|û¡G¥m¾´10141821 µoªí®É¶¡:2016/6/9 ¤W¤È 01:07:38²Ä 1931 ½g¦^À³
|
¦³»~·|¡A¼á²M¡A¹Dºp´N¦n¡A¤Ó·P°Ê¤F! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/9 ¤W¤È 12:56:54²Ä 1930 ½g¦^À³
|
Pie¤j §Aªº«Øij¤]«Ü´Î¡A±M·~¥H¥~¥æµ¹¶ÀÁ`¡A§Ú̳£¦³Æ[¹î¨ì¶ÀÁ`«Ü¦³¿Ë¦X¤O¡A·|¹ªÀyû¤u¡A¶ÀÁ`±`À°¦£±i¸³±Ä·Ù¨®¡A±i¸³«®É®Ä¡A·Q½Ä¯}§x¹Ò¡A¶}³Ð·s§½¡A·í½Ä¹LÀY®É¶ÀÁ`·|¤U¹F·Ù¥O¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/9 ¤W¤È 12:25:39²Ä 1929 ½g¦^À³
|
µL¤j¤j ¹ï¤£°_¡Aì¨Ó¬O§Ú»~¸Ñ¤F¡A±i¸³¨ä¹ê«ÜÁ¿¸q®ð¡A³ßÅw®ü¬v¡A´¼ªÌ¼Ö¤ô¡A¬O¦³«H¥õ«¸Û«Hªº°ò·þ±Ð®{¡A¤µ¤Ñ¤½¥q¤U¤Èªº¤½§i¤º®e¥Rº¡¦P²z¤ß¡A·ÓÅUªÑªFªºì«h©l²×¦p¤@¡A¿ï¥Í§Þ¤½¥q³Ì«nªº¬O¿ït³d¤Hªº¤H«~,¸gÅç,¤~¯à,Ä@´º»P¦M¾÷³B²z¯à¤O°t¦X³Ð·s¤S¦³Ävª§¤Oªº²£«~½u»PÀu¨qªº¬ãµo¹Î¶¤»PºÞ²z¹Î¶¤¡C§Ú̬O¦P¤@°êªº! |
|
|
·|û¡Gpie10141536 µoªí®É¶¡:2016/6/9 ¤W¤È 12:14:16²Ä 1928 ½g¦^À³
|
±i¸³¦b¨Æ·~¤Wªº¦¨¥\, ¦b¥xÆW¥Í§Þ²£·~ªº°^Äm, ¹ï¯E¹©ªÑªFªºt³d, ¹ï®z¶Õ¦ù¥Xªº´©¤â, ¬O¦³¥Ø¦@¸@ªº §Ú¹ï¥L¤F¸Ñªº¤£¦h, ¦ý¨¬¥HÅý§Ú¤Q¤Àªº·q¨Ø¥L ·P©Ê¤W, §Ú³ßÅwÅ¥¥LÁ¿¸Ü, ¼ö±¡¯u¸Û¦³¤º²[ ²z©Ê¤W, ÁÙ¬O«Øij, ±¹ï§ë¸ê¤Hªº·¾³q, ±M·~ªº³¡¤À¥H¥~, ºÉ¶qÅý¶ÀÁ`¨Ó§a |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/6/9 ¤W¤È 12:01:02²Ä 1927 ½g¦^À³
|
¥xÁÞ¤j.. ¤£¦n·N«ä,©êºp©Ô.. §Ú¨S¦³n»Ä§O¤Hªº·N«ä,§Ú¬On±j½Õ§Ú¹ï±i¸³ªºÆ[¹î»P¬Ýªk,»P±z̨â¦ì¤j¤j¤@¼Ë.. §Ú¤Ó³ßÅw³on¥¿ª½¤S¼ö¸Û.©Z¸Ûªº¤H.. ¤]³\,¦³®É¸Ü¥i¯àÁ¿¦h¤FÂI,¦ý³£¦³ÅÞ¿è©Ê»Pì«h.. ´N¬O¦]¬°±i¸³±¹ï§ë¸ê¤H,«D±`¼ö¸Û.¼ö¤ß.. §Ú¤Ó³ßÅw³o¼Ëªº¦ÑÁó°Õ.. ¨S§Oªº·N«ä.. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤U¤È 11:13:35²Ä 1926 ½g¦^À³
|
¤Ñ©R¤j Slide 13 Æ[¹î¨ì 2015¦~10¤ë©³¤î. ²Ä32Ó¤ë¹êÅç²Õ224¤HÁ`¦º¤`¤H¼Æ50¤H ¨ì¤µ¦~©³±N¹F¨ì46Ó¤ë (32+14=46)(2015¦~10¤ë¦Ü2016¦~12¤ë=14Ó¤ë) ¤Ñ©R¤j¥i¥H¹w¦ô¹êÅç²Õ224¤HÁ`¦º¤`¤H¼Æ¨ì112¤H »Ý¨ì¦ó¦~¦ó¤ë? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤U¤È 10:58:16²Ä 1925 ½g¦^À³
|
¤Ñ©R¤j ÁÂÁ¤ѩR¤j»¡©ú,§Úµ§»~À³¬O¥H¤ë¬°³æ¦ì,§ó¥¿«á±q¶K¤@¦¸¤Ñ©R¤j¦^µª, ¦³¿ù¦A§ó¥¿ Q ²Ä32Ó¤ë ÁÙ¦³47¤H( N at risk ) À³¸Ó¬O¯E§J¤j©Ò»¡ªº ÃnÀI¤H¼Æ 224¤H- 47¤H(ÃnÀI¤H¼Æ) - X( ³]¸ê®Æ) = ¦º¤`¤H¼Æ ½Ð°Ý¦º¤`¤H¼Æ¤w¹L¥b ¬°¦óP13¦s¬¡¦±½u ¦b32Ó¤ë®É °ª±¾ 0.7 ¦ì¸m ? Ans, 16~32¤ë ÁÙ¦³, ¤j±À¤H¬¡µÛ¬°³]¸ê®Æ. ²Ä16Ó¤ë(§t)¥H¤W ÃnÀI¤H¼Æ 163¤H ²Ä20Ó¤ë(§t)¥H¤W ÃnÀI¤H¼Æ 133¤H, ²Ä24Ó¤ë(§t)¥H¤W ÃnÀI¤H¼Æ 107¤H, ²Ä28Ó¤ë(§t)¥H¤W ÃnÀI¤H¼Æ 77¤H, ²Ä32Ó¤ë(§t)¥H¤W ÃnÀI¤H¼Æ 47¤H ²Ä32Ӥ릺¤`¥u¦³50¤H,n112¤H¤~¹L¥b ( ¦s¬¡¦±½u©¹¥k¤U°¨ì¹F0.5) 2 Total Events N=50 ,Á`¦º¤`¤H¼Æ50¤H ¬O¬ù¦b²Ä´XÓ¤ëµo¥Í? Ans.²Ä32Ó¤ë |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤U¤È 10:26:52²Ä 1924 ½g¦^À³
|
µL¤j¤j ¤£n¶K§Ú»P©Ó¤Ñ¤jªº¶K¤å©ÎÆ[ÂI¥h»Ä§O¤H «Ü¤£Â§»ª ¤½¥q±Á{®À§é»Ýn¤j®aÅé½Ì»P¤ä«ù |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2016/6/8 ¤U¤È 10:19:27²Ä 1923 ½g¦^À³
|
¤Ñ©R¤j 1 ¦pªG32¶g ÁÙ¦³47¤H¬¡µÛ 224-47-X- =¦º¤`¤H¼Æ X ¥i¯à¬O°h¥X ½Ð°Ý¦º¤`¤H¼Æ¤w¹L¥b ¬°¦óP13¦s¬¡¦±½u ¦b32¶g®É °ª±¾ 0.7 ¦ì¸m ? 2 Total Events N=50 ,Á`¦º¤`50¤H ¬O¬ù¦b²Ä´X¶gµo¥Í? |
|
|
·|û¡GµL¤j10141864 µoªí®É¶¡:2016/6/8 ¤U¤È 09:56:35²Ä 1922 ½g¦^À³
|
±i¸³ÅÞ¿è²M´· ±ø²z¤À©ú ¥Ñ¥L¨Ó¦^µª°ÝÃD«D±`¦X¾A ¦³¬ü°ê³Ð·~¦¨¥\ªº¸gÅç ¥x³Ð·~§ä¦^ÄÝ©ó¥xÆWºaÄ£¤§¤ß ¦^µª°ÝÃD®É·|§â¥i¯à±¡ªp»¡©ú,¹ï¨Sµo¥Íªº¨Æ¤£·|¥h¹w´ú ¤£¤îÃö¤ß¯E¹©ªºµo®i,¤]Ãö¤ß¥xÆW¥Í§Þ²£·~ªºµo®i §Ú³Ì³ßÅwÅ¥¥L½×z°ÝÃD §A»Ýn¦hÁA¸Ñ±i¸³ ~~~~ ¥xÁÞ¤j..©Ó¤Ñ¤j.. ¬Oªº..±i¸³³oºØ¤½¥q¦ÑÁó,«D±`¦n.«D±`´Î¤F,¥¿ª½+¼ö¸Û+ª½²v..¤Ö¨£¤F.. |
|
|
·|û¡G©Ó¤Ñ10142520 µoªí®É¶¡:2016/6/8 ¤U¤È 09:10:03²Ä 1921 ½g¦^À³
|
±i¸³¯uªº«ÜÁ¾¨õ ¸³¨Æªø¬O³o¼Ëªº¤H®æ¯S½èÀ³¸Ón¦n¦n¤ä«ù |
|
|
|